30
Average Days in Review
96%
Percent of Research Articles Cited within Two Years of Publication
9
Average Days to Publication from Acceptance
Annual HTML+PDF Usage

CURRENT ISSUE

Volume 59Issue 7June 2021

EDITOR IN CHIEF: Dr. Alexander J. McAdam

Explore JCM

Editor in Chief

JCM EiC McAdam
Dr. Alexander J. McAdam

Editor in Chief (2025) | Boston Children’s Hospital

Alexander J. McAdam is the Medical Director of the Infectious Diseases Diagnostic Laboratory and Vice-Chair of the Department of Laboratory Medicine at Boston Children’s Hospital and an Associate Professor of Pathology at Harvard Medical School. His research is on the utility of diagnostic tests for infectious diseases in children.

Editorial Board

  • Journal of Clinical MicrobiologyArticle
    Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017−2018 INFORM-RSV Study

    ABSTRACT

    Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection among infants and young children, resulting in annual epidemics worldwide. INFORM-RSV is a multiyear clinical study designed to describe the global molecular epidemiology of RSV in children under 5 years of age by monitoring temporal and geographical evolution of current circulating RSV strains, F protein antigenic sites, and their relationships with clinical features of RSV disease. During the pilot season (2017–2018), 410 RSV G-F gene sequences were obtained from 476 RSV-positive nasal samples collected from 8 countries (United Kingdom, Spain, The Netherlands, Finland, Japan, Brazil, South Africa, and Australia). RSV B (all BA9 genotype) predominated over RSV A (all ON1 genotype) globally (69.0% versus 31.0%) and in all countries except South Africa. Geographic clustering patterns highlighted wide transmission and continued evolution with viral spread. Most RSV strains were from infants of <1 year of age (81.2%), males (56.3%), and patients hospitalized for >24 h (70.5%), with no differences in subtype distribution. Compared to 2013 reference sequences, variations at F protein antigenic sites were observed for both RSV A and B strains, with high-frequency polymorphisms at antigenic site Ø (I206M/Q209R) and site V (L172Q/S173L/K191R) in RSV B strains. The INFORM-RSV 2017–2018 pilot season establishes an important molecular baseline of RSV strain distribution and sequence variability with which to track the emergence of new strains and provide an early warning system of neutralization escape variants that may impact transmission or the effectiveness of vaccines and MAbs under development.

    REFERENCES

    1.
    Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. 2009. The burden of respiratory syncytial virus infection in young children. N Engl J Med 360:588–598.
    2.
    Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, Alassani I, Ali A, Antonio M, Awasthi S, Awori JO, Azziz-Baumgartner E, Baggett HC, Baillie VL, Balmaseda A, Barahona A, Basnet S, Bassat Q, Basualdo W, Bigogo G, Bont LJ, Breiman RF, Brooks WA, Broor S, Bruce N, Bruden D, Buchy P, Campbell S, Carosone-Link P, Chadha M, Chipeta J, Chou M, Clara W, Cohen C, de Cuellar E, Dang D-A, Dash-Yandag B, Deloria-Knoll M, Dherani M, Eap T, Ebruke BE, Echavarria M, de Freitas Lázaro Emediato CC, Fasce RA, Feikin DR, Feng L, et al. 2017. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 390:946–958.
    3.
    Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodriguez-Tenreiro C, Sly P, Ramilo O, Mejias A, Baraldi E, Papadopoulos NG, Nair H, Nunes MC, Kragten-Tabatabaie L, Heikkinen T, Greenough A, Stein RT, Manzoni P, Bont LJ, Martinon-Torres F. 2018. Respiratory syncytial virus seasonality: a global overview. J Infect Dis 217:1356–1364.
    4.
    Broberg EK, Waris M, Johansen K, Snacken R, Penttinen P, Network EIS. 2018. Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016. Euro Surveill 23:17-00284.
    5.
    Simoes EAF. 2003. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. The J Pediatrics 143:118–126.
    6.
    Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS, Englund JA, Mejias A, Karron RA, Simões EAF, Knezevic I, Ramilo O, Piedra PA, Chu HY, Falsey AR, Nair H, Kragten-Tabatabaie L, Greenough A, Baraldi E, Papadopoulos NG, Vekemans J, Polack FP, Powell M, Satav A, Walsh EE, Stein RT, Graham BS, Bont LJ, Respiratory Syncytial Virus Network (ReSViNET) Foundation. 2018. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis 18:e295–e311.
    7.
    American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. 2014. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134:e620-38.
    8.
    PATH. 2020. RSV vaccine and mAb snapshot. [Accessed March 12, 2020]. https://vaccineresources.org/details.php?i=1562.
    9.
    Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP. 2020. Single dose nirsevimab for prevention of RSV disease in preterm infants. N Engl J Med 383:415–425.
    10.
    Rima B, Collins P, Easton A, Fouchier R, Kurath G, Lamb RA, Lee B, Maisner A, Rota P, Wang L, ICTV Report Consortium. 2017. ICTV virus taxonomy profile: Pneumoviridae. J Gen Virol 98:2912–2913.
    11.
    Tabatabai J, Prifert C, Pfeil J, Grulich-Henn J, Schnitzler P. 2014. Novel respiratory syncytial virus (RSV) genotype ON1 predominates in Germany during winter season 2012-13. PLoS One 9:e109191.
    12.
    Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, Moldt B, Khan A, Svabek C, McAuliffe JM, Wrapp D, Patel NK, Cook KE, Richter BWM, Ryan PC, Yuan AQ, Suzich JA. 2017. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med 9:eaaj1928.
    13.
    Gilman MS, Castellanos CA, Chen M, Ngwuta JO, Goodwin E, Moin SM, Mas V, Melero JA, Wright PF, Graham BS, McLellan JS, Walker LM. 2016. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol 1:eaaj1879.
    14.
    Broadbent L, Groves H, Shields MD, Power UF. 2015. Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. Influenza Other Respir Viruses 9:169–178.
    15.
    Bose ME, He J, Shrivastava S, Nelson MI, Bera J, Halpin RA, Town CD, Lorenzi HA, Noyola DE, Falcone V, Gerna G, De Beenhouwer H, Videla C, Kok T, Venter M, Williams JV, Henrickson KJ. 2015. Sequencing and analysis of globally obtained human respiratory syncytial virus A and B genomes. PLoS One 10:e0120098.
    16.
    Elawar F, Griffiths CD, Zhu D, Bilawchuk LM, Jensen LD, Forss L, Tang J, Hazes B, Drews SJ, Marchant DJ. 2017. A virological and phylogenetic analysis of the emergence of new clades of respiratory syncytial virus. Sci Rep 7:12232.
    17.
    Rodriguez-Fernandez R, Tapia LI, Yang CF, Torres JP, Chavez-Bueno S, Garcia C, Jaramillo LM, Moore-Clingenpeel M, Jafri HS, Peeples ME, Piedra PA, Ramilo O, Mejias A. 2017. Respiratory syncytial virus genotypes, host immune profiles, and disease severity in young children hospitalized with bronchiolitis. J Infect Dis 217:24–34.
    18.
    Langedijk AC, Lebbink RJ, Naaktgeboren C, Evers A, Viveen MC, Greenough A, Heikkinen T, Stein RT, Richmond P, Martinón-Torres F, Nunes M, Hosoya M, Keller C, Bauck M, Cohen R, Papenburg J, Pernica J, Hennus MP, Jin H, Tabor DE, Tovchigrechko A, Ruzin A, Abram ME, Wilkins D, Wildenbeest JG, Kragten-Tabatabaie L, Coenjaerts FEJ, Esser MT, Bont LJ. 2020. Global molecular heterogeneity of RSV—the “INFORM RSV” study. BMJ Infect Dis 20:450.
    19.
    Tovchigrechko A, Aspinal E, Slidel T, Liu H, Lu B, Ruzin A, Lebbink RJ, Jin H, Abram ME, Esser MT, Tabor DE. 2020. NGS-MSTB: Next Generation Sequencing Microbial Surveillance Toolbox for scalable de-novo assembly of viral genomes and bacterial genes. Zenodo doi:
    20.
    McLellan JS, Yang Y, Graham BS, Kwong PD. 2011. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85:7788–7796.
    21.
    Yu J, Liu C, Xiao Y, Xiang Z, Zhou H, Chen L, Shen K, Xie Z, Ren L, Wang J. 2019. Respiratory syncytial virus seasonality, Beijing, China, 2007-2015. Emerg Infect Dis 25:1127–1135.
    22.
    Lu B, Liu H, Tabor DE, Tovchigrechko A, Qi Y, Ruzin A, Esser MT, Jin H. 2019. Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015-17. Sci Rep 9:3898.
    23.
    Ruzin A, Pastula ST, Levin-Sparenberg E, Jiang X, Fryzek J, Tovchigrechko A, Lu B, Qi Y, Liu H, Jin H, Yu L, Hackett J, Villafana T, Esser MT. 2018. Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States. PLoS One 13:e0200319.
    24.
    Comas-Garcia A, Noyola DE, Cadena-Mota S, Rico-Hernandez M, Bernal-Silva S. 2018. Respiratory syncytial virus-A ON1 genotype emergence in central Mexico in 2009 and evidence of multiple duplication events. J Infect Dis 217:1089–1098.
    25.
    Liu H, Lu B, Tabor DE, Tovchigrechko A, Wilkins D, Jin H, Madhi SA, Soofie N, Esser MT, Nunes MC. 2020. Characterization of human respiratory syncytial virus (RSV) isolated from HIV-exposed-uninfected and HIV-unexposed infants in South Africa during 2015–2017. Influenza Other Respir Viruses 14:403–411.
    26.
    Otieno JR, Agoti CN, Gitahi CW, Bett A, Ngama M, Medley GF, Cane PA, Nokes DJ. 2016. Molecular evolutionary dynamics of respiratory syncytial virus group A in recurrent epidemics in coastal Kenya. J Virol 90:4990–5002.
    27.
    Di Giallonardo F, Kok J, Fernandez M, Carter I, Geoghegan JL, Dwyer DE, Holmes EC, Eden JS. 2018. Evolution of human respiratory syncytial virus (RSV) over multiple seasons in New South Wales, Australia. Viruses 10:476.
    28.
    Vandini S, Biagi C, Lanari M. 2017. Respiratory syncytial virus: the influence of serotype and genotype variability on clinical course of infection. Int J Mol Sci 18:1717.
    29.
    Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita CB, Simões EAF, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545–1555.
    30.
    Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, Simoes EA, Carbonell-Estrany X. 2016. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect Dis Ther 5:271–298.
    31.
    Hause AM, Henke DM, Avadhanula V, Shaw CA, Tapia LI, Piedra PA. 2017. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. PLoS One 12:e0175792.
    32.
    Chen X, Xu B, Guo J, Li C, An S, Zhou Y, Chen A, Deng L, Fu Z, Zhu Y, Liu C, Xu L, Wang W, Shen K, Xie Z. 2018. Genetic variations in the fusion protein of respiratory syncytial virus isolated from children hospitalized with community-acquired pneumonia in China. Sci Rep 8:4491.
    33.
    Fernandes F, Tabor DE, Lu B, Layman H, Nair V, Chaudhuri V, Qi Y, Tovchigrechko A, Wilkins D, Ruzin A, Villafana T, Esser MT, Abram ME. 2019. OUTSMART-RSV molecular surveillance in the United States over the 2016–2019 RSV seasons. Poster Presentation at RSVVW'19, Accra, Ghana, 12–14 November 2019.
    34.
    Ruckwardt TJ, Morabito KM, Graham BS. 2019. Immunological lessons from respiratory syncytial virus vaccine development. Immunity 51:429–442.
    35.
    Oliveira DB, Iwane MK, Prill MM, Weinberg GA, Williams JV, Griffin MR, Szilagyi PG, Edwards KM, Staat MA, Hall CB, Durigon EL, Erdman DD. 2015. Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis. J Clin Virol 65:26–31.
    36.
    Zhu Q, Patel NK, McAuliffe JM, Zhu W, Wachter L, McCarthy MP, Suzich JA. 2012. Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab. J Infect Dis 205:635–638.
    37.
    Simoes EAF, Forleo-Neto E, Geba GP, Kamal M, Yang F, Cicirello H, Houghton MR, Rideman R, Zhao Q, Benvin SL, Hawes A, Fuller ED, Wloga E, Pizarro JMN, Munoz FM, Rush SA, McLellan JS, Lipsich L, Stahl N, Yancopoulos GD, Weinreich DM, Kyratsous CA, Sivapalasingam S. 2020. Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. Clin Infect Dis doi:
    38.
    Zhu Q, Lu B, McTamney P, Palaszynski S, Diallo S, Ren K, Ulbrandt ND, Kallewaard N, Wang W, Fernandes F, Wong S, Svabek C, Moldt B, Esser MT, Jing H, Suzich JA. 2018. Prevalence and significance of substitutions in the fusion protein of respiratory syncytial virus resulting in neutralization escape from antibody MEDI8897. J Infect Dis 218:572–580.
    39.
    Fall A, Dia N, Cisse el HA, Kiori DE, Sarr FD, Sy S, Goudiaby D, Richard V, Niang MN. 2016. Epidemiology and molecular characterization of human respiratory syncytial virus in Senegal after four consecutive years of surveillance, 2012–2015. PLoS One 11:e0157163.
    40.
    Mas V, Nair H, Campbell H, Melero JA, Williams TC. 2018. Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset. Vaccine 36:6660–6673.
    41.
    Fan R, Fan C, Zhang J, Wen B, Lei Y, Liu C, Chen L, Liu W, Wang C, Qu X. 2017. Respiratory syncytial virus subtype ON1/NA1/BA9 predominates in hospitalized children with lower respiratory tract infections. J Med Virol 89:213–221.
    42.
    Hirve S, Crawford N, Palekar R, Zhang W, WHO RSV Surveillance Group. 2019. Clinical characteristics, predictors, and performance of case definition-Interim results from the WHO global respiratory syncytial virus surveillance pilot. Influenza Other Respir Viruses doi:
    43.
    Pandya MC, Callahan SM, Savchenko KG, Stobart CC. 2019. A contemporary view of respiratory syncytial virus (RSV) biology and strain-specific differences. Pathogens 8:67.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 59Number 117 December 2020
    eLocator: e01828-20
    Editor: Yi-Wei Tang
    Cepheid

    History

    Received: 14 July 2020
    22 August 2020
    Accepted: 15 October 2020
    Published online: 21 October 2020

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. evolution
    2. genetic variation
    3. molecular epidemiology
    4. resistance
    5. respiratory syncytial virus
    6. surveillance

    Contributors

    Authors

    David E. Tabor
    Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
    Fiona Fernandes
    Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, San Francisco, California, USA
    Annefleur C. Langedijk
    Department of Paediatrics, Division of Paediatric Infectious Diseases, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
    Deidre Wilkins
    Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
    Robert Jan Lebbink
    Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands
    Andrey Tovchigrechko
    Data Sciences & Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
    Alexey Ruzin
    Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
    Leyla Kragten-Tabatabaie
    ReSViNET Foundation, Zeist, The Netherlands
    Julius Clinical, Zeist, The Netherlands
    Hong Jin
    Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, San Francisco, California, USA
    Mark T. Esser
    Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
    Louis J. Bont
    Department of Paediatrics, Division of Paediatric Infectious Diseases, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
    ReSViNET Foundation, Zeist, The Netherlands
    Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
    the INFORM-RSV Study Group

    Editor

    Yi-Wei Tang
    Editor
    Cepheid

    Notes

    Address correspondence to Michael E. Abram, [email protected].
    David E. Tabor, Fiona Fernandes, and Annefleur C. Langedijk contributed equally to this work. Author order was determined on the basis of seniority.

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Detection of Respiratory Viruses and Subtype Identification of Influenza A Viruses by GreeneChipResp Oligonucleotide Microarray

    ABSTRACT

    Acute respiratory infections are significant causes of morbidity, mortality, and economic burden worldwide. An accurate, early differential diagnosis may alter individual clinical management as well as facilitate the recognition of outbreaks that have implications for public health. Here we report on the establishment and validation of a comprehensive and sensitive microarray system for detection of respiratory viruses and subtyping of influenza viruses in clinical materials. Implementation of a set of influenza virus enrichment primers facilitated subtyping of influenza A viruses through the differential recognition of hemagglutinins 1 through 16 and neuraminidases 1 through 9. Twenty-one different respiratory virus species were accurately characterized, including a recently identified novel genetic clade of rhinovirus.

    REFERENCES

    1.
    Altschul, S. F., and D. J. Lipman.1990. Protein database searches for multiple alignments. Proc. Natl. Acad. Sci. USA87:5509-5513.
    2.
    Bailey, T. L., and C. Elkan.1995. The value of prior knowledge in discovering motifs with MEME, p. 21-29. Proc. 3rd Int. Conf. Intell. Syst. Mol. Biol. AAAI Press, Menlo Park, CA.
    3.
    Bailey, T. L., and M. Gribskov.1998. Combining evidence using p-values: application to sequence homology searches. Bioinformatics14:48-54.
    4.
    Benguigui, Y., F. J. Lopez Antunano, G. Schmunis, and J. Yunes (ed.).1999. Respiratory infections in children. Series HCT/AIEPI-1.I. Pan American Health Organization, Washington, DC.
    5.
    Bohlander, S. K., R. Espinosa III, M. M. Le Beau, J. D. Rowley, and M. O. Diaz.1992. A method for the rapid sequence-independent amplification of microdissected chromosomal material. Genomics13:1322-1324.
    6.
    Briese, T., G. Palacios, M. Kokoris, O. Jabado, Z. Liu, N. Renwick, V. Kapoor, I. Casas, F. Pozo, R. Limberger, P. Perez-Brena, J. Ju, and W. I. Lipkin.2005. Diagnostic system for rapid and sensitive differential detection of pathogens. Emerg. Infect. Dis.11:310-313.
    7.
    Brunstein, J., and E. Thomas.2006. Direct screening of clinical specimens for multiple respiratory pathogens using the Genaco respiratory panels 1 and 2. Diagn. Mol. Pathol.15:169-173.
    8.
    Cashat-Cruz, M., J. J. Morales-Aguirre, and M. Mendoza-Azpiri.2005. Respiratory tract infections in children in developing countries. Semin. Pediatr. Infect. Dis.16:84-92.
    9.
    Coiras, M. T., J. C. Aguilar, M. L. Garcia, I. Casas, and P. Perez-Brena.2004. Simultaneous detection of fourteen respiratory viruses in clinical specimens by two multiplex reverse transcription nested-PCR assays. J. Med. Virol.72:484-495.
    10.
    Coiras, M. T., P. Perez-Brena, M. L. Garcia, and I. Casas.2003. Simultaneous detection of influenza A, B, and C viruses, respiratory syncytial virus, and adenoviruses in clinical samples by multiplex reverse transcription nested-PCR assay. J. Med. Virol.69:132-144.
    11.
    Dawson, E. D., C. L. Moore, J. A. Smagala, D. M. Dankbar, M. Mehlmann, M. B. Townsend, C. B. Smith, N. J. Cox, R. D. Kuchta, and K. L. Rowlen.2006. MChip: a tool for influenza surveillance. Anal. Chem.78:7610-7615.
    12.
    Fan, J., K. J. Henrickson, and L. L. Savatski.1998. Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization assay (Hexaplex). Clin. Infect. Dis.26:1397-1402.
    13.
    Fendrick, A. M., A. S. Monto, B. Nightengale, and M. Sarnes.2003. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch. Intern. Med.163:487-494.
    14.
    Jabado, O. J., G. Palacios, V. Kapoor, J. Hui, N. Renwick, J. Zhai, T. Briese, and W. I. Lipkin.2006. Greene SCPrimer: a rapid comprehensive tool for designing degenerate primers from multiple sequence alignments. Nucleic Acids Res.34:6605-6611.
    15.
    Kessler, N., O. Ferraris, K. Palmer, W. Marsh, and A. Steel.2004. Use of the DNA flow-thru chip, a three-dimensional biochip, for typing and subtyping of influenza viruses. J. Clin. Microbiol.42:2173-2185.
    16.
    Khanna, M., J. Fan, K. Pehler-Harrington, C. Waters, P. Douglass, J. Stallock, S. Kehl, and K. J. Henrickson.2005. The pneumoplex assays, a multiplex PCR-enzyme hybridization assay that allows simultaneous detection of five organisms, Mycoplasma pneumoniae, Chlamydia (Chlamydophila) pneumoniae, Legionella pneumophila, Legionella micdadei, and Bordetella pertussis, and its real-time counterpart. J. Clin. Microbiol.43:565-571.
    17.
    Kilbourne, E. D.2006. Influenza pandemics of the 20th century. Emerg. Infect. Dis.12:9-14.
    18.
    Lamson, D., N. Renwick, V. Kapoor, Z. Liu, G. Palacios, J. Ju, A. Dean, K. St. George, T. Briese, and W. I. Lipkin.2006. MassTag polymerase-chain-reaction detection of respiratory pathogens, including a new rhinovirus genotype, that caused influenza-like illness in New York State during 2004-2005. J. Infect. Dis.194:1398-1402.
    19.
    Lin, B., K. M. Blaney, A. P. Malanoski, A. G. Ligler, J. M. Schnur, D. Metzgar, K. L. Russell, and D. A. Stenger.2007. Using a resequencing microarray as a multiple respiratory pathogen detection assay. J. Clin. Microbiol.45:443-452.
    20.
    Lodes, M. J., D. Suciu, M. Elliott, A. G. Stover, M. Ross, M. Caraballo, K. Dix, J. Crye, R. J. Webby, W. J. Lyon, D. L. Danley, and A. McShea.2006. Use of semiconductor-based oligonucleotide microarrays for influenza A virus subtype identification and sequencing. J. Clin. Microbiol.44:1209-1218.
    21.
    Lopez-Huertas, M. R., I. Casas, B. Acosta-Herrera, M. L. Garcia, M. T. Coiras, and P. Perez-Brena.2005. Two RT-PCR based assays to detect human metapneumovirus in nasopharyngeal aspirates. J. Virol. Methods129:1-7.
    22.
    Mackay, I. M., K. C. Jacob, D. Woolhouse, K. Waller, M. W. Syrmis, D. M. Whiley, D. J. Siebert, M. Nissen, and T. P. Sloots.2003. Molecular assays for detection of human metapneumovirus. J. Clin. Microbiol.41:100-105.
    23.
    Mulholland, K.2003. Global burden of acute respiratory infections in children: implications for interventions. Pediatr. Pulmonol.36:469-474.
    24.
    Nijhuis, M., N. van Maarseveen, R. Schuurman, S. Verkuijlen, M. de Vos, K. Hendriksen, and A. M. van Loon.2002. Rapid and sensitive routine detection of all members of the genus Enterovirus in different clinical specimens by real-time PCR. J. Clin. Microbiol.40:3666-3670.
    25.
    Palacios, G., P. L. Quan, O. J. Jabado, S. Conlan, D. L. Hirschberg, Y. Liu, J. Zhai, N. Renwick, J. Hui, H. Hegyi, A. Grolla, J. E. Strong, J. S. Towner, T. W. Geisbert, P. B. Jahrling, C. Buchen-Osmond, H. Ellerbrok, M. P. Sanchez-Seco, Y. Lussier, P. Formenty, M. S. Nichol, H. Feldmann, T. Briese, and W. I. Lipkin.2007. Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg. Infect. Dis.13:73-81.
    26.
    Schoub, B., and D. Martin.2006. Influenza pandemic preparedness. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/disease/influenza/southafricaplan.pdf.
    27.
    Schweiger, B., I. Zadow, R. Heckler, H. Timm, and G. Pauli.2000. Application of a fluorogenic PCR assay for typing and subtyping of influenza viruses in respiratory samples. J. Clin. Microbiol.38:1552-1558.
    28.
    Syrmis, M. W., D. M. Whiley, M. Thomas, I. M. Mackay, J. Williamson, D. J. Siebert, M. D. Nissen, and T. P. Sloots.2004. A sensitive, specific, and cost-effective multiplex reverse transcriptase-PCR assay for the detection of seven common respiratory viruses in respiratory samples. J. Mol. Diagn.6:125-131.
    29.
    Templeton, K. E., S. A. Scheltinga, M. F. Beersma, A. C. Kroes, and E. C. Claas.2004. Rapid and sensitive method using multiplex real-time PCR for diagnosis of infections by influenza A and influenza B viruses, respiratory syncytial virus, and parainfluenza viruses 1, 2, 3, and 4. J. Clin. Microbiol.42:1564-1569.
    30.
    Townsend, M. B., E. D. Dawson, M. Mehlmann, J. A. Smagala, D. M. Dankbar, C. L. Moore, C. B. Smith, N. J. Cox, R. D. Kuchta, and K. L. Rowlen.2006. Experimental evaluation of the FluChip diagnostic microarray for influenza virus surveillance. J. Clin. Microbiol.44:2863-2871.
    31.
    van Elden, L. J., A. M. van Loon, A. van der Beek, K. A. Hendriksen, A. I. Hoepelman, M. G. van Kraaij, P. Schipper, and M. Nijhuis.2003. Applicability of a real-time quantitative PCR assay for diagnosis of respiratory syncytial virus infection in immunocompromised adults. J. Clin. Microbiol.41:4378-4381.
    32.
    Wang, D., A. Urisman, Y. T. Liu, M. Springer, T. G. Ksiazek, D. D. Erdman, E. R. Mardis, M. Hickenbotham, V. Magrini, J. Eldred, J. P. Latreille, R. K. Wilson, D. Ganem, and J. L. DeRisi.2003. Viral discovery and sequence recovery using DNA microarrays. PLoS Biol.1:E2.
    33.
    Wang, Z., L. T. Daum, G. J. Vora, D. Metzgar, E. A. Walter, L. C. Canas, A. P. Malanoski, B. Lin, and D. A. Stenger.2006. Identifying influenza viruses with resequencing microarrays. Emerg. Infect. Dis.12:638-646.
    34.
    Williams, B. G., E. Gouws, C. Boschi-Pinto, J. Bryce, and C. Dye.2002. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect. Dis.2:25-32.
    35.
    Zhai, J., T. Briese, E. Dai, X. Wang, X. Pang, Z. Du, H. Liu, J. Wang, H. Wang, Z. Guo, Z. Chen, L. Jiang, D. Zhou, Y. Han, O. Jabado, G. Palacios, W. I. Lipkin, and R. Tang.2004. Real-time polymerase chain reaction for detecting SARS coronavirus, Beijing, 2003. Emerg. Infect. Dis.10:300-303.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 45Number 8August 2007
    Pages: 2359 - 2364

    History

    Received: 4 April 2007
    Revision received: 15 May 2007
    Accepted: 21 May 2007
    Published online: 6 June 2007

    Permissions

    Request permissions for this article.

    Contributors

    Authors

    Phenix-Lan Quan
    Jerome L. and Dawn Greene Infectious Disease Laboratory, Mailman School of Public Health, Columbia University, New York, New York
    Gustavo Palacios
    Jerome L. and Dawn Greene Infectious Disease Laboratory, Mailman School of Public Health, Columbia University, New York, New York
    Omar J. Jabado
    Jerome L. and Dawn Greene Infectious Disease Laboratory, Mailman School of Public Health, Columbia University, New York, New York
    Sean Conlan
    Jerome L. and Dawn Greene Infectious Disease Laboratory, Mailman School of Public Health, Columbia University, New York, New York
    David L. Hirschberg
    Stanford School of Medicine, Palo Alto, California
    Francisco Pozo
    Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Madrid, Spain
    Philippa J. M. Jack
    CSIRO Livestock Industries, Australian Animal Health Laboratory, Victoria, Australia
    Daniel Cisterna
    Instituto Nacional de Enfermedades Infecciosas, ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina
    Neil Renwick
    Jerome L. and Dawn Greene Infectious Disease Laboratory, Mailman School of Public Health, Columbia University, New York, New York
    Jeffrey Hui
    Jerome L. and Dawn Greene Infectious Disease Laboratory, Mailman School of Public Health, Columbia University, New York, New York
    Andrew Drysdale
    Jerome L. and Dawn Greene Infectious Disease Laboratory, Mailman School of Public Health, Columbia University, New York, New York
    Rachel Amos-Ritchie
    CSIRO Livestock Industries, Australian Animal Health Laboratory, Victoria, Australia
    Elsa Baumeister
    Instituto Nacional de Enfermedades Infecciosas, ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina
    Vilma Savy
    Instituto Nacional de Enfermedades Infecciosas, ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina
    Kelly M. Lager
    National Animal Disease Center, USDA, Ames, Iowa
    Jürgen A. Richt
    National Animal Disease Center, USDA, Ames, Iowa
    David B. Boyle
    CSIRO Livestock Industries, Australian Animal Health Laboratory, Victoria, Australia
    Adolfo García-Sastre
    Department of Microbiology and Emerging Pathogens Institute, Mount Sinai School of Medicine, New York, New York
    Inmaculada Casas
    Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Madrid, Spain
    Pilar Perez-Breña
    Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Madrid, Spain
    Thomas Briese
    Jerome L. and Dawn Greene Infectious Disease Laboratory, Mailman School of Public Health, Columbia University, New York, New York
    Jerome L. and Dawn Greene Infectious Disease Laboratory, Mailman School of Public Health, Columbia University, New York, New York

    Notes

    Supplemental material for this article may be found at http://jcm.asm.org/.

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Clinical Performance of the Novel GenMark Dx ePlex Blood Culture ID Gram-Positive Panel

    ABSTRACT

    Rapid identification from positive blood cultures is standard of care (SOC) in many clinical microbiology laboratories. The GenMark Dx ePlex Blood Culture Identification Gram-Positive (BCID-GP) Panel is a multiplex nucleic acid amplification assay based on competitive DNA hybridization and electrochemical detection using eSensor technology. This multicenter study compared the investigational-use-only (IUO) BCID-GP Panel to other methods of identification of 20 Gram-positive bacteria, four antimicrobial resistance genes, and both Pan Candida and Pan Gram-Negative targets that are unique to the BCID-GP Panel. Ten microbiology laboratories throughout the United States collected residual, deidentified positive blood culture samples for analysis. Five laboratories tested both clinical and contrived samples with the BCID-GP Panel. Comparator identification methods included each laboratory’s SOC, which included matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) and automated identification systems as well as targeted PCR/analytically validated real-time PCR (qPCR) with bidirectional sequencing. A total of 2,342 evaluable samples (1,777 clinical and 565 contrived) were tested with the BCID-GP Panel. The overall sample accuracy for on-panel organisms was 89% before resolution of discordant results. For pathogenic Gram-positive targets (Bacillus cereus group, Enterococcus spp., Enterococcus faecalis, Enterococcus faecium, Staphylococcus spp., Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Listeria spp., Listeria monocytogenes, Streptococcus spp., Streptococcus agalactiae, Streptococcus anginosus group, Streptococcus pneumoniae, and Streptococcus pyogenes), positive percent agreement (PPA) and negative percent agreement (NPA) ranged from 93.1% to 100% and 98.8% to 100%, respectively. For contamination rule-out targets (Bacillus subtilis group, Corynebacterium, Cutibacterium acnes, Lactobacillus, and Micrococcus), PPA and NPA ranged from 84.5% to 100% and 99.9% to 100%, respectively. Positive percent agreement and NPA for the Pan Candida and Pan Gram-Negative targets were 92.4% and 95.7% for the former and 99.9% and 99.6% for the latter. The PPAs for resistance markers were as follows: mecA, 97.2%; mecC, 100%; vanA, 96.8%; and vanB, 100%. Negative percent agreement ranged from 96.6% to 100%. In conclusion, the ePlex BCID-GP Panel compares favorably to SOC and targeted molecular methods for the identification of 20 Gram-positive pathogens and four antimicrobial resistance genes in positive blood culture bottles. This panel detects a broad range of pathogens and mixed infections with yeast and Gram-negative organisms from the same positive blood culture bottle.

    REFERENCES

    1.
    Xu J, Murphy SL, Kochanek KC, Bastian B, Arias E. 2018. Deaths: final data for 2016. Natl Vital Stat Rep 67:1–77.
    2.
    Vallés J, Palomar M, Alvárez-Lerma F, Rello J, Blanco A, Garnacho-Montero J, Martín-Loeches I, GTEI/SEMICYUC Working Group on Bacteremia. 2013. Evolution over a 15-year period of clinical characteristics and outcomes of critically ill patients with community-acquired bacteremia. Crit Care Med 41:76–83.
    3.
    de Kraker ME, Jarlier V, Monen JC, Heuer OE, van de Sande N, Grundmann H. 2013. The changing epidemiology of bacteremias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect 19:860–868.
    4.
    Buetti N, Atkinson A, Marschall J, Kronenberg A, Swiss Centre for Antibiotic Resistance (ANRESIS). 2017. Incidence of bloodstream infections: a nationwide surveillance of acute care hospitals in Switzerland 2008–2014. BMJ Open 7:e013665.
    5.
    Sogaard M, Norgaard M, Dethlefsen C, Schonheyder HC. 2011. Temporal changes in the incidence and 30-day mortality associated with bacteremia in hospitalized patients from 1992 through 2006: a population-based cohort study. Clin Infect Dis 52:61–69.
    6.
    Goto M, Al-Hasan MN. 2013. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect 19:50C1-09.
    7.
    Zasowski EJ, Claeys KC, Lagnf AM, Davis SL, Rybak MJ. 2016. Time is of the essence: the impact of delayed antibiotic therapy on patient outcomes in hospital-onset enterococcal bloodstream infections. Clin Infect Dis 62:1242–1250.
    8.
    Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. 2003. Community-acquired bloodstream infection in critically ill adult patients. Chest 123:1615–1624.
    9.
    Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596.
    10.
    Retamar P, Portillo MM, López-Prieto MD, Rodríguez-López F, de Cueto M, García MV, Gómez MJ, Del Arco A, Muñoz A, Sánchez-Porto A, Torres-Tortosa M, Martín-Aspas A, Arroyo A, García-Figueras C, Acosta F, Corzo JE, León-Ruiz L, Escobar-Lara T, Rodríguez-Baño J, SAEI/SAMPAC Bacteremia Group. 2012. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother 56:472–478.
    11.
    Avdic E, Wang R, Li DX, Tamma PD, Shulder SE, Carroll KC, Cosgrove SE. 2017. Sustained impact of a rapid microarray-based assay with antimicrobial stewardship interventions on optimizing therapy in patients with Gram-positive bacteraemia. J Antimicrob Chemother 72:3191–3198.
    12.
    Banerjee R, Teng CB, Cunningham SA, Ihde SM, Steckelberg JM, Moriarty JP, Shah ND, Mandrekar JN, Patel R. 2015. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis 61:1071–1080.
    13.
    Neuner EA, Pallotta AM, Lam SW, Stowe D, Gordon SM, Procop GW, Richter SS. 2016. Experience with rapid microarray-based diagnostic technology and antimicrobial stewardship for patients with gram-positive bacteremia. Infect Control Hosp Epidemiol 37:1361–1366.
    14.
    Messacar K, Hurst AL, Child J, Campbell K, Palmer C, Hamilton S, Dowell E, Robinson CC, Parker SK, Dominguez SR. 2017. Clinical impact and provider acceptability of real-time antimicrobial stewardship decision support for rapid diagnostics in children with positive blood culture results. J Pediatric Infect Dis Soc 6:267–274.
    15.
    Timbrook TT, Morton JB, McConeghy KW, Caffrey AR, Mylonakis E, LaPlante KL. 2017. The effect of molecular rapid diagnostic testing on clinical and outcomes in bloodstream infections: a systematic review and meta-analysis. Clin Infect Dis 64:15–23.
    16.
    Osthoff M, Gurtler N, Bassetti S, Balestra G, Marsch S, Pargger H, Weisser M, Egli A. 2017. Impact of MALDI-TOF-MS-based identification directly from positive blood cultures on patient management: a controlled clinical trial. Clin Microbiol Infect 23:78–85.
    17.
    Scohy A, Noel A, Boeras A, Brassinne L, Laurent T, Rodriguez-Villalobos H, Verroken A. 2018. Evaluation of the Bruker MBT Sepsityper IVD module for the identification of polymicrobial blood cultures with MALDI-TOF MS. Eur J Clin Microbiol Infect Dis doi:
    18.
    Ledeboer NA, Lopansri BK, Dhiman N, Cavagnolo R, Carroll KC, Granato P, Thomson R, Jr, Butler-Wu SM, Berger H, Samuel L, Pancholi P, Swyers L, Hansen GT, Tran NK, Polage CR, Thomson KS, Hanson ND, Winegar R, Buchan BW. 2015. Identification of gram-negative bacteria and genetic resistance determinants from positive blood culture broths by use of the Verigene gram-negative blood culture multiplex microarray-based molecular assay. J Clin Microbiol 3:2460–2472.
    19.
    Altun O, Almuhayawi M, Ullberg M, Ozenci V. 2013. Clinical evaluation of the FilmArray blood culture identification panel in identification of bacteria and yeasts from positive blood cultures. J Clin Microbiol 51:4130–4136.
    20.
    Schmitz JE, Tang YW. 2018. The GenMark ePlex®: another weapon in the syndromic arsenal for infection diagnosis. Future Microbiol 13:1697–1708.
    21.
    Bernard K. 2012. The genus Corynebacterium and other medically relevant coryneform-like bacteria. J Clin Microbiol 50:3152–3158.
    22.
    Spanu T, Sanguinetti M, Ciccaglione D, D’Inzeo T, Romano L, Leone F, Fadda G. 2003. Use of the VITEK 2 system for rapid identification of clinical isolates of staphylococci from bloodstream infections. J Clin Microbiol 41:4259–4263.
    23.
    Kocsubé S, Tóth M, Vágvölgyi C, Dóczi I, Pesti M, Pócsi I, Szabó J, Varga J. 2007. Occurrence and genetic variability of Candida parapsilosis sensu lato in Hungary. J Med Microbiol 56:190–195.
    24.
    Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. 2008. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to closely related species Candida parapsilosis. J Clin Microbiol 46:2659–2664.
    25.
    Salimnia H, Fairfax MR, Lephart PR, Schreckenberger P, Desjarlais SM, Johnson JK, Robinson G, Carroll KC, Greer A, Morgan M, Chan R, Loeffelholz M, Valencia-Shelton F, Jenkins S, Schuetz AN, Daly JA, Barney T, Hemmert A, Kanack KJ. 2016. Evaluation of the FilmArray blood culture identification panel: results of a multicenter controlled trial. J Clin Microbiol 54:687–698.
    26.
    Buchan BW, Ginocchio CC, Manii R, Cavagnolo R, Pancholi P, Swyers L, Thomson RB, Anderson C, Kaul K, Ledeboer NA. 2013. Multiplex identification of Gram-positive bacteria and resistance determinants directly from positive blood culture broths: evaluation of an automated microarray-based nucleic acid test. PLoS Med 10:e1001478.
    27.
    Ganesan A, Crawford K, Mende K, Murray CK, Lloyd B, Ellis M, Tribble DR, Weintrob AC. 2013. Evaluation for a novel methicillin resistance (mecC) homologue in methicillin-resistant Staphylococcus aureus isolates obtained from injured military personnel. J Clin Microbiol 51:3073–3075.
    28.
    Mendes RE, Watters AA, Rhomberg PR, Farrell DJ, Jones RN. 2016. Performance of the BD Max StaphSR for screening of methicillin-resistant Staphylococcus aureus isolates among a contemporary and diverse collection from 146 institutions located in nine U.S. Census regions: prevalence of mecA dropout mutants. J Clin Microbiol 54:204–207.
    29.
    Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Kumar A, Simon D, Peters C, Ahsan M, Chateau D, Cooperative Antimicrobial Therapy of Septic Shock Database Research Group. 2009. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136:1237–1248.
    30.
    Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. 2003. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31:2742–2751.
    31.
    Sinha M, Jupe J, Mack H, Coleman TP, Lawrence SM, Fraley SI. 2018. Emerging technologies for molecular diagnosis of sepsis. Clin Microbiol Rev 31:e00089-17.
    32.
    Peker N, Couto N, Sinha B, Rossen JW. 2018. Diagnosis of bloodstream infections from positive blood cultures and directly from blood samples: recent developments in molecular approaches. Clin Microbiol Infect 24:944–955.
    33.
    Ramanan P, Bryson AL, Binnicker MJ, Pritt BS, Patel R. 2018. Syndromic panel-based testing in clinical microbiology. Clin Microbiol Rev 31:e00024-17.
    34.
    Huang TD, Melnik E, Bogaerts P, Evrard S, Glupczynski Y. 2018. Evaluation of the ePlex blood culture identification panels for detection of pathogens in bloodstream infections. J Clin Microbiol 57:e01597-18.
    35.
    Ward C, Stocker K, Begum J, Wade P, Ebrahimsa U, Goldenberg SD. 2015. Performance evaluation of the Verigene (Nanosphere) and FilmArray (BioFire) molecular assays for identifications of causative organisms in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis 34:487–496.
    36.
    Bhatti MM, Boonlayangoor S, Beavis KG, Tesic V. 2014. Rapid identification of positive blood cultures by matrix-assisted laser desorption ionization-time of flight mass spectrometry using prewarmed agar plates. J Clin Microbiol 52:4334–4338.
    37.
    Bottone EJ. 2010. Bacillus cereus, a volatile human pathogen. Clin Microbiol Rev 23:382–398.
    38.
    Tusgul S, Prod'hom G, Senn L, Meuli R, Bochud P-Y, Giulieri SG. 2017. Bacillus cereus bacteraemia: comparison between haematologic and nonhaemotological patients. New Microbes New Infect 15:65–71.
    39.
    Lassmann B, Gustafson DR, Wood CM, Rosenblatt JE. 2007. Reemergence of anaerobic bacteremia. Clin Infect Dis 44:895–900.
    40.
    Simmon KE, Mirrett S, Reller LB, Petti CA. 2008. Genotypic diversity of anaerobic isolates from bloodstream infections. J Clin Microbiol 46:1596–1601.
    41.
    Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, Reller LB. 1997. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 24:584–602.
    42.
    Stevens DL, Aldape MJ, Bryant AE. 2012. Life-threatening clostridial infections. Anaerobe 18:254–259.
    43.
    Ny P, Ozaki A, Pallares J, Nieberg P, Wong-Beringer A. 2019. Antimicrobial stewardship opportunities in patients with bacteremia not identified by BioFire FilmArray. J Clin Microbiol 57:e01941-18.
    44.
    Sango A, McCarter YS, Johnson D, Ferreira J, Guzman N, Jankowski CA. 2013. Stewardship approach for optimizing antimicrobial therapy through use of a rapid microarray assay on blood cultures positive for Enterococcus species. J Clin Microbiol 51:4008–4011.
    45.
    Roshdy DG, Tran A, LeCroy N, Zeng D, Ou FS, Daniels LM, Weber DJ, Alby K, Miller MB. 2015. Impact of a rapid microarray-based assay for identification of positive blood cultures for treatment optimization for patients with streptococcal and enterococcal bacteremia. J Clin Microbiol 53:1411–1414.
    46.
    Miller WR, Munita JM, Arias CA. 2014. Mechanisms of antibiotic resistance in enterococci. Expert Rev Anti Infect Ther 12:1221–1236.
    47.
    Taha L, Stegger M, Soderquist B. 2019. Staphylococcus lugdunensis: antimicrobial susceptibility and optimal treatment options. Eur J Clin Microbiol Infect Dis 38:1449–1455.
    48.
    Lakhundi S, Zhang K. 2018. Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology. Clin Microbiol Rev 31:e00020-18.
    49.
    Garcia-Alvarez L, Holden MT, Lindsay G, Webb CR, Brown DF, Curran MD, Walpole E, Brooks K, Pickard DJ, Teale C, Parkhill J, Bentley SD, Edwards GF, Girvan EK, Kearns AM, Pichon B, Hill RL, Larsen AR, Skov LR, Peacock SJ, Maskell DJ, Holmes MA. 2011. Methicillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study. Lancet Infect Dis 11:595–603.
    50.
    Shore AC, Deasy EC, Slickers P, Brennan G, O'Connell B, Monecke S, Ehricht R, Coleman DC. 2011. Detection of staphylococcal cassette chromosome mec type XI carrying highly divergent mecA, mecI, mecR1, blaZ, and ccr genes in human clinical isolates of clonal complex 130 methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 55:3765–3773.
    51.
    Garcia-Garrote F, Cercenado E, Marin M, Bal M, Trincado P, Corredoira J, Ballesteros C, Pita J, Alonso P, Vindel A. 2014. Methicillin-resistant Staphylococcus aureus carrying the mecC gene: emergence in Spain and report of a fatal case of bacteraemia. J Antimicrob Chemother 69:45–50.
    52.
    Kerschner H, Harrison EM, Hartl R, Holmes MA, Apfalter P. 2015. First report of mecC MRSA in human samples from Austria: molecular characteristics and clinical data. New Microbes New Infect 3:4–9.
    53.
    Romero-Gómez MP, Mora-Rillo M, Lázaro-Perona F, Gómez-Gil MR, Mingorance J. 2013. Bacteraemia due to methicillin-resistant Staphylococcus aureus carrying the mecC gene in a patient with urothelial carcinoma. J Med Microbiol 62:1914–1916.
    54.
    Dupieux C, Bouchiat C, Larsen AR, Pichon B, Holmes M, Teale C, Edwards G, Hill R, Decousser JW, Trouillet-Assant S, Petersen A, Skov R, Kearns A, Laurent F. 2017. Detection of mecC-positive Staphylococcus aureus: what to expect from immunological tests targeting PBP2a? J Clin Microbiol 55:1961–1963.
    55.
    Kriegeskorte A, Idelevich EA, Schlattmann A, Layer F, Strommenger B, Denis O, Paterson GK, Holmes MA, Werner G, Becker K. 2017. Comparison of different phenotypic approaches to screen and detect mecC-harboring methicillin-resistant Staphylococcus aureus. J Clin Microbiol 56:e00826-17.
    56.
    MacVane SH, Nolte FS. 2016. Benefits of adding a rapid PCR-based blood culture identification panel to an established antimicrobial stewardship program. J Clin Microbiol 54:2455–2463.
    57.
    Bates DW, Goldman L, Lee TH. 1991. Contaminant blood cultures and resource utilization: the true consequences of false-positive results. JAMA 265:365–369.
    58.
    Souvenir D, Anderson DE, Palpant S, Mroch H, Askin S, Anderson J, Claridge J, Eiland J, Malone C, Garrison MW, Watson P, Campbell DM. 1998. Blood cultures positive for coagulase-negative staphylococci: antisepsis, pseudobacteremia, and therapy of patients. J Clin Microbiol 36:1923–1926.
    59.
    Lee CC, Lin WJ, Shih HI, Wu CH, Chen PL, Lee HC, Lee NY, Chang CM, Wang LR, Ko WC. 2007. Clinical significance of potential contaminants in blood cultures among patients in a medical center. J Microbiol Immunol Infect 40:438–444.
    60.
    van der Heijden YF, Miller G, Wright PW, Shepherd BE, Daniels TL, Talbot TR. 2011. Clinical impact of blood cultures contaminated with coagulase-negative staphylococci at an academic medical center. Infect Control Hosp Epidemiol 32:623–625.
    61.
    Bekeris LG, Tworke JA, Walsh MK, Valenstein PN. 2005. Trends in blood culture contamination: a College of American Pathologists Q-Tracks study of 356 institutions. Arch Pathol Lab Med 129:1222–1225.
    62.
    Zwang O, Albert RK. 2006. Analysis of strategies to improve cost effectiveness in blood cultures. J Hosp Med 1:272–276.
    63.
    Alahmadi YM, Aldeyab MA, McElnay JC, Scott MG, Darwish Elhajji FW, Magee FA, Dowds M, Edwards C, Fullerton L, Tate A, Kearney MP. 2011. Clinical and economic impact of contaminated blood cultures within the hospital setting. J Hosp Infect 77:233–236.
    64.
    Dodemont M, De Mendonca R, Nonhoff C, Roisin S, Denis O. 2015. Evaluation of Verigene Gram-positive blood culture assay performance for bacteremic patients. Eur J Clin Microbiol Infect Dis 34:473–477.
    65.
    Timbrook T, Boger MS, Steed LL, Hurst JM. 2015. Unanticipated multiplex PCR identification of polymicrobial blood culture resulting in earlier isolation, susceptibilities, and optimization of clinical care. J Clin Microbiol 53:2371–2373.
    66.
    Claeys KC, Heil EL, Pogue JM, Lephart PR, Johnson JK. 2018. The Verigene dilemma: Gram-negative polymicrobial bloodstream infections and clinical decision making. Diagn Microbiol Infect Dis 91:144–146.
    67.
    Samuel LP, Balada-Llasat JM, Harrington A, Cavagnolo R. 2016. Multicenter assessment of Gram stain error rates. J Clin Microbiol 54:442–1447.
    68.
    Rand KH, Tillan M. 2006. Errors in the interpretation of Gram stains from positive blood cultures. Am J Clin Pathol 126:686–690.
    69.
    She RC, Bender JM. 2019. Advances in rapid molecular blood culture diagnostics: healthcare impact, laboratory implications, and multiplex technologies. J Appl Lab Med 3:617–630.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 58Number 425 March 2020
    eLocator: e01730-19
    Editor: Sandra S. Richter
    bioMérieux

    History

    Received: 12 October 2019
    2 November 2019
    Accepted: 18 January 2020
    Published online: 29 January 2020

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. blood culture
    2. eSensor technology
    3. Gram-positive bacteria
    4. identification
    5. multiplex nucleic acid test
    6. resistance marker

    Contributors

    Authors

    Karen C. Carroll
    Division of Medical Microbiology, Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Jennifer L. Reid
    GenMark Diagnostics Inc., Carlsbad, California, USA
    Adam Thornberg
    GenMark Diagnostics Inc., Carlsbad, California, USA
    GenMark Diagnostics Inc., Carlsbad, California, USA
    Deirdre Trainor
    GenMark Diagnostics Inc., Carlsbad, California, USA
    Shawna Lewis
    Division of Medical Microbiology, Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Teresa Wakefield
    Division of Medical Microbiology, Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Thomas E. Davis
    Indiana University School of Medicine, Indianapolis, Indiana, USA
    Keisha G. Church
    Medical University of South Carolina, Charleston, South Carolina, USA
    Linoj Samuel
    Henry Ford Health System, Detroit, Michigan, USA
    Ray Mills
    Tricore Reference Laboratories, Albuquerque, New Mexico, USA
    Patricia Jim
    Tricore Reference Laboratories, Albuquerque, New Mexico, USA
    Stephen Young
    Tricore Reference Laboratories, Albuquerque, New Mexico, USA
    Frederick S. Nolte
    Medical University of South Carolina, Charleston, South Carolina, USA

    Editor

    Sandra S. Richter
    Editor
    bioMérieux

    Notes

    Address correspondence to Karen C. Carroll, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Genomic Surveillance Enables Suitability Assessment of Salmonella Gene Targets Used for Culture-Independent Diagnostic Testing

    ABSTRACT

    Salmonella is a highly diverse genus consisting of over 2,600 serovars responsible for high-burden food- and waterborne gastroenteritis worldwide. Sensitivity and specificity of PCR-based culture-independent diagnostic testing (CIDT) systems for Salmonella, which depend on a highly conserved gene target, can be affected by single nucleotide polymorphisms (SNPs), indels, and genomic rearrangements within primer and probe sequences. This report demonstrates the value of prospectively collected genomic data for verifying CIDT targets. We utilized the genomes of 3,165 Salmonella isolates prospectively collected and sequenced in Australia. The sequences of Salmonella CIDT PCR gene targets (ttrA, spaO, and invA) were systematically interrogated to measure nucleotide dissimilarity. Analysis of 52 different serovars and 79 multilocus sequencing types (MLST) demonstrated dissimilarity within and between PCR gene targets ranging between 0 and 81.3 SNP/kbp (0 and 141 SNPs). The lowest average dissimilarity was observed in the ttrA target gene used by the Roche LightMix at 2.0 SNP/kbp (range, 0 to 46.7); however, entropy across the gene demonstrates that it may not be the most stable CIDT target. While debate continues over the benefits and pitfalls of replacing bacterial culture with molecular assays, the growing volumes of genomic surveillance data enable periodic regional reassessment and validation of CIDT targets against both prevalent and emerging serovars. If PCR systems are to become the primary screening and diagnostic tool for laboratory diagnosis of salmonellosis, ongoing monitoring of the genomic diversity in PCR target regions is warranted, as is the potential inclusion of two Salmonella PCR targets in frontline diagnostic systems.

    REFERENCES

    1.
    Kirk MD, Pires SM, Black RE, Caipo M, Crump JA, Devleesschauwer B, Döpfer D, Fazil A, Fischer-Walker CL, Hald T, Hall AJ, Keddy KH, Lake RJ, Lanata CF, Torgerson PR, Havelaar AH, Angulo FJ. 2015. World Health Organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoal, and viral diseases, 2010: a data synthesis. PLoS Med 12:e1001921.
    2.
    Ashbolt R, Kirk MD. 2006. Salmonella Mississippi infections in Tasmania: the role of native Australian animals and untreated drinking water. Epidemiol Infect 134:1257–1265.
    3.
    Iveson JB, Bradshaw SD, Smith DW. 2017. The movement of humans and the spread of Salmonella into existing and pristine ecosystems. Microbiol Aust 38:201–203.
    4.
    Centers for Disease Control and Prevention. 2016. National enteric disease surveillance: Salmonella annual report, 2016. Centers for Disease Control and Prevention, Atlanta, GA.
    5.
    Berenger B, Chui L, Reimer AR, Allen V, Alexander D, Domingo M-C, Haldane D, Hoang L, Levett P, MacKeen A, Marcino D, Sheitoyan-Pesant C, Zahariadis G, Canadian Public Health Laboratory Network. 2017. Canadian Public Health Laboratory Network position statement: non-culture based diagnostics for gastroenteritis and implications for public health investigations. Can Commun Dis Rep 43:279–281.
    6.
    European Food Safety Authority. 2018. The European Union summary report on trends and sources of zoonoses, zoonotic agents and food‐borne outbreaks in 2017. EFSA J 16:5500.
    7.
    The Institute of Environmental Science and Research Ltd. 2019. Notifiable diseases in New Zealand: annual report 2017. Institute of Environmental Science and Research Ltd., Porirua, New Zealand.
    8.
    May FJ, Stafford RJ, Carroll H, Robson JM, Vohra R, Nimmo GR, Bates J, Kirk MD, Fearnley EJ, Polkinghorne BG. 2017. The effects of culture independent diagnostic testing on the diagnosis and reporting of enteric bacterial pathogens in Queensland, 2010 to 2014. Commun Dis Intell Q Rep 41:E223–E230.
    9.
    Shea S, Kubota KA, Maguire H, Gladbach S, Woron A, Atkinson-Dunn R, Couturier MR, Miller MB. 2017. Clinical microbiology laboratories’ adoption of culture-independent diagnostic tests is a threat to foodborne-disease surveillance in the United States. J Clin Microbiol 55:10–19.
    10.
    Tack DM, Marder EP, Griffin PM, Cieslak PR, Dunn J, Hurd S, Scallan E, Lathrop S, Muse A, Ryan P, Smith K, Tobin-D'Angelo M, Vugia DJ, Holt KG, Wolpert BJ, Tauxe R, Geissler AL. 2019. Preliminary incidence and trends of infections with pathogens transmitted commonly through food—Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2015–2018. MMWR Morb Mortal Wkly Rep 68:369–373.
    11.
    Ripa T, Nilsson P. 2006. A variant of Chlamydia trachomatis with deletion in cryptic plasmid: implications for use of PCR diagnostic tests. Euro Surveill 11:E061109.2.
    12.
    Dahlberg J, Hadad R, Elfving K, Larsson I, Isaksson J, Magnuson A, Fredlund H, Unemo M, Herrmann B. 2018. Ten years transmission of the new variant of Chlamydia trachomatis in Sweden: prevalence of infections and associated complications. Sex Transm Infect 94:100–104.
    13.
    Whiley DM, Lambert SB, Bialasiewicz S, Goire N, Nissen MD, Sloots TP. 2008. False-negative results in nucleic acid amplification tests—do we need to routinely use two genetic targets in all assays to overcome problems caused by sequence variation? Crit Rev Microbiol 34:71–76.
    14.
    Besser JM. 2018. Salmonella epidemiology: a whirlwind of change. Food Microbiol 71:55–59.
    15.
    Sintchenko V, Holmes EC. 2015. The role of pathogen genomics in assessing disease transmission. BMJ 350:h1314.
    16.
    Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30:2114–2120.
    17.
    Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477.
    18.
    Gurevich A, Saveliev V, Vyahhi N, Tesler G. 2013. QUAST: quality assessment tool for genome assemblies. Bioinformatics 29:1072–1075.
    19.
    Yoshida CE, Kruczkiewicz P, Laing CR, Lingohr EJ, Gannon VPJ, Nash JHE, Taboada EN. 2016. The Salmonella In Silico Typing Resource (SISTR): an open web-accessible tool for rapidly typing and subtyping draft Salmonella genome assemblies. PLoS One 11:e0147101.
    20.
    Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30:2068–2069.
    21.
    Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, Fookes M, Falush D, Keane JA, Parkhill J. 2015. Roary: rapid large-scale prokaryote pan genome analysis. Bioinformatics 31:3691–3693.
    22.
    Nguyen LT, Schmidt HA, Von Haeseler A, Minh BQ. 2015. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol 32:268–274.
    23.
    Argimón S, Abudahab K, Goater RJE, Fedosejev A, Bhai J, Glasner C, Feil EJ, Holden MTG, Yeats CA, Grundmann H, Spratt BG, Aanensen DM. 2016. Microreact: visualizing and sharing data for genomic epidemiology and phylogeography. Microb Genom 2:e000093.
    24.
    Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. 2009. BLAST+: architecture and applications. BMC Bioinformatics 10:421–429.
    25.
    Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30:772–780.
    26.
    Keane JA, Page AJ, Delaney AJ, Taylor B, Seemann T, Harris SR, Soares J. 2016. SNP-sites: rapid efficient extraction of SNPs from multi-FASTA alignments. Microb Genom 2:e000056.
    27.
    Lefever S, Pattyn F, Hellemans J, Vandesompele J. 2013. Single-nucleotide polymorphisms and other mismatches reduce performance of quantitative PCR assays. Clin Chem 59:1470–1480.
    28.
    Cronquist AB, Mody RK, Atkinson R, Besser J, D’Angelo MT, Hurd S, Robinson T, Nicholson C, Mahon BE. 2012. Impacts of culture-independent diagnostic practices on public health surveillance for bacterial enteric pathogens. Clin Infect Dis 54:S432–S439.
    29.
    Communicable Diseases Branch. 2019. OzFoodNet NSW Annual Report: 2018. Health Protection NSW, Sydney, Australia.
    30.
    Whiley DM, Sloots TP. 2005. Sequence variation in primer targets affects the accuracy of viral quantitative PCR. J Clin Virol 34:104–107.
    31.
    Klungthong C, Chinnawirotpisan P, Hussem K, Phonpakobsin T, Manasatienkij W, Ajariyakhajorn C, Rungrojcharoenkit K, Gibbons RV, Jarman RG. 2010. The impact of primer and probe-template mismatches on the sensitivity of pandemic influenza A/H1N1/2009 virus detection by real-time RT-PCR. J Clin Virol 48:91–95.
    32.
    McLauchlin J, Aird H, Andrews N, Chattaway M, de Pinna E, Elviss N, Jørgensen F, Larkin L, Willis C. 2019. Public health risks associated with Salmonella contamination of imported edible betel leaves: analysis of results from England, 2011–2017. Int J Food Microbiol 298:1–10.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 58Number 924 August 2020
    eLocator: e00038-20
    Editor: John P. Dekker
    National Institute of Allergy and Infectious Diseases

    History

    Received: 9 January 2020
    7 February 2020
    Accepted: 13 June 2020
    Published online: 24 June 2020

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. culture-independent diagnostic testing
    2. pathogen genomics
    3. Salmonella
    4. public health

    Contributors

    Authors

    Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
    Centre for Infectious Diseases and Microbiology–Public Health, Westmead Hospital, Westmead, New South Wales, Australia
    Centre for Infectious Diseases and Microbiology–Public Health, Westmead Hospital, Westmead, New South Wales, Australia
    Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead, New South Wales, Australia
    Centre for Infectious Diseases and Microbiology–Public Health, Westmead Hospital, Westmead, New South Wales, Australia
    Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead, New South Wales, Australia
    Peter Howard
    Centre for Infectious Diseases and Microbiology–Public Health, Westmead Hospital, Westmead, New South Wales, Australia
    Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
    Centre for Infectious Diseases and Microbiology–Public Health, Westmead Hospital, Westmead, New South Wales, Australia
    Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead, New South Wales, Australia

    Editor

    John P. Dekker
    Editor
    National Institute of Allergy and Infectious Diseases

    Notes

    Address correspondence to Rebecca J. Rockett, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Advances in Molecular Diagnosis of Tuberculosis

    ABSTRACT

    Molecular tests for tuberculosis (TB) have the potential to help reach the three million people with TB who are undiagnosed or not reported each year and to improve the quality of care TB patients receive by providing accurate, quick results, including rapid drug-susceptibility testing. The World Health Organization (WHO) has recommended the use of molecular nucleic acid amplification tests (NAATs) tests for TB detection instead of smear microscopy, as they are able to detect TB more accurately, particularly in patients with paucibacillary disease and in people living with HIV. Importantly, some of these WHO-endorsed tests can detect mycobacterial gene mutations associated with anti-TB drug resistance, allowing clinicians to tailor effective TB treatment. Currently, a wide array of molecular tests for TB detection is being developed and evaluated, and while some tests are intended for reference laboratory use, others are being aimed at the point-of-care and peripheral health care settings. Notably, there is an emergence of molecular tests designed, manufactured, and rolled out in countries with high TB burden, of which some are explicitly aimed for near-patient placement. These developments should increase access to molecular TB testing for larger patient populations. With respect to drug susceptibility testing, NAATs and next-generation sequencing can provide results substantially faster than traditional phenotypic culture. Here, we review recent advances and developments in molecular tests for detecting TB as well as anti-TB drug resistance.

    REFERENCES

    1.
    World Health Organization. 2019. Global tuberculosis report 2019. World Health Organization, Geneva, Switzerland.
    2.
    World Health Organization. 2015. WHO End TB Strategy. World Health Organization, Geneva, Switzerland.
    3.
    Stop TB Partnership. 2020. The potential impact of the COVID-19 response on tuberculosis in high-burden countries: a modelling analysis. Stop TB Partnership, Geneva, Switzerland.
    4.
    Boyd R, Ford N, Padgen P, Cox H. 2017. Time to treatment for rifampicin-resistant tuberculosis: systematic review and meta-analysis. Int J Tuber Lung Dis 21:1173–1180.
    5.
    Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K. 2014. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 383:424–435.
    6.
    MacLean E, Broger T, Yerlikaya S, Fernandez-Carballo BL, Pai M, Denkinger CM. 2019. A systematic review of biomarkers to detect active tuberculosis. Nat Microbiol 4:748–758.
    7.
    Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, Metcalfe JZ, Cattamanchi A, Dowdy DW, Dheda K, Banaei N. 2014. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 27:3–20.
    8.
    Denkinger CM, Kik SV, Cirillo DM, Casenghi M, Shinnick T, Weyer K, Gilpin C, Boehme CC, Schito M, Kimerling M, Pai M. 2015. Defining the needs for next generation assays for tuberculosis. J Infect Dis 211:S29–S38.
    9.
    Denkinger CM, Dolinger D, Schito M, Wells W, Cobelens F, Pai M, Zignol M, Cirillo DM, Alland D, Casenghi M, Gallarda J, Boehme CC, Perkins MD. 2015. Target product profile of a molecular drug-susceptibility test for use in microscopy centers. J Infect Dis 211:S39–S49.
    10.
    Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. 2016. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J 48:516–525.
    11.
    Cazabon D, Pande T, Kik S, Van Gemert W, Sohn H, Denkinger C, Qin ZZ, Waning B, Pai M. 2018. Market penetration of Xpert MTB/RIF in high tuberculosis burden countries: a trend analysis from 2014–2016. Gates Open Res 2:35–38.
    12.
    Singhroy DN, MacLean E, Kohli M, Lessem E, Branigan D, England K, Suleiman K, Drain PK, Ruhwald M, Schumacher SG, Denkinger CM, Waning B, Van Gemert W, Pai M. 2020. Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers [version 1; peer review: 2 approved]. Gates Open Res 4:24.
    13.
    Pai M, Furin J. 2017. Tuberculosis innovations mean little if they cannot save lives. eLife 6:e25956.
    14.
    World Health Organization. 2008. Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis: policy statement. World Health Organization, Geneva, Switzerland.
    15.
    World Health Organization. 2016. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. World Health Organization, Geneva, Switzerland.
    16.
    World Health Organization. 2016. The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis: policy guidance. World Health Organization, Geneva, Switzerland.
    17.
    Shete PB, Farr K, Strnad L, Gray CM, Cattamanchi A. 2019. Diagnostic accuracy of TB-LAMP for pulmonary tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 19:268.
    18.
    World Health Organization. 2010. WHO endorses new rapid tuberculosis test. World Health Organization, Geneva, Switzerland.
    19.
    World Health Organization. 2013. Policy update. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. World Health Organization, Geneva, Switzerland.
    20.
    World Health Organization. 2017. Next-generation Xpert MTB/RIF Ultra assay recommended by WHO. World Health Organization, Geneva, Switzerland.
    21.
    World Health Organization. 2020. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis—rapid diagnostics for tuberculosis detection. World Health Organization, Geneva, Switzerland. https://www.who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection. Accessed 12 August 2020.
    22.
    Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, Schumacher SG, Ochodo EA, Pai M, Steingart KR. 2019. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 6:CD009593.
    23.
    Mishra H, Reeve BWP, Palmer Z, Caldwell J, Dolby T, Naidoo CC, Jackson JG, Schumacher SG, Denkinger CM, Diacon AH, van Helden PD, Marx FM, Warren RM, Theron G. 2020. Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study. Lancet Respir Med 8:P368–P382.
    24.
    Bahr NC, Nuwagira E, Evans EE, Cresswell FV, Bystrom PV, Byamukama A, Bridge SC, Bangdiwala AS, Meya DB, Denkinger CM, Muzoora C, Boulware DR, Williams DA, Taseera K, Nyehangane D, Ivan M, Orikiriza P, Rhein J, Hullsiek KH, Musubire A, Pastick K, Nabeta P, Mwesigye J, Rajasingham R, ASTRO-CM Trial Team. 2018. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis 18:68–75.
    25.
    Donovan J, Thu DDA, Phu NH, Dung VTM, Quang TP, Nghia HDT, Oanh PKN, Nhu TB, Chau NVV, Ha VTN, Hang VTT, Trinh DHK, Geskus RB, Tan LV, Thuong NTT, Thwaites GE. 2020. Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study. Lancet Infect Dis 20:299–307.
    26.
    Cresswell FV, Tugume L, Bahr NC, Kwizera R, Bangdiwala AS, Musubire AK, Rutakingirwa M, Kagimu E, Nuwagira E, Mpoza E, Rhein J, Williams DA, Muzoora C, Grint D, Elliott AM, Meya DB, Boulware DR. 2020. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infect Dis 20:P308–P317.
    27.
    Antel K, Oosthuizen J, Malherbe F, Louw VJ, Nicol MP, Maartens G, Verburgh E. 2020. Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis. BMC Infect Dis 20:33.
    28.
    Wang G, Wang S, Yang X, Sun Q, Jiang G, Huang M, Huo F, Ma Y, Chen X, Huang H. 2020. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest 157:268–275.
    29.
    Kohli M, Schiller I, Dendukuri N, Dheda K, Denkinger CM, Schumacher SG, Steingart KR. 2018. Xpert((R)) MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database Syst Rev 8:Cd012768.
    30.
    Pai M. 2020. Global health technologies: time to re-think the ‘trickle down’ model. Forbes.
    31.
    Indian Council of Medical Research. 2017. India moving forward in research towards new tools for tuberculosis, p 1–2. Government of India, New Delhi, India.
    32.
    Nikam C, Jagannath M, Narayanan MM, Ramanabhiraman V, Kazi M, Shetty A, Rodrigues C. 2013. Rapid diagnosis of Mycobacterium tuberculosis with Truenat MTB: a near-care approach. PLoS One 8:e51121.
    33.
    Xie YL, Chakravorty S, Armstrong DT, Hall SL, Via LE, Song T, Yuan X, Mo X, Zhu H, Xu P, Gao Q, Lee M, Lee J, Smith LE, Chen RY, Joh JS, Cho Y, Liu X, Ruan X, Liang L, Dharan N, Cho SN, Barry CE, III, Ellner JJ, Dorman SE, Alland D. 2017. Evaluation of a rapid molecular drug-susceptibility test for tuberculosis. N Engl J Med 377:1043–1054.
    34.
    World Health Organization. 2020. WHO consolidated guidelines on tuberculosis. Module 4: Treatment—drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland. who.int/publications/i/item/9789240007048. Accessed 2 July 2020.
    35.
    Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J, McHugh TD, Wills GH, Bateson A, Hunt R, Van Niekerk C, Li M, Olugbosi M, Spigelman M, Nix-TB Trial Team. 2020. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 382:893–902.
    36.
    Treatment Action Group. 2019. Pipeline report: tuberculosis diagnostics. Treatment Action Group, New York, NY.
    37.
    Ortega C, Wood R, Murton H, Andama A, Cattamanchi A, Dixon R, Morgan G, Madan D, Somoskovi A, Cangelose G. 2019. Diagnosis of pulmonary tuberculosis by oral swab analysis (OSA): optimisation and development of non-sputum, point-of-care methods. Int J Tuber Lung Dis 23:S211.
    38.
    Deng S, Sun Y, Xia H, Liu Z, Gao L, Yang J, Zhao Y, Huang F, Feng J, Wang L, Huan S, Zhan S. 2019. Accuracy of commercial molecular diagnostics for the detection of pulmonary tuberculosis in china: a systematic review. Sci Rep 9:4553.
    39.
    Sun Y, Gao L, Xia H, Yang Z, Deng S, Yang J, Zhao Y, Wang L, Feng J, Huang F, Huan S, Zhan S. 2019. Accuracy of molecular diagnostic tests for drug-resistant tuberculosis detection in China: a systematic review. Int J Tuber Lung Dis 23:931–942.
    40.
    Unitaid. 2017. UNITAID end-of-project evaluation: TB GeneXpert—scaling up access to contemporary diagnostics for TB. Unitaid, Geneva, Switzerland.
    41.
    Yan L, Tang S, Yang Y, Shi X, Ge Y, Sun W, Liu Y, Hao X, Gui X, Yin H, He Y, Zhang Q. 2016. A large cohort study on the clinical value of simultaneous amplification and testing for the diagnosis of pulmonary tuberculosis. Medicine (Baltimore, MD) 95:e2597.
    42.
    Pang Y, Dong H, Tan Y, Deng Y, Cai X, Jing H, Xia H, Li Q, Ou X, Su B, Li X, Zhang Z, Li J, Zhang J, Huan S, Zhao Y. 2016. Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China. Sci Rep 6:25330–25330.
    43.
    Guo Y, Zhou Y, Wang C, Zhu L, Wang S, Li Q, Jiang G, Zhao B, Huang H, Yu H, Xing W, Mitchelson K, Cheng J, Zhao Y. 2009. Rapid, accurate determination of multidrug resistance in M. tuberculosis isolates and sputum using a biochip system. Int J Tuber Lung Dis 13:914–920.
    44.
    Nathavitharana RR, Cudahy PGT, Schumacher SG, Steingart KR, Pai M, Denkinger CM. 2017. Under review. Diagnostic accuracy of centralized assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis. Eur Respir J 49:1601075.
    45.
    World Health Organization. 2019. Evaluation of centralized assays for TB detection and detection of resistance to rifampicin and isoniazid: WHO Technical Expert Consultation Report. World Health Organization, Geneva, Switzerland.
    46.
    Tang N, Frank A, Pahalawatta V, Lampinen J, Coblenz-Korte A, Dunn C, Li C, Cloherty G, Abravaya K, Leckie G. 2015. Analytical and clinical performance of Abbott RealTime MTB, an assay for detection of Mycobacterium tuberculosis in pulmonary specimens. Tuberculosis (Edinb) 95:613–619.
    47.
    Hofmann-Thiel S, Hoffman H. 2014. Evaluation of Fluorotype MTB for detection of Mycobacterium tuberculosis complex DNA in clinical specimens from a low-incidence country. BMC Infect Dis 14:59.
    48.
    Roche Molecular Systems. 2018. Cobas(R) MTB: nucleic acid test for use on the Cobas(R) 6800/8800 systems. Roche Molecular Systems, Basel, Switzerland.
    49.
    Rocchetti TT, Silbert S, Gostnell A, Kubasek C, Widen R. 2016. Validation of a multiplex real-time PCR assay for detection of Mycobacterium spp., Mycobacterium tuberculosis complex, and Mycobacterium avium complex directly from clinical samples by use of the BD Max open system. J Clin Microbiol 54:1644–1647.
    50.
    Shah M, Paradis S, Betz J, Beylis N, Bharadwaj R, Caceres T, Gotuzzo E, Joloba M, Mave V, Nakiyingi L, Nicol MP, Pradhan N, King B, Armstrong D, Knecht D, Maus CE, Cooper CK, Dorman SE, Manabe YC. 2019. Multicenter study of the accuracy of the BD MAX MDR-TB assay for detection of Mycobacterium tuberculosis complex and mutations associated with resistance to rifampin and isoniazid. Clin Infect Dis ciz932.
    51.
    FIND. 2020. Diagnostics pipeline tracker: tuberculosis, on FIND. https://www.finddx.org/dx-pipeline-status/.
    52.
    Lee RS, Pai M. 2017. Real-time sequencing of Mycobacterium tuberculosis: are we there yet? J Clin Microbiol 55:1249–1254.
    53.
    Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, Iqbal Z, Feuerriegel S, Niehaus KE, Wilson DJ, Clifton DA, Kapatai G, Ip CLC, Bowden R, Drobniewski FA, Allix-Béguec C, Gaudin C, Parkhill J, Diel R, Supply P, Crook DW, Smith EG, Walker AS, Ismail N, Niemann S, Peto TEA, Modernizing Medical Microbiology (MMM) Informatics Group. 2015. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 15:1193–1202.
    54.
    World Health Organization. 2018. Technical guide on next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex. World Health Organization, Geneva, Switzerland.
    55.
    World Health Organization. 2019. Relational sequencing TB data platform [website]. World Health Organization, Geneva, Switzerland.
    56.
    El-Halfawy OM, Valvano MA. 2015. Antimicrobial heteroresistance: an emerging field in need of clarity. Clin Microbiol Rev 28:191–207.
    57.
    Genoscreen. 2019. Deeplex(R) Myc-TB: from clinical samples to drug resistance profile. Genoscreen, Lille, France.
    58.
    Yozwiak S. 2019. TGen and ABL plan global rollout of advanced test for TB, one of the world's most deadly pathogens. TGen, Phoenix, AZ.
    59.
    Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, Andres S, Barbova A, Borbe-Reyes A, Chin DP, Cirillo DM, Colvin C, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Hussain A, Ismail N, Kamal SMM, Khanzada FM, Kimerling M, Kohl TA, Mansjo M, Miotto P, Mukadi YD, Mvusi L, Niemann S, Omar SV, Rigouts L, Schito M, Sela I, Seyfaddinova M, Skenders G, Skrahina A, Tahseen S, Wells WA, Zhurilo A, Weyer K, Floyd K, Raviglione MC. 2018. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. Lancet Infect Dis 18:675–683.
    60.
    Meehan CJ, Goig GA, Kohl TA, Verboven L, Dippenaar A, Ezewudo M, Farhat MR, Guthrie JL, Laukens K, Miotto P, Ofori-Anyinam B, Dreyer V, Supply P, Suresh A, Utpatel C, van Soolingen D, Zhou Y, Ashton PM, Brites D, Cabibbe AM, de Jong BC, de Vos M, Menardo F, Gagneux S, Gao Q, Heupink TH, Liu Q, Loiseau C, Rigouts L, Rodwell TC, Tagliani E, Walker TM, Warren RM, Zhao Y, Zignol M, Schito M, Gardy J, Cirillo DM, Niemann S, Comas I, Van Rie A. 2019. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nat Rev Microbiol 17:533–545.
    61.
    Shea J, Halse TA, Lapierre P, Shudt M, Kohlerschmidt D, Van Roey P, Limberger R, Taylor J, Escuyer V, Musser KA. 2017. Comprehensive whole-genome sequencing and reporting of drug resistance profiles on clinical cases of Mycobacterium tuberculosis in New York State. J Clin Microbiol 55:1871–1882.
    62.
    Armstrong GL, MacCannell DR, Taylor J, Carleton HA, Neuhaus EB, Bradbury RS, Posey JE, Gwinn M. 2019. Pathogen genomics in public health. N Engl J Med 381:2569–2580.
    63.
    Revised National Tuberculosis Control Programme. 2017. National strategic plan for tuberculosis elimination 2017–2025. Directorate General of Health Services, New Delhi, India.
    64.
    National Institute for Communicable Diseases. 2018. National Institute for Communicable Diseases annual overview 2018/2019. National Institute for Communicable Diseases, Capetown, South Africa.
    65.
    Fiocruz de Notícias A. 2018. Fiocruz establishes partnership with Chinese scientific institutions. Oswaldo Cruz Foundation, São Paulo, Brazil.
    66.
    Cabibbe AM, Battaglia S, Spitaleri A, Suresh A, Colman RE, Uplekar S, Rodwell TC, Cirillo DM. 2019. A portable real-time solution for next generation sequencing-based diagnosis of drug-resistant tuberculosis direct from clinical samples. Int J Tuber Lung Dis 23:S268.
    67.
    Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, Lemmer D, Engelthaler DM, Catanzaro DG, Young AG, Denkinger CM, Rodwell TC. 2019. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: a performance, ease-of-use, and cost evaluation. PLoS Med 16:e1002794.
    68.
    Venkatesan P. 2020. COVID-19 diagnostics—not at the expense of other diseases. Lancet Microbe 1:e64.
    69.
    Amimo F, Lambert B, Magit A. 2020. What does the COVID-19 pandemic mean for HIV, tuberculosis, and malaria control? Trop Med Health 48:32.
    70.
    United States Food and Drug Administration. 2020. Coronavirus (COVID-19) update: FDA issues first emergency use authorization for point of care diagnostic. United States Food and Drug Administration, Atlanta, GA.
    71.
    Moore NM, Li H, Schejbal D, Lindsley J, Hayden MK. 2020. Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCoV RT-PCR assay for the detection of SARS-CoV-2. J Clin Microbiol 58:e00938-20.
    72.
    Broder K, Babiker A, Myers C, White T, Jones H, Cardella J, Burd EM, Hill CE, Kraft CS. 2020. Test agreement between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 assays at high cycle threshold ranges. J Clin Microbiol 58:e01187-20.
    73.
    Molbio Diagnostics Private Limited. 2020. New Launch: truenat SARS CoV-2 chip-based real time PCR test for COVID-19. Molbio Diagnostics Private Limited, Goa, India.
    74.
    Lessells RJ, Cooke GS, McGrath N, Nicol MP, Newell ML, Godfrey-Faussett P. 2017. Impact of point-of-care Xpert MTB/RIF on tuberculosis treatment initiation. A cluster-randomized trial. Am J Respir Crit Care Med 196:901–910.
    75.
    Pereira GR, Barbosa MS, Dias NJD, Almeida CPB, Silva DR. 2018. Impact of introduction of Xpert MTB/RIF test on tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil. PLoS One 13:e0193988.
    76.
    Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, Little F, Azevedo V, Simpson J, Boehme CC, Nicol MP. 2014. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLoS Med 11:e1001760.
    77.
    Auld AF, Fielding KL, Gupta-Wright A, Lawn SD. 2016. Xpert MTB/RIF—why the lack of morbidity and mortality impact in intervention trials? Trans R Soc Trop Med Hyg 110:432–444.
    78.
    Di Tanna GL, Khaki AR, Theron G, McCarthy K, Cox H, Mupfumi L, Trajman A, Zijenah LS, Mason P, Bandason T, Durovni B, Bara W, Hoelscher M, Clowes P, Mangu C, Chanda D, Pym A, Mwaba P, Cobelens F, Nicol MP, Dheda K, Churchyard G, Fielding K, Metcalfe JZ. 2019. Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. Lancet Global Health 7:e191–e199.
    79.
    Schumacher SG, Denkinger CM. 2019. The impact of Xpert MTB/RIF—do we have a final answer? Lancet Glob Health 7:e161–e162.
    80.
    Pai M, Schumacher SG, Abimbola S. 2018. Surrogate endpoints in global health research: still searching for killer apps and silver bullets? BMJ Glob Health 3:e000755.
    81.
    Ochodo E, Kalema N, Schumacher S, Steingart K, Young T, Mallett S, Deeks J, Cobelens F, Bossuyt P, Nicol M, Cattamanchi A. 2019. Variation in the observed effect of Xpert MTB/RIF testing for tuberculosis on mortality: a systematic review and analysis of trial design considerations [version 1; peer review: 1 approved with reservations]. Wellcome Open Res 4:173.
    82.
    Schumacher SG, Sohn H, Qin ZZ, Gore G, Davis JL, Denkinger CM, Pai M. 2016. Impact of molecular diagnostics for tuberculosis on patient-important outcomes: a systematic review of study methodologies. PLoS One 11:e0151073.
    83.
    Stop TB Partnership, McGill International TB Centre, Arcady Group. 2020. Re-Imagining TB Care. https://www.reimaginingtbcare.org/. Accessed 12 August 2020.
    84.
    World Health Organization. 2016. The use of the Xpert MTB/RIF assay for the diagnosis of TB. Meeting Report. World Health Organization, Geneva, Switzerland. https://www.who.int/tb/laboratory/xpert_report_2016.pdf. Accessed 12 August 2020.
    85.
    FIND. 16 July 2020. New rapid molecular test for tuberculosis can simultaneously detect resistance to first- and second-line drugs. FIND, Geneva, Switzerland. https://www.finddx.org/newsroom/pr-16jul20/.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 58Number 1022 September 2020
    eLocator: e01582-19
    Editor: Colleen Suzanne Kraft
    Emory University

    History

    Published online: 5 August 2020

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. accuracy
    2. diagnostics
    3. molecular
    4. tuberculosis

    Contributors

    Authors

    Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada
    McGill International TB Centre, McGill University, Montreal, Canada
    Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada
    McGill International TB Centre, McGill University, Montreal, Canada
    Stefan F. Weber
    Department of Infectious Diseases, University of Heidelberg, Heidelberg, Germany
    Anita Suresh
    Foundation for Innovative New Diagnostics, Geneva, Switzerland
    Foundation for Innovative New Diagnostics, Geneva, Switzerland
    McGill International TB Centre, McGill University, Montreal, Canada
    Department of Infectious Diseases, University of Heidelberg, Heidelberg, Germany
    Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada
    McGill International TB Centre, McGill University, Montreal, Canada
    Manipal McGill Program for Infectious Diseases, Manipal Academy of Higher Education, Manipal, India

    Editor

    Colleen Suzanne Kraft
    Editor
    Emory University

    Notes

    Address correspondence to Madhukar Pai, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Enterohepatic Helicobacter Species Are Prevalent in Mice from Commercial and Academic Institutions in Asia, Europe, and North America

    Enterohepatic Helicobacter Species Are Prevalent in Mice from Commercial and Academic Institutions in Asia, Europe, and North America

    ABSTRACT

    The discovery of Helicobacter hepaticus and its role in hepatitis, hepatocellular carcinoma, typhlocolitis, and lower-bowel carcinoma in murine colonies was followed by the isolation and characterization of other Helicobacter spp. involved in enterohepatic disease. Colonization of mouse colonies with members of the family Helicobacteriaceae has become an increasing concern for the research community. From 2001 to 2005, shipments of selected gift mice from other institutions and mice received from specified commercial vendors were screened for Helicobacter spp. by culture of cecal tissue. The identities of the isolates were confirmed by genus-specific PCR, followed by species-specific PCR and restriction fragment length polymorphism analysis. Sequencing of the 16S rRNA gene was performed if the species identity was not apparent. The survey included 79 mice from 34 sources: 2 commercial sources and 16 research sources from the United States and 1 commercial source and 15 research sources from Canada, Europe, or Asia. Helicobacter spp. were cultured from the ceca of 62 of 79 mice. No Helicobacter spp. were found in mice from advertised Helicobacter-free production areas from two U.S. vendors. Multiple Helicobacter spp. were found in mice from one vendor's acknowledged Helicobacter-infected production area. The European commercial vendor had mice infected with novel Helicobacter sp. strain MIT 96-1001. Of the U.S. academic institutions, 6 of 16 (37%) had mice infected with Helicobacter hepaticus; but monoinfection with H. bilis, H. mastomyrinus, H. rodentium, and MIT 96-1001 was also encountered, as were mice infected simultaneously with two Helicobacter spp. Non-U.S. academic institutions had mice that were either monoinfected with H. hepaticus, monoinfected with seven other Helicobacter spp., or infected with a combination of Helicobacter spp. This survey indicates that 30 of 34 (88%) commercial and academic institutions in Canada, Europe, Asia, Australia, and the United States have mouse colonies infected with Helicobacter spp. Mice from 20 of the 34 institutions (59%) were most commonly colonized with H. hepaticus alone or in combination with other Helicobacter spp. These results indicate that a broad range of Helicobacter spp. infect mouse research colonies. The potential impact of these organisms on in vivo experiments continues to be an important issue for mice being used for biomedical research.

    REFERENCES

    1.
    Bohr, U. R., M. Selgrad, C. Ochmann, S. Backert, W. Konig, A. Fenske, T. Wex, and P. Malfertheiner.2006. Prevalence and spread of enterohepatic Helicobacter species in mice reared in a specific-pathogen-free animal facility. J. Clin. Microbiol.44:738-742.
    2.
    Erdman, S. E., T. Poutahidis, M. Tomczak, A. B. Rogers, K. Cormier, B. Plank, B. H. Horwitz, and J. G. Fox.2003. CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am. J. Pathol.162:691-702.
    3.
    Feng, S., K. Ku, E. Hodzic, E. Lorenzana, K. Freet, and S. W. Barthold.2005. Differential detection of five mouse-infecting Helicobacter species by multiplex PCR. Clin. Diagn. Lab. Immunol.12:531-536.
    4.
    Fox, J. G., F. E. Dewhirst, Z. Shen, Y. Feng, N. S. Taylor, B. J. Paster, R. L. Ericson, C. N. Lau, P. Correa, J. C. Araya, and I. Roa.1998. Hepatic Helicobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. Gastroenterology114:755-763.
    5.
    Fox, J. G., F. E. Dewhirst, J. G. Tully, B. J. Paster, L. Yan, N. S. Taylor, M. J. Collins, Jr., P. L. Gorelick, and J. M. Ward.1994. Helicobacter hepaticus sp. nov., a microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice. J. Clin. Microbiol.32:1238-1245.
    6.
    Fox, J. G., P. L. Gorelick, M. C. Kullberg, Z. Ge, F. E. Dewhirst, and J. M. Ward.1999. A novel urease-negative Helicobacter species associated with colitis and typhlitis in interleukin-10-deficient mice. Infect. Immun.67:1757-1762.
    7.
    Fox, J. G., X. Li, L. Yan, R. J. Cahill, R. Hurley, R. Lewis, and J. C. Murphy.1996. Chronic proliferative hepatitis in A/JCr mice associated with persistent Helicobacter hepaticus infection: a model of helicobacter-induced carcinogenesis. Infect. Immun.64:1548-1558.
    8.
    Fox, J. G., A. B. Rogers, M. T. Whary, N. S. Taylor, S. Xu, Y. Feng, and S. Keys.2004. Helicobacter bilis-associated hepatitis in outbred mice. Comp. Med.54:571-577.
    9.
    Fox, J. G., L. Yan, B. Shames, J. Campbell, J. C. Murphy, and X. Li.1996. Persistent hepatitis and enterocolitis in germfree mice infected with Helicobacter hepaticus. Infect. Immun.64:3673-3681.
    10.
    Fox, J. G., L. L. Yan, F. E. Dewhirst, B. J. Paster, B. Shames, J. C. Murphy, A. Hayward, J. C. Belcher, and E. N. Mendes.1995. Helicobacter bilis sp. nov., a novel Helicobacter species isolated from bile, livers, and intestines of aged, inbred mice. J. Clin. Microbiol.33:445-454.
    11.
    Franklin, C. L., P. L. Gorelick, L. K. Riley, F. E. Dewhirst, R. S. Livingston, J. M. Ward, C. S. Beckwith, and J. G. Fox.2001. Helicobacter typhlonius sp. nov., a novel murine urease-negative Helicobacter species. J. Clin. Microbiol.39:3920-3926.
    12.
    Franklin, C. L., L. K. Riley, R. S. Livingston, C. S. Beckwith, C. L. Besch-Williford, and R. R. Hook, Jr.1998. Enterohepatic lesions in SCID mice infected with Helicobacter bilis. Lab. Anim. Sci.48:334-339.
    13.
    Goto, K., H. Ohashi, A. Takakura, and T. Itoh.2000. Current status of Helicobacter contamination of laboratory mice, rats, gerbils, and house musk shrews in Japan. Curr. Microbiol.41:161-166.
    14.
    Grehan, M., G. Tamotia, B. Robertson, and H. Mitchell.2002. Detection of Helicobacter colonization of the murine lower bowel by genus-specific PCR-denaturing gradient gel electrophoresis. Appl. Environ. Microbiol.68:5164-5166.
    15.
    Hailey, J. R., J. K. Haseman, J. R. Bucher, A. E. Radovsky, D. E. Malarkey, R. T. Miller, A. Nyska, and R. R. Maronpot.1998. Impact of Helicobacter hepaticus infection in B6C3F1 mice from twelve National Toxicology Program two-year carcinogenesis studies. Toxicol. Pathol.26:602-611.
    16.
    Ihrig, M., M. D. Schrenzel, and J. G. Fox.1999. Differential susceptibility to hepatic inflammation and proliferation in AXB recombinant inbred mice chronically infected with Helicobacter hepaticus. Am. J. Pathol155:571-582.
    17.
    Maggio-Price, L., D. Shows, K. Waggie, A. Burich, W. Zeng, S. Escobar, P. Morrissey, and J. L. Viney.2002. Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a/) mice. Am. J. Pathol.160:739-751.
    18.
    Maurer, K. J., M. M. Ihrig, A. B. Rogers, V. Ng, G. Bouchard, M. R. Leonard, M. C. Carey, and J. G. Fox.2005. Identification of cholelithogenic enterohepatic Helicobacter species and their role in murine cholesterol gallstone formation. Gastroenterology128:1023-1033.
    19.
    Myles, M. H., R. S. Livingston, and C. L. Franklin.2004. Pathogenicity of Helicobacter rodentium in A/JCr and SCID mice. Comp. Med.54:549-557.
    20.
    Nilsson, H. O., I. S. Ouis, U. Stenram, A. Ljungh, A. P. Moran, T. Wadstrom, and W. A. Al-Soud.2004. High prevalence of Helicobacter species detected in laboratory mouse strains by multiplex PCR-denaturing gradient gel electrophoresis and pyrosequencing. J. Clin. Microbiol.42:3781-3788.
    21.
    Paster, B. J., and F. Dewhirst.1988. Phylogeny of Campylobacter, wolinellas, Bacteroides gracilis, and Bacteroides ureolyticus by 16S ribosomal ribonucleic acid sequencing. Int. J. Syst. Bacteriol.38:56-62.
    22.
    Queiroz, D. M., C. Contigli, R. S. Coimbra, A. M. Nogueira, E. N. Mendes, G. A. Rocha, and S. B. Moura.1992. Spiral bacterium associated with gastric, ileal and caecal mucosa of mice. Lab. Anim.26:288-294.
    23.
    Riley, L. K., C. L. Franklin, R. R. Hook, Jr., and C. Besch-Williford.1996. Identification of murine helicobacters by PCR and restriction enzyme analyses. J. Clin. Microbiol.34:942-946.
    24.
    Robertson, B. R., J. L. O'Rourke, P. Vandamme, S. L. On, and A. Lee.2001. Helicobacter ganmani sp. nov., a urease-negative anaerobe isolated from the intestines of laboratory mice. Int. J. Syst. Evol. Microbiol.51:1881-1889.
    25.
    Shames, B., J. G. Fox, F. Dewhirst, L. Yan, Z. Shen, and N. S. Taylor.1995. Identification of widespread Helicobacter hepaticus infection in feces in commercial mouse colonies by culture and PCR assay. J. Clin. Microbiol.33:2968-2972.
    26.
    Shen, Z., Y. Feng, and J. G. Fox.2000. Identification of enterohepatic Helicobacter species by restriction fragment-length polymorphism analysis of the 16S rRNA gene. Helicobacter5:121-128.
    27.
    Shen, Z., J. G. Fox, F. E. Dewhirst, B. J. Paster, C. J. Foltz, L. Yan, B. Shames, and L. Perry.1997. Helicobacter rodentium sp. nov., a urease-negative Helicobacter species isolated from laboratory mice. Int. J. Syst. Bacteriol.47:627-634.
    28.
    Shomer, N. H., C. A. Dangler, R. P. Marini, and J. G. Fox.1998. Helicobacter bilis/Helicobacter rodentium co-infection associated with diarrhea in a colony of SCID mice. Lab. Anim. Sci.48:455-459.
    29.
    Shomer, N. H., C. A. Dangler, M. D. Schrenzel, M. T. Whary, S. Xu, Y. Feng, B. J. Paster, F. E. Dewhirst, and J. G. Fox.2001. Cholangiohepatitis and inflammatory bowel disease induced by a novel urease-negative Helicobacter species in A/J and Tac:ICR:HascidfRF mice. Exp. Biol. Med. (Maywood)226:420-428.
    30.
    Vandamme, P., C. S. Harrington, K. Jalava, and S. L. On.2000. Misidentifying helicobacters: the Helicobacter cinaedi example. J. Clin. Microbiol.38:2261-2266.
    31.
    Ward, J. M., J. G. Fox, M. R. Anver, D. C. Haines, C. V. George, M. J. Collins, Jr., P. L. Gorelick, K. Nagashima, M. A. Gonda, R. V. Gilden, et al.1994. Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J. Natl. Cancer Inst.86:1222-1227.
    32.
    Whary, M. T., and J. G. Fox.2004. Natural and experimental Helicobacter infections. Comp. Med.54:128-158.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 45Number 7July 2007
    Pages: 2166 - 2172

    History

    Received: 18 January 2007
    Revision received: 12 April 2007
    Accepted: 6 May 2007
    Published online: 16 May 2007

    Permissions

    Request permissions for this article.

    Contributors

    Authors

    Nancy S. Taylor
    Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
    Shilu Xu
    Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
    Prashant Nambiar
    Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
    Floyd E. Dewhirst
    Department of Molecular Genetics, The Forsyth Institute, Boston, Massachusetts 02115
    Department of Oral and Developmental Biology, Harvard School of Dental Medicine, Boston, Massachusetts 02115
    James G. Fox [email protected]
    Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Persistent Transmission of Shigellosis in England Is Associated with a Recently Emerged Multidrug-Resistant Strain of Shigella sonnei

    Persistent Transmission of Shigellosis in England Is Associated with a Recently Emerged Multidrug-Resistant Strain of Shigella sonnei

    ABSTRACT

    Whole-genome sequencing has enhanced surveillance and facilitated detailed monitoring of the transmission of Shigella species in England. We undertook an epidemiological and phylogenetic analysis of isolates from all cases of shigellosis referred to Public Health England between 2015 and 2018 to explore recent strain characteristics and the transmission dynamics of Shigella species. Of the 4,950 confirmed cases of shigellosis identified during this period, the highest proportion of isolates was Shigella sonnei (54.4%), followed by S. flexneri (39.2%), S. boydii (4.1%), and S. dysenteriae (2.2%). Most cases were adults (82.9%) and male (59.5%), and 34.9% cases reported recent travel outside the United Kingdom. Throughout the study period, diagnoses of S. flexneri and S. sonnei infections were most common in men with no history of recent travel abroad. The species prevalence was not static, with cases of S. flexneri infection in men decreasing between 2015 and 2016 and the number of cases of S. sonnei infection increasing from 2017. Phylogenetic analysis showed this recent increase in S. sonnei infections was attributed to a novel clade that emerged from a Central Asia sublineage exhibiting resistance to ciprofloxacin and azithromycin. Despite changes in species prevalence, diagnoses of Shigella infections in England are persistently most common in adult males without a reported travel history, consistent with sexual transmission among men who have sex with men. The trend toward increasing rates of ciprofloxacin resistance in S. sonnei, in addition to plasmid-mediated azithromycin resistance, is of significant public health concern with respect to the transmission of multidrug-resistant gastrointestinal pathogens and the risk of treatment failures.

    REFERENCES

    1.
    GBD Diarrhoeal Diseases Collaborators. 2017. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 17:909–948.
    2.
    Drusin LM, Genvert G, Topf-Olstein B, Levy-Zombek E. 1976. Shigellosis. Another sexually transmitted disease? Br J Vener Dis 52:348–350.
    3.
    Dritz SK, Back AF. 1974. Shigella enteritis venereally transmitted. N Engl J Med 291:1194.
    4.
    Gilbart VL, Simms I, Jenkins C, Furegato M, Gobin M, Oliver I, Hart G, Gill ON, Hughes G. 2015. Sex, drugs and smart phone applications: findings from semistructured interviews with men who have sex with men diagnosed with Shigella flexneri 3a in England and Wales. Sex Transm Infect 91:598–602.
    5.
    Baker KS, Dallman TJ, Ashton PM, Day M, Hughes G, Crook PD, Gilbart VL, Zittermann S, Allen VG, Howden BP, Tomita T, Valcanis M, Harris SR, Connor TR, Sintchenko V, Howard P, Brown JD, Petty NK, Gouali M, Thanh DP, Keddy KH, Smith AM, Talukder KA, Faruque SM, Parkhill J, Baker S, Weill FX, Jenkins C, Thomson NR. 2015. Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-sectional study. Lancet Infect Dis 15:913–921.
    6.
    Mook P, McCormick J, Bains M, Cowley LA, Chattaway MA, Jenkins C, Mikhail A, Hughes G, Elson R, Day M, Manuel R, Dave J, Field N, Godbole G, Dallman T, Crook P. 2016. ESBL-producing and macrolide-resistant Shigella sonnei infections among men who have sex with men, England, 2015. Emerg Infect Dis 22:1948–1952.
    7.
    Liao YS, Liu YY, Lo YC, Chiou CS. 2016. Azithromycin non-susceptible Shigella flexneri 3a in men who have sex with men, Taiwan, 2015–2016. Emerg Infect Dis 23:345–346.
    8.
    Bowen A, Grass J, Bicknese A, Campbell D, Hurd J, Kirkcaldy RD. 2016. Elevated risk for antimicrobial drug-resistant Shigella infection among men who have sex with men, United States, 2011-2015. Emerg Infect Dis 22:1613–1616.
    9.
    Hoffmann C, Sahly H, Jessen A, Ingiliz P, Stellbrink HJ, Neifer S, Schewe K, Dupke S, Baumgarten A, Kuschel A, Krznaric I. 2013. High rates of quinolone-resistant strains of Shigella sonnei in HIV-infected MSM. Infection 41:999–1003.
    10.
    Valcanis M, Brown JD, Hazelton B, OʼSullivan MV, Kuzevski A, Lane CR, Howden BP. 2015. Outbreak of locally acquired azithromycin-resistant Shigella flexneri infection in men who have sex with men. Pathology 47:87–88.
    11.
    Gaudreau C, Barkati S, Leduc JM, Pilon PA, Favreau J, Bekal S. 2014. Shigella spp. with reduced azithromycin susceptibility, Quebec, Canada, 2012–2013. Emerg Infect Dis 20:854–856.
    12.
    Bowen A, Eikmeier D, Talley P, Siston A, Smith S, Hurd J, Smith K, Leano F, Bicknese A, Norton JC, Campbell D, Centers for Disease Control and Prevention (CDC). 2015. Notes from the field: outbreaks of Shigella sonnei infection with decreased susceptibility to azithromycin among men who have sex with men—Chicago and metropolitan Minneapolis-St. Paul, 2014. MMWR Morb Mortal Wkly Rep 64:597–598.
    13.
    Simms I, Field N, Jenkins C, Childs T, Gilbart VL, Dallman TJ, Mook P, Crook PD, Hughes G. 2015. Intensified shigellosis epidemic associated with sexual transmission in men who have sex with men—Shigella flexneri and S. sonnei in England, 2004 to end of February 2015. Euro Surveill 20(15):pii=21097. https://doi.org/10.2807/1560-7917.ES2015.20.15.21097.
    14.
    Borg ML, Modi A, Tostmann A, Gobin M, Cartwright J, Quigley C, Crook P, Boxall N, Paul J, Cheasty T, Gill N, Hughes G, Simms I, Oliver I. 2012. Ongoing outbreak of Shigella flexneri serotype 3a in men who have sex with men in England and Wales, data from 2009–2011. Euro Surveill 17(13):pii=20137. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20137.
    15.
    Baker KS, Dallman TJ, Behar A, Weill FX, Gouali M, Sobel J, Fookes M, Valinsky L, Gal-Mor O, Connor TR, Nissan I, Bertrand S, Parkhill J, Jenkins C, Cohen D, Thomson NR. 2016. Travel- and community-based transmission of multidrug-resistant Shigella sonnei lineage among international orthodox Jewish communities. Emerg Infect Dis 22:1545–1553.
    16.
    Baker KS, Dallman TJ, Field N, Childs T, Mitchell H, Day M, Weill FX, Lefèvre S, Tourdjman M, Hughes G, Jenkins C, Thomson N. 2018. Genomic epidemiology of Shigella in the United Kingdom shows transmission of pathogen sublineages and determinants of antimicrobial resistance. Sci Rep 8:7389.
    17.
    Baker KS, Dallman TJ, Field N, Childs T, Mitchell H, Day M, Weill FX, Lefèvre S, Tourdjman M, Hughes G, Jenkins C, Thomson N. 2018. Horizontal antimicrobial resistance transfer drives epidemics of multiple Shigella species. Nat Commun 9:1462.
    18.
    Rew V, Mook P, Trienekens S, Baker KS, Dallman TJ, Jenkins C, Crook PD, Thomson NR. 2018. Whole-genome sequencing revealed concurrent outbreaks of shigellosis in the English Orthodox Jewish Community caused by multiple importations of Shigella sonnei from Israel. Microb Genom 4:e000170.
    19.
    Holt KE, Baker S, Weill FX, Holmes EC, Kitchen A, Yu J, Sangal V, Brown DJ, Coia JE, Kim DW, Choi SY, Kim SH, da Silveira WD, Pickard DJ, Farrar JJ, Parkhill J, Dougan G, Thomson NR. 2012. Shigella sonnei genome sequencing and phylogenetic analysis indicate recent global dissemination from Europe. Nat Genet 44:1056–1059.
    20.
    Dallman TJ, Chattaway MA, Mook P, Godbole G, Crook PD, Jenkins C. 2016. Use of whole-genome sequencing for the public health surveillance of Shigella sonnei in England and Wales, 2015. J Med Microbiol 65:882–884.
    21.
    Ingle DJ, Easton M, Valcanis M, Seemann T, Kwong JC, Stephens N, Carter GP, Gonçalves da Silva A, Adamopoulos J, Baines SL, Holt KE, Chow EPF, Fairley CK, Chen MY, Kirk M, Howden BP, Williamson DA. 2019. Co-circulation of multidrug-resistant Shigella among men who have sex with men, Australia. Clin Infect Dis 69:1535–1544.
    22.
    Chattaway MA, Greig DR, Gentle A, Hartman HB, Dallman TJ, Jenkins C. 2017. Whole-genome sequencing for national surveillance of Shigella flexneri. Front Microbiol 8:1700.
    23.
    Mitchell HD, Mikhail AFW, Painset A, Dallman TJ, Jenkins C, Thomson NR, Field N, Hughes G. 5 November 2019. Use of whole-genome sequencing to identify clusters of Shigella flexneri associated with sexual transmission in men who have sex with men in England: a validation study using linked behavioural data. Microb Genom doi:
    24.
    Li H, Durbin R. 2010. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26:589–595.
    25.
    McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. 2010. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20:1297–1303.
    26.
    Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30:1312–1313.
    27.
    Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, Parkhill J, Harris SR. 2015. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. Nucleic Acids Res 43:e15.
    28.
    Dallman T, Ashton P, Schafer U, Jironkin A, Painset A, Shaaban S, Hartman H, Myers R, Underwood A, Jenkins C, Grant K. 2018. SnapperDB: a database solution for routine sequencing analysis of bacterial isolates. Bioinformatics 34:3028–3029.
    29.
    Chattaway MA, Schaefer U, Tewolde R, Dallman TJ, Jenkins C. 2017. Identification of Escherichia coli and Shigella species from whole-genome sequences. J Clin Microbiol 55:616–623.
    30.
    Sadouki Z, Day MR, Doumith M, Chattaway MA, Dallman TJ, Hopkins KL, Elson R, Woodford N, Godbole G, Jenkins C. 2017. Comparison of phenotypic and WGS-derived antimicrobial resistance profiles of Shigella sonnei isolated from cases of diarrhoeal disease in England and Wales, 2015. J Antimicrob Chemother 72:2496–2502.
    31.
    Drummond AJ, Suchard MA, Xie D, Rambaut A. 2012. Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol Biol Evol 29:1969–1973.
    32.
    Datta J, Reid D, Hughes G, Mercer CH, Wayal S, Weatherburn P. 2019. Awareness of and attitudes to sexually transmissible infections among gay men and other men who have sex with men in England: a qualitative study. Sex Health 16:18–24.
    33.
    Cohen D, Green MS, Block C, Slepon R, Ofek I. 1991. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol 29:386–389.
    34.
    Cohen D, Korin H, Bassal R, Perry Markovich M, Sivan Y, Goren S, Muhsen K. 2019. Burden and risk factors of Shigella sonnei shigellosis among children aged 0–59 months in hyperendemic communities in Israel. Int J Infect Dis 82:117–123.
    35.
    Clutterbuck D, Asboe D, Barber T, Emerson C, Field N, Gibson S, Hughes G, Jones R, Murchie M, Nori AV, Rayment M, Sullivan A. 16 January 2018. 2016 United Kingdom national guideline on the sexual health care of men who have sex with men. Int J STD AIDS doi:
    36.
    Mohammed H, Blomquist P, Ogaz D, Duffell S, Furegato M, Checchi M, Irvine N, Wallace LA, Thomas DR, Nardone A, Dunbar JK, Hughes G. 2018. 100 years of STIs in the UK: a review of national surveillance data. Sex Transm Infect 94:553–558.
    37.
    Childs T, Simms I, Alexander S, Eastick K, Hughes G, Field N. 2015. Rapid increase in lymphogranuloma venereum in men who have sex with men, United Kingdom, 2003 to September 2015. Euro Surveill 20(48):pii=30076. https://doi.org/10.2807/1560-7917.ES.2015.20.48.30076.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 58Number 425 March 2020
    eLocator: e01692-19
    Editor: Alexander Mellmann
    University Hospital Münster

    History

    Received: 8 October 2019
    29 October 2019
    Accepted: 7 January 2020
    Published online: 25 March 2020

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. shigellosis
    2. epidemiology
    3. whole-genome sequencing
    4. sexual transmission
    5. multidrug resistance

    Contributors

    Authors

    Megan Bardsley
    National Infection Service, Public Health England, London, United Kingdom
    Claire Jenkins
    National Infection Service, Public Health England, London, United Kingdom
    Holly D. Mitchell
    Institute for Global Health, University College London, London, United Kingdom
    National Infection Service, Public Health England, London, United Kingdom
    Kate S. Baker
    Institute for Integrative Biology, University of Liverpool, Liverpool, United Kingdom
    Kirsty Foster
    National Infection Service, Public Health England, London, United Kingdom
    Gwenda Hughes
    National Infection Service, Public Health England, London, United Kingdom
    Timothy J. Dallman
    National Infection Service, Public Health England, London, United Kingdom

    Editor

    Alexander Mellmann
    Editor
    University Hospital Münster

    Notes

    Address correspondence to Claire Jenkins, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Genomic Investigation Reveals Contaminated Detergent as the Source of an Extended-Spectrum-β-Lactamase-Producing Klebsiella michiganensis Outbreak in a Neonatal Unit

    ABSTRACT

    Klebsiella species are problematic pathogens in neonatal units and may cause outbreaks, for which the sources of transmission may be challenging to elucidate. We describe the use of whole-genome sequencing (WGS) to investigate environmental sources of transmission during an outbreak of extended-spectrum-β-lactamase (ESBL)-producing Klebsiella michiganensis colonizing neonates. Ceftriaxone-resistant Klebsiella spp. isolated from neonates (or their mothers) and the hospital environment were included. Short-read sequencing (Illumina) and long-read sequencing (MinION; Oxford Nanopore Technologies) were used to confirm species taxonomy, to identify antimicrobial resistance genes, and to determine phylogenetic relationships using single-nucleotide polymorphism profiling. A total of 21 organisms (10 patient-derived isolates and 11 environmental isolates) were sequenced. Standard laboratory methods identified the outbreak strain as an ESBL-producing Klebsiella oxytoca, but taxonomic assignment from WGS data suggested closer identity to Klebsiella michiganensis. Strains isolated from multiple detergent-dispensing bottles were either identical or closely related by single-nucleotide polymorphism comparison. Detergent bottles contaminated by K. michiganensis had been used for washing milk expression equipment. No new cases were identified once the detergent bottles were removed. Environmental reservoirs may be an important source in outbreaks of multidrug-resistant organisms. WGS, in conjunction with traditional epidemiological investigation, can be instrumental in revealing routes of transmission and guiding infection control responses.

    REFERENCES

    1.
    Stapleton PJ, Murphy M, McCallion N, Brennan M, Cunney R, Drew RJ. 2016. Outbreaks of extended spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units: a systematic review. Arch Dis Child Fetal Neonatal Ed 101:F72–F78.
    2.
    Saha R, Farrance CE, Verghese B, Hong S, Donofrio RS. 2013. Klebsiella michiganensis sp. nov., a new bacterium isolated from a tooth brush holder. Curr Microbiol 66:72–78.
    3.
    Zheng B, Xu H, Yu X, Lv T, Jiang X, Cheng H, Zhang J, Chen Y, Huang C, Xiao Y. 2018. Identification and genomic characterization of a KPC-2-, NDM-1- and NDM-5-producing Klebsiella michiganensis isolate. J Antimicrob Chemother 73:536–538.
    4.
    Hazen TH, Mettus R, McElheny CL, Bowler SL, Nagaraj S, Doi Y, Rasko DA. 2018. Diversity among blaKPC-containing plasmids in Escherichia coli and other bacterial species isolated from the same patients. Sci Rep 8:10291.
    5.
    Founou RC, Founou LL, Allam M, Ismail A, Essack SY. 2018. Genomic characterisation of Klebsiella michiganensis co-producing OXA-181 and NDM-1 carbapenemases isolated from a cancer patient in uMgungundlovu District, KwaZulu-Natal Province, South Africa. S Afr Med J 109:7–8.
    6.
    Seiffert SN, Wuthrich D, Gerth Y, Egli A, Kohler P, Nolte O. 2019. First clinical case of KPC-3-producing Klebsiella michiganensis in Europe. New Microbes New Infect 29:100516.
    7.
    Lowe C, Willey B, O'Shaughnessy A, Lee W, Lum M, Pike K, Larocque C, Dedier H, Dales L, Moore C, McGeer A. 2012. Outbreak of extended-spectrum β-lactamase-producing Klebsiella oxytoca infections associated with contaminated handwashing sinks. Emerg Infect Dis 18:1242–1247.
    8.
    Mete B, Aybar Bilir Y, Aygun G, Yilmaz M, Urkmez S, Dilmen Y, Ozturk R. 2013. Klebsiella oxytoca outbreak in an intensive care unit: a probable link to common insulin vial use. Anaesth Intensive Care 41:266–268.
    9.
    Vergara-López S, Domínguez MC, Conejo MC, Pascual Á, Rodríguez-Baño J. 2013. Wastewater drainage system as an occult reservoir in a protracted clonal outbreak due to metallo-β-lactamase-producing Klebsiella oxytoca. Clin Microbiol Infect 19:E490–E498.
    10.
    Leitner E, Zarfel G, Luxner J, Herzog K, Pekard-Amenitsch S, Hoenigl M, Valentin T, Feierl G, Grisold AJ, Hogenauer C, Sill H, Krause R, Zollner-Schwetz I. 2015. Contaminated handwashing sinks as the source of a clonal outbreak of KPC-2-producing Klebsiella oxytoca on a hematology ward. Antimicrob Agents Chemother 59:714–716.
    11.
    Schmithausen RM, Sib E, Exner M, Hack S, Rosing C, Ciorba P, Bierbaum G, Savin M, Bloomfield SF, Kaase M, Jacobshagen A, Gemein S, Gebel J, Engelhart S, Exner D. 2019. The washing machine as a reservoir for transmission of extended-spectrum-beta-lactamase (CTX-M-15)-producing Klebsiella oxytoca ST201 to newborns. Appl Environ Microbiol 85:e01435-19.
    12.
    Arakawa Y, Ohta M, Kido N, Mori M, Ito H, Komatsu T, Fujii Y, Kato N. 1989. Chromosomal β-lactamase of Klebsiella oxytoca, a new class A enzyme that hydrolyzes broad-spectrum β-lactam antibiotics. Antimicrob Agents Chemother 33:63–70.
    13.
    Fevre C, Jbel M, Passet V, Weill FX, Grimont PA, Brisse S. 2005. Six groups of the OXY β-lactamase evolved over millions of years in Klebsiella oxytoca. Antimicrob Agents Chemother 49:3453–3462.
    14.
    Joris B, De Meester F, Galleni M, Frere JM, Van Beeumen J. 1987. The K1 β-lactamase of Klebsiella pneumoniae. Biochem J 243:561–567.
    15.
    Fournier B, Lagrange PH, Philippon A. 1996. β-Lactamase gene promoters of 71 clinical strains of Klebsiella oxytoca. Antimicrob Agents Chemother 40:460–463.
    16.
    Jeong SH, Kim WM, Chang CL, Kim JM, Lee K, Chong Y, Hwang HY, Baek YW, Chung HK, Woo IG, Ku JY. 2001. Neonatal intensive care unit outbreak caused by a strain of Klebsiella oxytoca resistant to aztreonam due to overproduction of chromosomal β-lactamase. J Hosp Infect 48:281–288.
    17.
    Zarate MS, Gales AC, Picao RC, Pujol GS, Lanza A, Smayevsky J. 2008. Outbreak of OXY-2-producing Klebsiella oxytoca in a renal transplant unit. J Clin Microbiol 46:2099–2101.
    18.
    Then RL, Glauser MP, Angehrn P, Arisawa M. 1983. Cephalosporin resistance in strains of Klebsiella oxytoca isolated during antibiotic therapy. Zentralbl Bakteriol Mikrobiol Hyg A 254:469–479.
    19.
    Potz NA, Colman M, Warner M, Reynolds R, Livermore DM. 2004. False-positive extended-spectrum β-lactamase tests for Klebsiella oxytoca strains hyperproducing K1 β-lactamase. J Antimicrob Chemother 53:545–547.
    20.
    Bush K, Jacoby GA. 2010. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 54:969–976.
    21.
    Hart CA. 1993. Klebsiellae and neonates. J Hosp Infect 23:83–86.
    22.
    Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. 2005. Hospital-acquired neonatal infections in developing countries. Lancet 365:1175–1188.
    23.
    European Committee on Antimicrobial Susceptibility Testing. 2017. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance, version 2.0. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf.
    24.
    Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30:2114–2120.
    25.
    Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, Rolain JM. 2014. ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes. Antimicrob Agents Chemother 58:212–220.
    26.
    Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, Tomita T, Zobel J, Holt KE. 2014. SRST2: rapid genomic surveillance for public health and hospital microbiology labs. Genome Med 6:90.
    27.
    Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, Parkhill J, Harris SR. 2015. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. Nucleic Acids Res 43:e15.
    28.
    Wood DE, Salzberg SL. 2014. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol 15:R46.
    29.
    Federhen S, Rossello-Mora R, Klenk H-P, Tindall BJ, Konstantinidis KT, Whitman WB, Brown D, Labeda D, Ussery D, Garrity GM, Colwell RR, Hasan N, Graf J, Parte A, Yarza P, Goldberg B, Sichtig H, Karsch-Mizrachi I, Clark K, McVeigh R, Pruitt KD, Tatusova T, Falk R, Turner S, Madden T, Kitts P, Kimchi A, Klimke W, Agarwala R, DiCuccio M, Ostell J. 2016. Meeting report: GenBank microbial genomic taxonomy workshop (12–13 May, 2015). Stand Genomic Sci 11:15.
    30.
    Ronning TG, Aas CG, Stoen R, Bergh K, Afset JE, Holte MS, Radtke A. 2019. Investigation of an outbreak caused by antibiotic-susceptible Klebsiella oxytoca in a neonatal intensive care unit in Norway. Acta Paediatr 108:76–82.
    31.
    Ransjo U, Good Z, Jalakas K, Kuhn I, Siggelkow I, Aberg B, Anjou E. 1992. An outbreak of Klebsiella oxytoca septicemias associated with the use of invasive blood pressure monitoring equipment. Acta Anaesthesiol Scand 36:289–291.
    32.
    Toldos CM, Ortiz G, Camara M, Segovia M. 1997. Application of pulsed-field gel electrophoresis in an outbreak of infection due to Klebsiella oxytoca. J Med Microbiol 46:889–890.
    33.
    Watson JT, Jones RC, Siston AM, Fernandez JR, Martin K, Beck E, Sokalski S, Jensen BJ, Arduino MJ, Srinivasan A, Gerber SI. 2005. Outbreak of catheter-associated Klebsiella oxytoca and Enterobacter cloacae bloodstream infections in an oncology chemotherapy center. Arch Intern Med 165:2639–2643.
    34.
    Tindall BJ, Rosselló-Móra R, Busse H-J, Ludwig W, Kämpfer P. 2010. Notes on the characterization of prokaryote strains for taxonomic purposes. Int J Syst Evol Microbiol 60:249–266.
    35.
    Liao TL, Lin AC, Chen E, Huang TW, Liu YM, Chang YH, Lai JF, Lauderdale TL, Wang JT, Chang SC, Tsai SF, Chen YT. 2012. Complete genome sequence of Klebsiella oxytoca E718, a New Delhi metallo-β-lactamase-1-producing nosocomial strain. J Bacteriol 194:5454.
    36.
    Reiss I, Borkhardt A, Füssle R, Sziegoleit A, Gortner L. 2000. Disinfectant contaminated with Klebsiella oxytoca as a source of sepsis in babies. Lancet 356:310.
    37.
    Paczosa MK, Mecsas J. 2016. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol Rev 80:629–661.
    38.
    Shukor MY, Husin WS, Rahman MF, Shamaan NA, Syed MA. 2009. Isolation and characterization of an SDS-degrading Klebsiella oxytoca. J Environ Biol 30:129–134.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 58Number 523 April 2020
    eLocator: e01980-19
    Editor: Alexander Mellmann
    University Hospital Münster

    History

    Received: 30 November 2019
    8 January 2020
    Accepted: 20 February 2020
    Published online: 26 February 2020

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. Klebsiella oxytoca
    2. Klebsiella michiganensis
    3. whole-genome sequencing
    4. extended-spectrum β-lactamase
    5. outbreak

    Contributors

    Authors

    Paul Chapman
    Infectious Diseases Unit, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia
    Infection Prevention and Control, Caboolture Hospital, Caboolture, QLD, Australia
    Queensland Institute of Medical Research Berghofer, Herston, QLD, Australia
    School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia
    Leah W. Roberts
    School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia
    Haakon Bergh
    Microbiology Department, Central Laboratory, Pathology Queensland, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia
    Debra Vesey
    Infection Prevention and Control, Caboolture Hospital, Caboolture, QLD, Australia
    Public Health Microbiology, Forensic, and Scientific Services, Queensland Health, Brisbane, QLD, Australia
    Susan Moss
    Public Health Microbiology, Forensic, and Scientific Services, Queensland Health, Brisbane, QLD, Australia
    University of Queensland Centre for Clinical Research, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia
    David L. Paterson
    Infectious Diseases Unit, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia
    University of Queensland Centre for Clinical Research, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia
    School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia
    Microbiology Department, Central Laboratory, Pathology Queensland, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia
    University of Queensland Centre for Clinical Research, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia

    Editor

    Alexander Mellmann
    Editor
    University Hospital Münster

    Notes

    Address correspondence to Scott A. Beatson, [email protected], or Patrick N. A. Harris, [email protected].
    Paul Chapman and Brian M. Forde contributed equally to this work. First authorship was decided on the basis of Paul Chapman being the clinical lead for the outbreak.

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Distinct Bacteriophages Encoding Panton-Valentine Leukocidin (PVL) among International Methicillin-Resistant Staphylococcus aureus Clones Harboring PVL

    Distinct Bacteriophages Encoding Panton-Valentine Leukocidin (PVL) among International Methicillin-Resistant Staphylococcus aureus Clones Harboring PVL

    ABSTRACT

    Genetically diverse community-associated methicillin resistant Staphylococcus aureus (CA-MRSA) can harbor a bacteriophage encoding Panton-Valentine leukocidin (PVL) lysogenized into its chromosome (prophage). Six PVL phages (ΦPVL, Φ108PVL, ΦSLT, ΦSa2MW, ΦSa2USA, and ΦSa2958) are known, and single-nucleotide polymorphisms (SNPs) in the PVL genes have been reported. We sought to determine the distribution of lysogenized PVL phages among MRSA strains with PVL (PVL-MRSA strains), the PVL gene sequences, and the chromosomal phage insertion sites in 114 isolates comprising nine clones of PVL-MRSA that were selected for maximal underlying genetic diversity. The six PVL phages were identified by PCR; ΦSa2USA was present in the highest number of different lineages (multilocus sequence type clonal complex 1 [CC1], CC5, CC8, and sequence type 93 [ST93]) (n = 37 isolates). Analysis of 92 isolates confirmed that PVL phages inserted into the same chromosomal insertion locus in CC22, -30, and -80 but in a different locus in isolates of CC1, -5, -8, -59, and -88 and ST93 (and CC22 in two isolates). Within the two different loci, specific attachment motifs were found in all cases, although some limited inter- and intralineage sequence variation occurred. Overall, lineage-specific relationships between the PVL phage, the genes that encode the toxin, and the position at which the phage inserts into the host chromosome were identified. These analyses provide important insights into the microepidemiology of PVL-MRSA, will prove a valuable adjunct in outbreak investigation, and may help predict the emergence of new strains.

    REFERENCES

    1.
    Baba T. et al. 2002. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 359:1819–1827.
    2.
    Besseyre des Horts T. et al. 2010. A histidine-to-arginine substitution in Panton-Valentine leukocidin from USA300 community-acquired methicillin-resistant Staphylococcus aureus does not impair its leukotoxicity. Infect. Immun. 78:260–264.
    3.
    Boakes E. et al. 2010. Molecular diversity within clonal complex 22 methicillin-resistant Staphylococcus aureus encoding Panton-Valentine leukocidin in England and Wales. Clin. Microbiol. Infect. doi:
    4.
    Boyle-Vavra S., Ereshefsky B., Wang C. C., and Daum R. S.. 2005. Successful multiresistant community-associated methicillin-resistant Staphylococcus aureus lineage from Taipei, Taiwan, that carries either the novel Staphylococcal chromosome cassette mec (SCCmec) type VT or SCCmec type IV. J. Clin. Microbiol. 43:4719–4730.
    5.
    Bubeck Wardenburg J., Bae T., Otto M., DeLeo F. R., and Schneewind O.. 2007. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat. Med. 13:1405–1406.
    6.
    Bubeck Wardenburg J., Palazzolo-Ballance A. M., Otto M., Schneewind O., and DeLeo F. R.. 2008. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J. Infect. Dis. 198:1166–1170.
    7.
    Canchaya C., Proux C., Fournous G., Bruttin A., and Brussow H.. 2003. Prophage genomics. Microbiol. Mol. Biol. Rev. 67:238–276.
    8.
    Cremieux A. C. et al. 2009. Panton-Valentine leukocidin enhances the severity of community-associated methicillin-resistant Staphylococcus aureus rabbit osteomyelitis. PLoS One 4:e7204.
    9.
    Daum R. S. et al. 2002. A novel methicillin-resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J. Infect. Dis. 186:1344–1347.
    10.
    Diep B. A. et al. 2010. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc. Natl. Acad. Sci. U. S. A. 107:5587–5592.
    11.
    Diep B. A. et al. 2006. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 367:731–739.
    12.
    Diep B. A. and Otto M.. 2008. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol. 16:361–369.
    13.
    Diep B. A. et al. 2008. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS One 3:e3198.
    14.
    Dorgai L., Sloan S., and Weisberg R. A.. 1998. Recognition of core binding sites by bacteriophage integrases. J. Mol. Biol. 277:1059–1070.
    15.
    Dumitrescu O. et al. 2008. Polymorphism of the Staphylococcus aureus Panton-Valentine leukocidin genes and its possible link with the fitness of community-associated methicillin-resistant S. aureus. J. Infect. Dis. 198:792–794.
    16.
    Ellington M. J. et al. 2010. First international spread and dissemination of the virulent Queensland community-associated methicillin-resistant Staphylococcus aureus strain. Clin. Microbiol. Infect. 16:1009–10012.
    17.
    Ellington M. J., Ganner M., Warner M., Cookson B. D., and Kearns A. M.. 2010. Polyclonal multiply antibiotic-resistant methicillin-resistant Staphylococcus aureus with Panton-Valentine leucocidin in England. J. Antimicrob. Chemother. 65:46–50.
    18.
    Ellington M. J. et al. 2009. Clinical and molecular epidemiology of ciprofloxacin-susceptible MRSA encoding PVL in England and Wales. Eur. J. Clin. Microbiol. Infect. Dis. 28:1113–1121.
    19.
    Ellington M. J., Yearwood L., Ganner M., East C., and Kearns A. M.. 2008. Distribution of the ACME-arcA gene among methicillin-resistant Staphylococcus aureus from England and Wales. J. Antimicrob. Chemother. 61:73–77.
    20.
    Gillet Y. et al. 2002. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359:753–759.
    21.
    Guindon S. and Gascuel O.. 2003. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst. Biol. 52:696–704.
    22.
    Hasegawa M., Kishino H., and Yano T.. 1985. Dating of the human-ape splitting by a molecular clock of mitochondrial DNA. J. Mol. Evol. 22:160–174.
    23.
    Herold B. C. et al. 1998. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279:593–598.
    24.
    Higuchi W., Takano T., Teng L. J., and Yamamoto T.. 2008. Structure and specific detection of staphylococcal cassette chromosome mec type VII. Biochem. Biophys. Res. Commun. 377:752–756.
    25.
    Ito T. et al. 2004. Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob. Agents Chemother. 48:2637–2651.
    26.
    Kaneko J., Kimura T., Narita S., Tomita T., and Kamio Y.. 1998. Complete nucleotide sequence and molecular characterization of the temperate staphylococcal bacteriophage phiPVL carrying Panton-Valentine leukocidin genes. Gene 215:57–67.
    27.
    Labandeira-Rey M. et al. 2007. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 315:1130–1133.
    28.
    Lina G. et al. 1999. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin. Infect. Dis. 29:1128–1132.
    29.
    Ma X. X. et al. 2008. Two different Panton-Valentine leukocidin phage lineages predominate in Japan. J. Clin. Microbiol. 46:3246–3258.
    30.
    Ma X. X. et al. 2002. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. 46:1147–1152.
    31.
    O'Hara F. P. et al. 2008. A geographic variant of the Staphylococcus aureus Panton-Valentine leukocidin toxin and the origin of community-associated methicillin-resistant S. aureus USA300. J. Infect. Dis. 197:187–194.
    32.
    Orendi J. M. et al. 2010. Community and nosocomial transmission of Panton-Valentine leucocidin-positive community-associated meticillin-resistant Staphylococcus aureus: implications for healthcare. J. Hosp. Infect. 75:258–264.
    33.
    Otter J. A., Kearns A. M., French G. L., and Ellington M. J.. 2010. Panton-Valentine leukocidin-encoding bacteriophage and gene sequence variation in community-associated methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 16:68–73.
    34.
    Popovich K. J., Weinstein R. A., and Hota B.. 2008. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin. Infect. Dis. 46:787–794.
    35.
    Takano T. et al. 2008. Novel characteristics of community-acquired methicillin-resistant Staphylococcus aureus strains belonging to multilocus sequence type 59 in Taiwan. Antimicrob. Agents Chemother. 52:837–845.
    36.
    Tamura K., Dudley J., Nei M., and Kumar S.. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24:1596–1599.
    37.
    Vandenesch F. et al. 2003. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg. Infect. Dis. 9:978–984.
    38.
    Varshney A. K. et al. 2010. Augmented production of Panton-Valentine leukocidin toxin in methicillin-resistant and methicillin-susceptible Staphylococcus aureus is associated with worse outcome in a murine skin infection model. J. Infect. Dis. 201:92–96.
    39.
    Voyich J. M. et al. 2006. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J. Infect. Dis. 194:1761–1770.
    40.
    Waldron D. E. and Lindsay J. A.. 2006. SauI: a novel lineage-specific type I restriction-modification system that blocks horizontal gene transfer into Staphylococcus aureus and between S. aureus isolates of different lineages. J. Bacteriol. 188:5578–5585.
    41.
    Wirtz C., Witte W., Wolz C., and Goerke C.. 2010. Insertion of host DNA into PVL-encoding phages of the Staphylococcus aureus lineage ST80 by intra-chromosomal recombination. Virology 406:322–327.
    42.
    Wolter D. J., Tenover F. C., and Goering R. V.. 2007. Allelic variation in genes encoding Panton-Valentine leukocidin from community-associated Staphylococcus aureus. Clin. Microbiol. Infect. 13:827–830.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 49Number 2February 2011
    Pages: 684 - 692

    History

    Received: 21 September 2010
    18 October 2010
    Accepted: 15 November 2010
    Published online: 4 February 2011

    Permissions

    Request permissions for this article.

    Contributors

    Authors

    Staphylococcus Reference Unit, Centre for Infections, Health Protection Agency, London NW9 5EQ, United Kingdom
    A. M. Kearns
    Staphylococcus Reference Unit, Centre for Infections, Health Protection Agency, London NW9 5EQ, United Kingdom
    M. Ganner
    Staphylococcus Reference Unit, Centre for Infections, Health Protection Agency, London NW9 5EQ, United Kingdom
    C. Perry
    Staphylococcus Reference Unit, Centre for Infections, Health Protection Agency, London NW9 5EQ, United Kingdom
    R. L. Hill
    Antibiotic Resistance Evaluation Unit, Centre for Infections, Health Protection Agency, London NW9 5EQ, United Kingdom
    M. J. Ellington
    Staphylococcus Reference Unit, Centre for Infections, Health Protection Agency, London NW9 5EQ, United Kingdom
    Present address: Health Protection Agency Cambridge Microbiology and Public Health Laboratory, Addenbrooke's Hospital, Cambridge CB2 0QW, United Kingdom.

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Optimizing DNA Extraction Methods for Nanopore Sequencing of Neisseria gonorrhoeae Directly from Urine Samples

    Optimizing DNA Extraction Methods for Nanopore Sequencing of Neisseria gonorrhoeae Directly from Urine Samples

    ABSTRACT

    Empirical gonorrhea treatment at initial diagnosis reduces onward transmission. However, increasing resistance to multiple antibiotics may necessitate waiting for culture-based diagnostics to select an effective treatment. There is a need for same-day culture-free diagnostics that identify infection and detect antimicrobial resistance. We investigated if Nanopore sequencing can detect sufficient Neisseria gonorrhoeae DNA to reconstruct whole genomes directly from urine samples. We used N. gonorrhoeae-spiked urine samples and samples from gonorrhea infections to determine optimal DNA extraction methods that maximize the amount of N. gonorrhoeae DNA sequenced while minimizing contaminating host DNA. In simulated infections, the Qiagen UCP pathogen mini kit provided the highest ratio of N. gonorrhoeae to human DNA and the most consistent results. Depletion of human DNA with saponin increased N. gonorrhoeae yields in simulated infections but decreased yields in clinical samples. In 10 urine samples from men with symptomatic urethral gonorrhea, ≥92.8% coverage of an N. gonorrhoeae reference genome was achieved in all samples, with ≥93.8% coverage breath at ≥10-fold depth in 7 (70%) samples. In simulated infections, if ≥104 CFU/ml of N. gonorrhoeae was present, sequencing of the large majority of the genome was frequently achieved. N. gonorrhoeae could also be detected from urine in cobas PCR medium tubes and from urethral swabs and in the presence of simulated Chlamydia coinfection. Using Nanopore sequencing of urine samples from men with urethral gonorrhea, sufficient data can be obtained to reconstruct whole genomes in the majority of samples without the need for culture.

    REFERENCES

    1.
    Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, Stevens G, Gottlieb S, Kiarie J, Temmerman M. 2015. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One 10:e0143304.
    2.
    Unemo M. 2015. Current and future antimicrobial treatment of gonorrhoea—the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis 15:364.
    3.
    Fifer H, Saunders J, Soni S, Sadiq T, Fitzgerald M. 2019. British Association for Sexual Health and HIV national guideline for the management of infection with Neisseria gonorrhoeae. British Association for Sexual Health and HIV, Bacclesfield, England. https://www.bashhguidelines.org/media/1208/gc-2019.pdf.
    4.
    Eyre DW, Town K, Street T, Barker L, Sanderson N, Cole MJ, Mohammed H, Pitt R, Gobin M, Irish C, Gardiner D, Sedgwick J, Beck C, Saunders J, Turbitt D, Cook C, Phin N, Nathan B, Horner P, Fifer H. 2019. Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018. Eurosurveillance 24:1900147.
    5.
    Eyre DW, Sanderson ND, Lord E, Regisford-Reimmer N, Chau K, Barker L, Morgan M, Newnham R, Golparian D, Unemo M, Crook DW, Peto TE, Hughes G, Cole MJ, Fifer H, Edwards A, Andersson MI. 2018. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Eurosurveillance 23:364.
    6.
    Workowski KA, Bolan GA, Centers for Disease Control and Prevention. 2015. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 64:1–137.
    7.
    Thakur SD, Parmar NR, Dillon J-A. 2018. Time to develop standardized molecular diagnostics for the simultaneous detection of Neisseria gonorrhoeae and its antimicrobial resistance. Sex Transm Dis 45:316–318.
    8.
    Whiley DM, Trembizki E, Buckley C, Freeman K, Baird RW, Beaman M, Chen M, Donovan B, Kundu RL, Fairley CK, Guy R, Hogan T, Kaldor JM, Karimi M, Limnios A, Regan DG, Ryder N, Su J-Y, Ward J, Lahra MM. 2017. Molecular antimicrobial resistance surveillance for Neisseria gonorrhoeae, Northern Territory, Australia. Emerg Infect Dis 23:1478–1485.
    9.
    Melendez JH, Hardick J, Barnes M, Barnes P, Geddes CD, Gaydos CA. 2018. Molecular characterization of markers associated with antimicrobial resistance in Neisseria gonorrhoeae identified from residual clinical samples. Sex Transm Dis 45:312–315.
    10.
    Chiu CY, Miller SA. 2019. Clinical metagenomics. Nat Rev Genet 20:341–355.
    11.
    Graham RMA, Doyle CJ, Jennison AV. 2017. Epidemiological typing of Neisseria gonorrhoeae and detection of markers associated with antimicrobial resistance directly from urine samples using next generation sequencing. Sex Transm Infect 93:65–67.
    12.
    Bachmann NL, Rockett RJ, Timms VJ, Sintchenko V. 2018. Advances in clinical sample preparation for identification and characterization of bacterial pathogens using metagenomics. Front Public Heal 6:363.
    13.
    Seth-Smith HMB, Harris SR, Skilton RJ, Radebe FM, Golparian D, Shipitsyna E, Duy PT, Scott P, Cutcliffe LT, O'Neill C, Parmar S, Pitt R, Baker S, Ison CA, Marsh P, Jalal H, Lewis DA, Unemo M, Clarke IN, Parkhill J, Thomson NR. 2013. Whole-genome sequences of Chlamydia trachomatis directly from clinical samples without culture. Genome Res 23:855–866.
    14.
    Christiansen MT, Brown AC, Kundu S, Tutill HJ, Williams R, Brown JR, Holdstock J, Holland MJ, Stevenson S, Dave J, Tong CW, Einer-Jensen K, Depledge DP, Breuer J. 2014. Whole-genome enrichment and sequencing of Chlamydia trachomatis directly from clinical samples. BMC Infect Dis 14:591.
    15.
    Schmidt K, Mwaigwisya S, Crossman LC, Doumith M, Munroe D, Pires C, Khan AM, Woodford N, Saunders NJ, Wain J, O'Grady J, Livermore DM. 2017. Identification of bacterial pathogens and antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing. J Antimicrob Chemother 72:104–114.
    16.
    Charalampous T, Kay GL, Richardson H, Aydin A, Baldan R, Jeanes C, Rae D, Grundy S, Turner DJ, Wain J, Leggett RM, Livermore DM, O'Grady J. 2019. Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection. Nat Biotechnol 37:783–792.
    17.
    Street TL, Sanderson ND, Atkins BL, Brent AJ, Cole K, Foster D, McNally MA, Oakley S, Peto L, Taylor A, Peto TEA, Crook DW, Eyre DW. 2017. Molecular diagnosis of orthopedic-device-related infection directly from sonication fluid by metagenomic sequencing. J Clin Microbiol 55:2334–2347.
    18.
    Herrera LJ, Raja S, Gooding WE, El-Hefnawy T, Kelly L, Luketich JD, Godfrey TE. 2005. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem 51:113–118.
    19.
    Whiley DM, Sloots TP. 2005. Comparison of three in-house multiplex PCR assays for the detection of Neisseria gonorrhoeae and Chlamydia trachomatis using real-time and conventional detection methodologies. Pathology 37:364–370.
    20.
    Kim D, Song L, Breitwieser FP, Salzberg SL. 2016. Centrifuge: rapid and sensitive classification of metagenomic sequences. Genome Res 26:1721–1729.
    21.
    Li H. 2018. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34:3094–3100.
    22.
    Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Subgroup 1000 Genome Project Data Processing. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25:2078–2079.
    23.
    Sanderson ND, Street TL, Foster D, Swann J, Atkins BL, Brent AJ, McNally MA, Oakley S, Taylor A, Peto TEA, Crook DW, Eyre DW. 2018. Real-time analysis of nanopore-based metagenomic sequencing from infected orthopaedic devices. BMC Genomics 19:714.
    24.
    Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, Burovski E, Peterson P, Weckesser W, Bright J, van der Walt SJ, Brett M, Wilson J, Millman KJ, Mayorov N, Nelson ARJ, Jones E, Kern R, Larson E, Carey C, Polat İ, Feng Y, Moore EW, VanderPlas J, Laxalde D, Perktold J, Cimrman R, Henriksen I, Quintero EA, Harris CR, Archibald AM, Ribeiro AH, Pedregosa F, van Mulbregt P, SciPy 1.0 Contributors. 2019. SciPy 1.0–fundamental algorithms for scientific computing in Python. arXiv 1907.10121 [q-bio.GN]. https://arxiv.org/abs/1907.10121.
    25.
    Hunter JD. 2007. Matplotlib: a 2D graphics environment. Comput Sci Eng 9:99–104.
    26.
    Tyler AD, Mataseje L, Urfano CJ, Schmidt L, Antonation KS, Mulvey MR, Corbett CR. 2018. Evaluation of Oxford Nanopore’s MinION sequencing device for microbial whole genome sequencing applications. Sci Rep 8:10931.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 58Number 324 February 2020
    eLocator: e01822-19
    Editor: Daniel J. Diekema
    University of Iowa College of Medicine

    History

    Received: 31 October 2019
    22 November 2019
    Accepted: 6 December 2019
    Published online: 18 December 2019

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. DNA extraction
    2. Nanopore sequencing
    3. Neisseria gonorrhoeae
    4. whole-genome sequencing

    Contributors

    Authors

    Teresa L. Street
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Leanne Barker
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Nicholas D. Sanderson
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    James Kavanagh
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Sarah Hoosdally
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Kevin Cole
    Department of Microbiology and Infection, Royal Sussex County Hospital, Brighton, United Kingdom
    Robert Newnham
    Microbiology Laboratory, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
    Mathyruban Selvaratnam
    Microbiology Laboratory, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
    Monique Andersson
    Microbiology Laboratory, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
    Martin J. Llewelyn
    Department of Microbiology and Infection, Royal Sussex County Hospital, Brighton, United Kingdom
    Justin O’Grady
    Quadram Institute Bioscience, Norwich, United Kingdom
    Derrick W. Crook
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, United Kingdom
    David W. Eyre
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, United Kingdom
    Big Data Institute, University of Oxford, Oxford, United Kingdom
    the GonFast Investigators Group

    Editor

    Daniel J. Diekema
    Editor
    University of Iowa College of Medicine

    Notes

    Address correspondence to Teresa L. Street, [email protected], or David W. Eyre, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Closing the Brief Case: Cutaneous Fungal Infection in a Pediatric Patient with Newly Diagnosed Acute Lymphocytic Leukemia

    Closing the Brief Case: Cutaneous Fungal Infection in a Pediatric Patient with Newly Diagnosed Acute Lymphocytic Leukemia

    Authors: Liye Suo and James J. Dunn

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 58Number 324 February 2020
    eLocator: e00788-19
    Editor: Carey-Ann D. Burnham
    Washington University School of Medicine

    History

    Published online: 24 February 2020

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. cutaneous fungal infection
    2. mucormycosis
    3. Rhizopus
    4. leukemia

    Contributors

    Authors

    Liye Suo
    Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA
    James J. Dunn
    Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA
    Department of Pathology, Texas Children’s Hospital, Houston, Texas, USA

    Editor

    Carey-Ann D. Burnham
    Editor
    Washington University School of Medicine

    Notes

    Address correspondence to James J. Dunn, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework

    Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework

    ABSTRACT

    Hybribio’s 14 High-Risk HPV with 16/18 genotyping real-time PCR (HBRT-H14) is a human papillomavirus (HPV) assay with approval from the China Food and Drug Administration that is widely used in China. VALGENT (VALidation of HPV GENotyping Tests) is an established framework for evaluating HPV tests’ clinical performance relative to validated comparators. The aim of this study was to assess the clinical accuracy of HBRT-H14 following international validation criteria. Within VALGENT-3, clinical performance of HBRT-H14 was compared with Hybrid Capture 2 (HC2), Linear Array HPV genotyping test (Linear Array), and Cobas 4800 HPV test (Cobas). VALGENT-3 comprised 1,300 consecutive samples and 300 abnormal cytological samples from the Slovenian cervical cancer screening program. Disease was defined as histologically confirmed cervical intraepithelial neoplasia scoring grade 2 or worse (CIN2+) and CIN3+, and two negative cytology results in a row were a proxy for nondisease. In the total study population, relative sensitivity and specificity of HBRT-H14 versus HC2 for detecting CIN2+ were 0.98 (95% confidence interval [CI], 0.94 to 1.03; P noninferiority[Pni] < 0.01) and 0.97 (95% CI, 0.96 to 0.99; Pni = 0.78), respectively. Applying an optimized a posteriori cutoff, defined using Linear Array and Cobas as bridging tests, yielded relative values of 0.98 (95% CI, 0.94 to 1.03; Pni < 0.01) and 1.01 (95% CI, 1.00 to 1.03; Pni < 0.01), respectively. In conclusion, HBRT-H14 was as sensitive but less specific than HC2 for detecting cervical precancer at the predefined cutoff. However, HBRT-H14 fulfilled international accuracy criteria for cervical cancer screening when using an optimized cutoff and might be attractive in low-resource settings given its low cost.

    REFERENCES

    1.
    Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer C, International HPV Screening Working Group. 2014. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383:524–532.
    2.
    Arbyn M, Ronco G, Anttila A, Meijer C, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J. 2012. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30:F88–F99.
    3.
    Poljak M, Kocjan BJ. 2010. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther 8:1139–1162.
    4.
    Poljak M, Kocjan BJ, Ostrbenk A, Seme K. 2016. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J Clin Virol 76:S3–S9.
    5.
    Arbyn M, Snijders PJ, Meijer C, Berkhof H, Cuschieri K, Kocjan BJ, Poljak M. 2015. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Micro Biol Infect 21:817–826.
    6.
    Meijer CJLM, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DAM, Snijders PJF. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124:516–520.
    7.
    Arbyn M, Depuydt C, Benoy I, Bogers J, Cuschieri K, Schmitt M, Pawlita M, Geraets D, Heard I, Gheit T, Tommasino M, Poljak M, Bonde J, Quint W. 2016. VALGENT: a protocol for clinical validation of human papillomavirus assays. J Clin Virol 76:S14–S21.
    8.
    Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, Arbyn M, Pawlita M, VALGENT Study Group, 2013. Prevalence and viral load of 51 genital human papillomavirus types and three subtypes. Int J Cancer 132:2395–2403.
    9.
    Schmitt M, Depuydt CE, Benoy I, Bogers J, Antoine J, Pawlita M, Arbyn M, on behalf of the VALGENT study group. 2013. Viral load of high-risk human papillomaviruses as reliable clinical predictor for the presence of cervical lesions. Cancer Epidemiol Biomarkers Prev 22:406–414.
    10.
    Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, Arbyn M, Pawlita M, on behalf of the VALGENT Study Group. 2013. Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities. J Clin Microbiol 51:1458–1464.
    11.
    Cuschieri K, Geraets DT, Moore C, Quint W, Duvall E, Arbyn M. 2015. Clinical and analytical performance of the Onclarity HPV assay using the VALGENT framework. J Clin Microbiol 53:3272–3279.
    12.
    Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C, Vanden Broeck D, Padalko E, Quint W, Arbyn M. 2016. Performance of a cartridge-based assay for the detection of clinically significant human papillomavirus infection - lessons from VALGENT (Validation of HPV Genotyping Tests). J Clin Microbiol 54:2337–2347.
    13.
    Geraets D, Cuschieri K, Koning M, van Doorn L, Snijders P, Meijer C, Quint W, Arbyn M. 2014. Clinical evaluation of a GP5+/6+-based Luminex assay having full high-risk HPV genotyping capability and an internal control. J Clin Microbiol 52:3996–4002.
    14.
    Heard I, Cuschieri K, Geraets DT, Quint W, Arbyn M. 2016. Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework. J Clin Virol 81:6–11.
    15.
    Polman NJ, Ostrbenk A, Xu L, Snijders P, Meijer C, Poljak M, Heideman DA, Arbyn M. 2017. Evaluation of the clinical performance of the HPV-Risk assay using the VALGENT-3 panel. J Clin Microbiol 55:3544–3551.
    16.
    Xu L, Ostrbenk A, Poljak M, Arbyn M. 2018. Assessment of the Roche Linear Array HPV genotyping test within the VALGENT framework. J Clin Virol 98:37–42.
    17.
    Xu L, Padalko E, Ostrbenk A, Poljak M, Arbyn M. 2018. Clinical evaluation of INNO-LiPA HPV genotyping EXTRA II assay using the VALGENT framework. Int J Mol Sci 19:2704.
    18.
    Ostrbenk A, Xu L, Arbyn M, Poljak M. 2018. Clinical and analytical evaluation of the Anyplex II HPV HR Detection assay within the VALGENT-3 framework. J Clin Microbiol 56:e01176-18.
    19.
    Viti J, Poljak M, Ostrbenk A, Bhatia R, Alcaniz BE, Cornall AM, Cuschieri K, Garland S, Xu L, Arbyn M. 2018. Validation of EUROArray HPV test using the VALGENT framework. J Clin Virol 108:38–42.
    20.
    Benoy I, Xu L, Vanden Broeck D, Poljak M, Oštrbenk Valenčak A, Arbyn M, Bogers J. 2019. Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay. J Clin Virol 120:57–62.
    21.
    Bonde J, Ejegod DM, Cuschieri K, Dillner J, Heideman DAM, Quint W, Pavon Ribas MA, Padalko E, Christiansen IK, Xu L, Arbyn M. 2018. The Valgent4 protocol: robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium. J Clin Virol 108:64–71.
    22.
    Heideman DAM, Xu L, Hesselink AT, Doorn S, Ejegod DM, Pedersen H, Quint WGV, Bonde J, Arbyn M. 2019. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel. J Clin Virol 121:104201–104201.
    23.
    Poljak M, Ostrbenk A, Seme K, Ucakar V, Hillemanns P, Bokal EV, Jancar N, Klavs I. 2011. Comparison of clinical and analytical performance of the Abbott RealTime High Risk HPV Test to the performance of Hybrid Capture 2 in population-based cervical cancer screening. J Clin Microbiol 49:1721–1729.
    24.
    Bian ML, Cheng JY, Ma L, Cong X, Liu J, Chen Y, Chen X. 2013. Evaluation of the detection of 14 high-risk human papillomaviruses with HPV 16 and HPV 18 genotyping for cervical cancer screening. Exp Ther Med 6:1332–1336.
    25.
    McNemar Q. 1947. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 12:153–157.
    26.
    Tang NS, Tang ML, Chan IS. 2003. On tests of equivalence via non-unity relative risk for matched-pair design. Stat Med 22:1217–1233.
    27.
    Xue P, Gao LL, Yin J, Han LL, Zhao J, Li L, Seery S, Han XY, Li TY, Jiang Y, Chen W, Shen J. 2019. A direct comparison of four high-risk human papillomavirus tests versus the cobas test: detecting CIN2+ in low-resource settings. J Med Virol 91:1342–1350.
    28.
    Arbyn M, Van Veen E-B, Andersson K, Bogers J, Boulet G, Bergeron C, von Knebel-Doeberitz M, Dillner J. 2010. Cervical cytology biobanking in Europe. Int J Biol Markers 25:117–125.
    29.
    Eklund C, Forslund O, Wallin KL, Dillner J. 2018. Continuing global improvement in human papillomavirus DNA genotyping services: the 2013 and 2014 HPV LabNet international proficiency studies. J Clin Virol 101:74–85.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 58Number 626 May 2020
    eLocator: e00234-20
    Editor: Angela M. Caliendo
    Rhode Island Hospital

    History

    Received: 7 February 2020
    4 March 2020
    Accepted: 19 March 2020
    Published online: 3 April 2020

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. Hybribio
    2. VALGENT
    3. HPV genotyping
    4. cervical cancer
    5. human papillomavirus
    6. test validation

    Contributors

    Authors

    Belgian Cancer Centre/Unit of Cancer Epidemiology, Sciensano, Brussels, Belgium
    Anja Oštrbenk Valenčak
    Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
    Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
    Marc Arbyn
    Belgian Cancer Centre/Unit of Cancer Epidemiology, Sciensano, Brussels, Belgium

    Editor

    Angela M. Caliendo
    Editor
    Rhode Island Hospital

    Notes

    Address correspondence to Marc Arbyn, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples

    Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples

    ABSTRACT

    Targeted next-generation sequencing (tNGS) has emerged as a comprehensive alternative to existing methods for drug susceptibility testing (DST) of Mycobacterium tuberculosis from patient sputum samples for clinical diagnosis of drug-resistant tuberculosis (DR-TB). However, the complexity of sequencing platforms has limited their uptake in low-resource settings. The goal of this study was to evaluate the use of the tNGS-based DST solution Genoscreen Deeplex Myc-TB, for use on the compact, low-cost Oxford Nanopore Technologies MinION sequencer. One hundred four DNA samples extracted from smear-positive sputum sediments, previously sequenced using the Deeplex assay on an Illumina MiniSeq, were resequenced on MinION after applying a custom library preparation. MinION read quality, mapping statistics, and variant calling were computed using an in-house pipeline and compared to the reference MiniSeq data. The average percentage of MinION reads mapped to an H37RV reference genome was 90.8%, versus 99.5% on MiniSeq. The mean depths of coverage were 4,151× and 4,177× on MinION and MiniSeq, respectively, with heterogeneous distribution across targeted genes. Composite reference coverage breadth was >99% for both platforms. We observed full concordance between technologies in reporting the clinically relevant drug-resistant markers, including full gene deletions. In conclusion, we demonstrated that the workflow and sequencing data obtained from Deeplex on MinION are comparable to those for the MiniSeq, despite the higher raw error rates on MinION, with the added advantage of MinION’s portability, versatility, and low capital costs. Targeted NGS on MinION is a promising DST solution for rapidly providing clinically relevant data to manage complex DR-TB cases.

    REFERENCES

    1.
    WHO. 2015. Implementing the end TB strategy: the essentials. World Health Organization, Geneva, Switzerland.
    2.
    WHO. 2019. Global tuberculosis report 2019. World Health Organization, Geneva, Switzerland.
    3.
    Gilpin C, Korobitsyn A, Weyer K. 2016. Current tools available for the diagnosis of drug-resistant tuberculosis. Ther Adv Infect Dis 3:145–151.
    4.
    Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K, TB-NEAT team. 2014. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 383:424–435.
    5.
    Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, Banada PP, Deshpande S, Shenai S, Gall A, Glass J, Krieswirth B, Schumacher SG, Nabeta P, Tukvadze N, Rodrigues C, Skrahina A, Tagliani E, Cirillo DM, Davidow A, Denkinger CM, Persing D, Kwiatkowski R, Jones M, Alland D. 2017. The New Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio 8:e00812-17.
    6.
    WHO. 2016. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance. World Health Organization, Geneva, Switzerland.
    7.
    Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. 2018. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog 14:e1007297.
    8.
    WHO. 2019. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland.
    9.
    Cabibbe AM, Walker TM, Niemann S, Cirillo DM. 2018. Whole genome sequencing of Mycobacterium tuberculosis. Eur Respir J 52:1801163.
    10.
    McNerney R, Clark TG, Campino S, Rodrigues C, Dolinger D, Smith L, Cabibbe AM, Dheda K, Schito M. 2017. Removing the bottleneck in whole genome sequencing of Mycobacterium tuberculosis for rapid drug resistance analysis: a call to action. Int J Infect Dis 56:130–135.
    11.
    Makhado NA, Matabane E, Faccin M, Pinçon C, Jouet A, Boutachkourt F, Goeminne L, Gaudin C, Maphalala G, Beckert P, Niemann S, Delvenne JC, Delmée M, Razwiedani L, Nchabeleng M, Supply P, de Jong BC, André E. 2018. Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study. Lancet Infect Dis 18:1350–1359.
    12.
    Tagliani E, Hassan MO, Waberi Y, De Filippo MR, Falzon D, Dean A, Zignol M, Supply P, Abdoulkader MA, Hassangue H, Cirillo DM. 2017. Culture and next-generation sequencing-based drug susceptibility testing unveil high levels of drug-resistant-TB in Djibouti: results from the first national survey. Sci Rep 7:17672.
    13.
    Colman RE, Anderson J, Lemmer D, Lehmkuhl E, Georghiou SB, Heaton H, Wiggins K, Gillece JD, Schupp JM, Catanzaro DG, Crudu V, Cohen T, Rodwell TC, Engelthaler DM. 2016. Rapid drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates directly from clinical samples by use of amplicon sequencing: a proof-of-concept study. J Clin Microbiol 54:2058–2067.
    14.
    Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, Lemmer D, Engelthaler DM, Catanzaro DG, Young AG, Denkinger CM, Rodwell TC. 2019. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: a performance, ease-of-use, and cost evaluation. PLoS Med 16:e1002794.
    15.
    Park J, Shin SY, Kim K, Park K, Shin S, Ihm C. 2018. Determining genotypic drug resistance by Ion semiconductor sequencing with the Ion AmpliSeq™ TB panel in multidrug-resistant Mycobacterium tuberculosis isolates. Ann Lab Med 38:316–323.
    16.
    Quick J, Loman NJ, Duraffour S, Simpson JT, Severi E, Cowley L, Bore JA, Koundouno R, Dudas G, Mikhail A, Ouédraogo N, Afrough B, Bah A, Baum JH, Becker-Ziaja B, Boettcher J-P, Cabeza-Cabrerizo M, Camino-Sanchez A, Carter LL, Doerrbecker J, Enkirch T, Dorival IGG, Hetzelt N, Hinzmann J, Holm T, Kafetzopoulou LE, Koropogui M, Kosgey A, Kuisma E, Logue CH, Mazzarelli A, Meisel S, Mertens M, Michel J, Ngabo D, Nitzsche K, Pallash E, Patrono LV, Portmann J, Repits JG, Rickett NY, Sachse A, Singethan K, Vitoriano I, Yemanaberhan RL, Zekeng EG, Trina R, Bello A, Sall AA, Faye O, Faye O, Magassouba N, Williams CV, Amburgey V, Winona L, Davis E, Gerlach J, Washington F, Monteil V, Jourdain M, Bererd M, Camara A, Somlare H, Camara A, Gerard M, Bado G, Baillet B, Delaune D, Nebie KY, Diarra A, Savane Y, Pallawo RB, Gutierrez GJ, Milhano N, Roger I, Williams CJ, Yattara F, Lewandowski K, Taylor J, Rachwal P, Turner D, Pollakis G, Hiscox JA, Matthews DA, O'Shea MK, Johnston AM, Wilson D, Hutley E, Smit E, Di Caro A, Woelfel R, Stoecker K, Fleischmann E, Gabriel M, Weller SA, Koivogui L, Diallo B, Keita S, Rambaut A, Formenty P, Gunther S, Carroll MW. 2016. Real-time, portable genome sequencing for Ebola surveillance. Nature 530:228–232.
    17.
    Votintseva AA, Bradley P, Pankhurst L, Del Ojo Elias C, Loose M, Nilgiriwala K, Chatterjee A, Smith EG, Sanderson N, Walker TM, Morgan MR, Wyllie DH, Walker AS, Peto TEA, Crook DW, Iqbal Z. 2017. Same-day diagnostic and surveillance data for tuberculosis via whole-genome sequencing of direct respiratory samples. J Clin Microbiol 55:1285–1298.
    18.
    Bainomugisa A, Duarte T, Lavu E, Pandey S, Coulter C, Marais BJ, Coin LM. 2018. A complete high-quality MinION nanopore assembly of an extensively drug-resistant Mycobacterium tuberculosis Beijing lineage strain identifies novel variation in repetitive PE/PPE gene regions. Microb Genom 4:e000188.
    19.
    Meehan CJ, Goig GA, Kohl TA, Verboven L, Dippenaar A, Ezewudo M, Farhat MR, Guthrie JL, Laukens K, Miotto P, Ofori-Anyinam B, Dreyer V, Supply P, Suresh A, Utpatel C, van Soolingen D, Zhou Y, Ashton PM, Brites D, Cabibbe AM, de Jong BC, de Vos M, Menardo F, Gagneux S, Gao Q, Heupink TH, Liu Q, Loiseau C, Rigouts L, Rodwell TC, Tagliani E, Walker TM, Warren RM, Zhao Y, Zignol M, Schito M, Gardy J, Cirillo DM, Niemann S, Comas I, Van Rie A. 2019. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nat Rev Microbiol 17:533–545.
    20.
    van Belkum A, Burnham CD, Rossen JWA, Mallard F, Rochas O, Dunne WM. 2020. Innovative and rapid antimicrobial susceptibility testing systems. Nat Rev Microbiol 18:299–311.
    21.
    Kohl TA, Utpatel C, Schleusener V, De Filippo MR, Beckert P, Cirillo DM, Niemann S. 2018. MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates. PeerJ 6:e5895.
    22.
    Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, Gilpin C, Niemann S, Denkinger CM, Fleming J, Warren RM, Crook D, Posey J, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Murray M, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, Ranganathan UDK, McNerney R, Ezewudo M, Cirillo DM, Schito M, Köser CU, Rodwell TC. 2017. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J 50:1701354.
    23.
    Allix-Béguec C, Arandjelovic I, Bi L, Beckert P, Bonnet M, Bradley P, Cabibbe AM, Cancino-Muñoz I, Caulfield MJ, Chaiprasert A, Cirillo DM, Clifton DA, Comas I, Crook DW, De Filippo MR, de Neeling H, Diel R, Drobniewski FA, Faksri K, Farhat MR, Fleming J, Fowler P, Fowler TA, Gao Q, Gardy J, Gascoyne-Binzi D, Gibertoni-Cruz A-L, Gil-Brusola A, Golubchik T, Gonzalo X, Grandjean L, He G, Guthrie JL, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Johnston J, Khanzada FM, Khor CC, Kohl TA, Kong C, Lipworth S, Liu Q, Maphalala G, Martinez E, Mathys V, Merker M, Miotto P, Mistry N, Moore DAJ, Murray M, Niemann S, Omar SV, Ong RT-H, Peto TEA, Posey JE, Prammananan T, Pym A, Rodrigues C, Rodrigues M, Rodwell T, Rossolini GM, Sánchez Padilla E, Schito M, Shen X, Shendure J, Sintchenko V, Sloutsky A, Smith EG, Snyder M, Soetaert K, Starks AM, Supply P, Suriyapol P, Tahseen S, Tang P, Teo Y-Y, Thuong TNT, Thwaites G, Tortoli E, van Soolingen D, Walker AS, Walker TM, Wilcox M, Wilson DJ, Wyllie D, Yang Y, Zhang H, Zhao Y, Zhu B, CRyPTIC Consortium and the 100,000 Genomes Project. 2018. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. N Engl J Med 379:1403–1415.
    24.
    Köser CU, Cirillo DM, Miotto P. 22 June 2020. How to optimally combine genotypic and phenotypic drug-susceptibility testing methods for pyrazinamide. Antimicrob Agents Chemother doi:
    25.
    Tyler AD, Mataseje L, Urfano CJ, Schmidt L, Antonation KS, Mulvey MR, Corbett CR. 2018. Evaluation of Oxford Nanopore's MinION sequencing device for microbial whole genome sequencing applications. Sci Rep 8:10931.
    26.
    Temesgen Z, Cirillo DM, Raviglione MC. 2019. Precision medicine and public health interventions: tuberculosis as a model? Lancet Public Health 4:e374.
    27.
    Mongan AE, Tuda JSB, Runtuwene LR. 2020. Portable sequencer in the fight against infectious disease. J Hum Genet 65:35–40.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 58Number 1022 September 2020
    eLocator: e00632-20
    Editor: Geoffrey A. Land
    Carter BloodCare and Baylor University Medical Center

    History

    Received: 1 April 2020
    11 June 2020
    Accepted: 21 July 2020
    Published online: 29 July 2020

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. direct test
    2. drug-resistant tuberculosis
    3. next-generation sequencing
    4. portable sequencer
    5. rapid drug susceptibility testing

    Contributors

    Authors

    Andrea M. Cabibbe
    Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
    Andrea Spitaleri
    Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
    Center for Omics Sciences, IRCCS San Raffaele Scientific Institute, Milan, Italy
    Simone Battaglia
    Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
    Rebecca E. Colman
    Foundation for Innovative New Diagnostics, Campus Biotech, Geneva, Switzerland
    Department of Medicine, University of California, San Diego, California, USA
    Anita Suresh
    Foundation for Innovative New Diagnostics, Campus Biotech, Geneva, Switzerland
    Swapna Uplekar
    Foundation for Innovative New Diagnostics, Campus Biotech, Geneva, Switzerland
    Timothy C. Rodwell
    Foundation for Innovative New Diagnostics, Campus Biotech, Geneva, Switzerland
    Department of Medicine, University of California, San Diego, California, USA
    Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Editor

    Geoffrey A. Land
    Editor
    Carter BloodCare and Baylor University Medical Center

    Notes

    Address correspondence to Daniela M. Cirillo, [email protected].
    Timothy C. Rodwell and Daniela M. Cirillo are co-senior authors.

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Evaluation of the Revogene Carba C Assay for Detection and Differentiation of Carbapenemase-Producing Gram-Negative Bacteria

    Evaluation of the Revogene Carba C Assay for Detection and Differentiation of Carbapenemase-Producing Gram-Negative Bacteria

    ABSTRACT

    The Revogene Carba C assay (formerly GenePOC Carba assay) is a multiplex nucleic acid-based in vitro diagnostic test intended for the detection of carbapenemase-producing Enterobacterales (CPE) from cultured colonies. This assay was evaluated directly on colonies of 118 well-characterized Enterobacterales with reduced susceptibility to carbapenems and on 49 multidrug-resistant (MDR) Pseudomonas aeruginosa and 40 MDR Acinetobacter baumannii isolates. The Revogene Carba C assay’s performance was high, as it was able to detect the five major carbapenemases (NDM, VIM, IMP, KPC, and OXA-48). In Enterobacterales, sensitivity and specificity were 100%. When extrapolating the results to the French CPE epidemiology between 2012 and 2018, this assay would have detected 99.28% of the 9,624 CPE isolates sent to the French NRC, missing 69 CPE isolates (2 GES-5, 10 OXA-23, 2 TMB-1, 1 SME-4, 53 IMI, and 1 FRI). The overall sensitivity and specificity for CP P. aeruginosa were 93.7 and 100%, respectively, as two rare IMP variants (IMP-31 and -46) were not detected. Extrapolating these results to the French epidemiology of CP P. aeruginosa in 2017, 93.3% would have been identified, missing only 1 DIM and 10 GES variants. The Revogene Carba C assay accurately identified the targeted carbapenemase genes in A. baumannii, but when extrapolating these results to the French CP A. baumannii epidemiology of 2017, only 12.50% of them could be detected, as OXA-23 is the most prevalent carbapenemase in CP A. baumannii. The Revogene Carba C assay showed excellent sensitivity and specificity for the five most common carbapenemases regardless of the bacterial host. It is well adapted to the CPE and CP P. aeruginosa epidemiology of many countries worldwide, which makes it suitable for use in the routine microbiology laboratory, with a time to result of ca. 85 min for eight isolates simultaneously.

    REFERENCES

    1.
    Logan LK, Weinstein RA. 2017. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 215:S28–S36.
    2.
    Gniadek TJ, Carroll KC, Simner PJ. 2016. Carbapenem-resistant non-glucose-fermenting Gram-negative bacilli: the missing piece to the puzzle. J Clin Microbiol 54:1700–1710.
    3.
    Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791–1798.
    4.
    Naas T, Dortet L, Iorga BI. 2016. Structural and functional aspects of class A carbapenemases. Curr Drug Targets 17:1006–1028.
    5.
    Nordmann P, Dortet L, Poirel L. 2012. Carbapenem resistance in Enterobacteriaceae: here is the storm!. Trends Mol Med 18:263–272.
    6.
    Bonnin RA, Nordmann P, Poirel L. 2013. Screening and deciphering antibiotic resistance in Acinetobacter baumannii: a state of the art. Expert Rev Anti Infect Ther 11:571–583.
    7.
    Queenan AM, Bush K. 2007. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20:440–458.
    8.
    Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL, European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. 2015. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries. Euro Surveill 20:30062.
    9.
    Potron A, Poirel L, Nordmann P. 2015. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents 45:568–585.
    10.
    Falagas ME, Karageorgopoulos DE, Nordmann P. 2011. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol 6:653–666.
    11.
    Alizadeh N, Rezaee MA, Kafil HS, Barhaghi MHS, Memar MY, Milani M, Hasani A, Ghotaslou R. 2018. Detection of carbapenem-resistant Enterobacteriaceae by chromogenic screening media. J Microbiol Methods 153:40–44.
    12.
    Girlich D, Bouihat N, Poirel L, Benouda A, Nordmann P. 2014. High rate of faecal carriage of extended-spectrum β-lactamase and OXA-48 carbapenemase-producing Enterobacteriaceae at a university hospital in Morocco. Clin Microbiol Infect 20:350–354.
    13.
    Nordmann P, Poirel L, Dortet L. 2012. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 18:1503–1507.
    14.
    Muntean MM, Muntean AA, Gauthier L, Creton E, Cotellon G, Popa MI, Bonnin RA, Naas T. 2018. Evaluation of the rapid carbapenem inactivation method (rCIM): a phenotypic screening test for carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 73:900–908.
    15.
    Boutal H, Vogel A, Bernabeu S, Devilliers K, Creton E, Cotellon G, Plaisance M, Oueslati S, Dortet L, Jousset A, Simon S, Naas T, Volland H. 2018. A multiplex lateral flow immunoassay for the rapid identification of NDM-, KPC-, IMP- and VIM-type and OXA-48-like carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 73:909–915.
    16.
    Glupczynski Y, Evrard S, Ote I, Mertens P, Huang TD, Leclipteux T, Bogaerts P. 2016. Evaluation of two new commercial immunochromatographic assays for the rapid detection of OXA-48 and KPC carbapenemases from cultured bacteria. J Antimicrob Chemother 71:1217–1222.
    17.
    Lasserre C, De Saint Martin L, Cuzon G, Bogaerts P, Lamar E, Glupczynski Y, Naas T, Tandé D. 2015. Efficient detection of carbapenemase activity in Enterobacteriaceae by matrix-assisted laser desorption ionization−time of flight mass spectrometry in less than 30 minutes. J Clin Microbiol 53:2163–2171.
    18.
    Bogaerts P, Yunus S, Massart M, Huang T-D, Glupczynski Y. 2016. Evaluation of the BYG Carba Test, a new electrochemical assay for rapid laboratory detection of carbapenemase-producing Enterobacteriaceae. J Clin Microbiol 54:349–358.
    19.
    Bernabeu S, Dortet L, Naas T. 2017. Evaluation of the β-CARBATM test, a colorimetric test for the rapid detection of carbapenemase activity in Gram-negative bacilli. J Antimicrob Chemother 72:1646–1658.
    20.
    Dortet L, Bernabeu S, Gonzalez C, Naas T. 2018. Evaluation of the Carbapenem Detection Set™ for the detection and characterization of carbapenemase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis doi:
    21.
    Doyle D, Peirano G, Lascols C, Lloyd T, Church DL, Pitout J. 2012. Laboratory detection of Enterobacteriaceae that produce carbapenemases. J Clin Microbiol 50:3877–3880.
    22.
    McMullen AR, Yarbrough ML, Wallace MA, Shupe A, Burnham C-A. 2017. Evaluation of genotypic and phenotypic methods to detect carbapenemase production in Gram-negative bacilli. Clin Chem 63:723–730.
    23.
    Ellington MJ, Ekelund O, Aarestrup FM, Canton R, Doumith M, Giske C, Grundman H, Hasman H, Holden MT, Hopkins KL, Iredell J, Kahlmeter G, Köser CU, MacGowan A, Mevius D, Mulvey M, Naas T, Peto T, Rolain JM, Samuelsen Ø, Woodford N. 2017. The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. Clin Microbiol Infect 23:2–22.
    24.
    Girlich D, Bernabeu S, Grosperrin V, Langlois I, Begasse C, Arangia N, Creton E, Cotellon G, Sauvadet A, Dortet L, Naas T. 2018. Evaluation of the Amplidiag CarbaR + MCR kit for the accurate detection of carbapenemase-producing and colistin-resistant bacteria. J Clin Microbiol 57:e01800-18.
    25.
    Oueslati S, Girlich D, Dortet L, Naas T. 2018. Evaluation of the Amplidiag CarbaR+VRE Kit for accurate detection of carbapenemase-producing bacteria. J Clin Microbiol 56:e01092-17.
    26.
    Nijhuis R, Samuelsen Ø, Savelkoul P, van Zwet A. 2013. Evaluation of a new real-time PCR assay (Check-Direct CPE) for rapid detection of KPC, OXA-48, VIM, and NDM carbapenemases using spiked rectal swabs. Diagn Microbiol Infect Dis 77:316–320.
    27.
    García-Fernández S, Morosini MI, Marco F, Gijón D, Vergara A, Vila J, Ruiz-Garbajosa P, Cantón R. 2015. Evaluation of the eazyplex SuperBug CRE system for rapid detection of carbapenemases and ESBLs in clinical Enterobacteriaceae isolates recovered at two Spanish hospitals. J Antimicrob Chemother 70:1047–1050.
    28.
    Girlich D, Bernabeu S, Fortineau N, Dortet L, Naas T. 2018. Evaluation of the CRE and ESBL ELITe MGB kits for the accurate detection of carbapenemase- or CTX-M–producing bacteria. Diagn Microbiol Infect Dis 92:1–7.
    29.
    Girlich D, Oueslati S, Bernabeu S, Fortineau N, Dortet L, Naas T. 2019. Detection of carbapenemase-producers directly from rectal swabs using the BD Max™ check-points CPO system, abstr CPHM-957. ASM Microbe, 20 to 27 June 2019, San Francisco, CA, USA.
    30.
    Dortet L, Fusaro M, Naas T. 2016. Improvement of the Xpert Carba-R kit for the detection of carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 60:3832–3837.
    31.
    Hoyos-Mallecot Y, Ouzani S, Dortet L, Fortineau N, Naas T. 2017. Performance of the Xpert Carba-R v2 in the daily workflow of a hygiene unit in a country with a low prevalence of carbapenemase-producing Enterobacteriaceae. Int J Antimicrob Agents 49:774–777.
    32.
    Dortet L, Cuzon G, Ponties V, Nordmann P. 2017. Trends in carbapenemase-producing Enterobacteriaceae, France, 2012 to 2014. Euro Surveill 22:30461.
    33.
    Lucena Baeza L, Pfennigwerth N, Hamprecht A. 2019. Rapid and easy detection of carbapenemases in Enterobacterales in the routine laboratory using the new GenePOC Carba/Revogene Carba C assay. J Clin Microbiol 57:e00597-19.
    34.
    Oueslati S, Nordmann P, Poirel L. 2015. Heterogeneous hydrolytic features for OXA-48-like β-lactamases. J Antimicrob Chemother 70:1059–1063.
    35.
    Dortet L, Naas T. 2017. Noncarbapenemase OXA-48 variants (OXA-163 and OXA-405) falsely detected as carbapenemases by the β Carba test. J Clin Microbiol 55:654–655.
    36.
    Dabos L, Bogaerts P, Bonnin RA, Zavala A, Sacré P, Iorga BI, Huang DT, Glupczynski Y, Naas T. 2018. Genetic and biochemical characterization of OXA-519, a novel OXA-48-like β-lactamase. Antimicrob Agents Chemother 62:e00469-18.
    37.
    Hoyos-Mallecot Y, Naas T, Bonnin RA, Patino R, Glaser P, Fortineau N, Dortet L. 2017. OXA-244-producing Escherichia coli isolates, a challenge for clinical microbiology laboratories. Antimicrob Agents Chemother 61:e00818-17.
    38.
    Naas T, Oueslati S, Bonnin RA, Dabos ML, Zavala A, Dortet L, Retailleau P, Iorga BI. 2017. Beta-lactamase database (BLDB)—structure and function. J Enzyme Inhib Med Chem 32:917–919.
    39.
    Jousset AB, Dabos L, Bonnin RA, Girlich D, Potron A, Cabanel N, Dortet L, Glaser P, Naas T. 2017. CTX-M-15-producing Shewanella species clinical isolate expressing OXA-535, a chromosome-encoded OXA-48 variant, putative progenitor of the plasmid-encoded OXA-436. Antimicrob Agents Chemother 62:e01879-17.
    40.
    Samuelsen Ø, Hansen F, Aasnæs B, Hasman H, Lund BA, Leiros H-K, Lilje B, Janice J, Jakobsen L, Littauer P, Søes LM, Holzknecht BJ, Andersen LP, Stegger M, Andersen PS, Hammerum AM. 2017. Dissemination and characteristics of a novel plasmid-encoded carbapenem-hydrolyzing class D β-lactamase, OXA-436, found in isolates from four patients at six different hospitals in Denmark. Antimicrob Agents Chemother 62:e01260-17.
    41.
    Dortet L, Oueslati S, Jeannot K, Tandé D, Naas T, Nordmann P. 2015. Genetic and biochemical characterization of OXA-405, an OXA-48-type extended-spectrum β-lactamase without significant carbapenemase activity. Antimicrob Agents Chemother 59:3823–3828.
    42.
    Arlet G, Decré D, Lavollay M, Podglajen I. 2017. Reply to “Noncarbapenemase OXA-48 variants (OXA-163 and OXA-405) falsely detected as carbapenemases by the β Carba test. J Clin Microbiol 55:656–657.
    43.
    Dabos L, Oueslati S, Bernabeu S, Jousset AB, Dortet L, Naas T. 2019. Oxa-48-like enzymes: carbapenemase or not?, abstr AAR-652. ASM Microbe, 20 to 27 June 2019, San Francisco, CA, USA.
    44.
    Hopkins KL, Meunier D, Naas T, Volland H, Woodford N. 2018. Evaluation of the NG-Test CARBA 5 multiplex immunochromatographic assay for the detection of KPC, OXA-48-like, NDM, VIM and IMP carbapenemases. J Antimicrob Chemother 73:3523–3526.
    46.
    Potron A, Fournier D, Emeraud C, Triponney P, Plésiat P, Naas T, Dortet L. 2019. Evaluation of the immunochromatographic NG-Test Carba 5 for rapid identification of carbapenemase in nonfermenters. Antimicrob Agents Chemother 63:e00968-19.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 58Number 425 March 2020
    eLocator: e01927-19
    Editor: Daniel J. Diekema
    University of Iowa College of Medicine

    History

    Received: 18 November 2019
    20 December 2019
    Accepted: 24 January 2020
    Published online: 25 March 2020

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. multiplex PCR
    2. Gram-negative bacteria
    3. real time
    4. screening

    Contributors

    Authors

    Delphine Girlich
    EA7361 “Structure, dynamic, function and expression of broad spectrum β-lactamases,” Université Paris-Saclay, LabEx Lermit, Faculty of Medicine, Le Kremlin-Bicêtre, France
    Evolution and Ecology of Resistance to Antibiotics Unit, Institut Pasteur-APHP, Paris, France
    Marine Laguide
    EA7361 “Structure, dynamic, function and expression of broad spectrum β-lactamases,” Université Paris-Saclay, LabEx Lermit, Faculty of Medicine, Le Kremlin-Bicêtre, France
    Evolution and Ecology of Resistance to Antibiotics Unit, Institut Pasteur-APHP, Paris, France
    EA7361 “Structure, dynamic, function and expression of broad spectrum β-lactamases,” Université Paris-Saclay, LabEx Lermit, Faculty of Medicine, Le Kremlin-Bicêtre, France
    Evolution and Ecology of Resistance to Antibiotics Unit, Institut Pasteur-APHP, Paris, France
    Bacteriology-Hygiene Unit, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France
    Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-producing Enterobacteriaceae, Le Kremlin-Bicêtre, France
    EA7361 “Structure, dynamic, function and expression of broad spectrum β-lactamases,” Université Paris-Saclay, LabEx Lermit, Faculty of Medicine, Le Kremlin-Bicêtre, France
    Evolution and Ecology of Resistance to Antibiotics Unit, Institut Pasteur-APHP, Paris, France
    Bacteriology-Hygiene Unit, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France
    Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-producing Enterobacteriaceae, Le Kremlin-Bicêtre, France

    Editor

    Daniel J. Diekema
    Editor
    University of Iowa College of Medicine

    Notes

    Address correspondence to Thierry Naas, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Using a Resequencing Microarray as a Multiple Respiratory Pathogen Detection Assay

    ABSTRACT

    Simultaneous testing for detection of infectious pathogens that cause similar symptoms (e.g., acute respiratory infections) is invaluable for patient treatment, outbreak prevention, and efficient use of antibiotic and antiviral agents. In addition, such testing may provide information regarding possible coinfections or induced secondary infections, such as virally induced bacterial infections. Furthermore, in many cases, detection of a pathogen requires more than genus/species-level resolution, since harmful agents (e.g., avian influenza virus) are grouped with other, relatively benign common agents, and for every pathogen, finer resolution is useful to allow tracking of the location and nature of mutations leading to strain variations. In this study, a previously developed resequencing microarray that has been demonstrated to have these capabilities was further developed to provide individual detection sensitivity ranging from 101 to 103 genomic copies for more than 26 respiratory pathogens while still retaining the ability to detect and differentiate between close genetic neighbors. In addition, the study demonstrated that this system allows unambiguous and reproducible sequence-based strain identification of the mixed pathogens. Successful proof-of-concept experiments using clinical specimens show that this approach is potentially very useful for both diagnostics and epidemic surveillance.

    REFERENCES

    1.
    Bellau-Pujol, S., A. Vabret, L. Legrand, J. Dina, S. Gouarin, J. Petitjean-Lecherbonnier, B. Pozzetto, C. Ginevra, and F. Freymuth.2005. Development of three multiplex RT-PCR assays for the detection of 12 respiratory RNA viruses. J. Virol. Methods126:53-63.
    2.
    Briese, T., G. Palacios, M. Kokoris, O. Jabado, Z. Liu, N. Renwick, V. Kapoor, I. Casas, F. Pozo, R. Limberger, P. Perez-Brena, J. Ju, and W. I. Lipkin.2005. Diagnostic system for rapid and sensitive differential detection of pathogens. Emerg. Infect. Dis.11:310-313.
    3.
    Brownie, J., S. Shawcross, J. Theaker, D. Whitcombe, R. Ferrie, C. Newton, and S. Little.1997. The elimination of primer-dimer accumulation in PCR. Nucleic Acids Res.25:3235-3241.
    4.
    Call, D. R., M. K. Bakko, M. J. Krug, and M. C. Roberts.2003. Identifying antimicrobial resistance genes with DNA microarrays. Antimicrob. Agents Chemother.47:3290-3295.
    5.
    Call, D. R., M. K. Borucki, and F. J. Loge.2003. Detection of bacterial pathogens in environmental samples using DNA microarrays. J. Microbiol. Methods53:235-243.
    6.
    Chizhikov, V., A. Rasooly, K. Chumakov, and D. D. Levy.2001. Microarray analysis of microbial virulence factors. Appl. Environ. Microbiol.67:3258-3263.
    7.
    Chizhikov, V., M. Wagner, A. Ivshina, Y. Hoshino, A. Z. Kapikian, and K. Chumakov.2002. Detection and genotyping of human group A rotaviruses by oligonucleotide microarray hybridization. J. Clin. Microbiol.40:2398-2407.
    8.
    Coiras, M. T., J. C. Aguilar, M. L. Garcia, I. Casas, and P. Perez-Brena.2004. Simultaneous detection of fourteen respiratory viruses in clinical specimens by two multiplex reverse transcription nested-PCR assays. J. Med. Virol.72:484-495.
    9.
    Coiras, M. T., M. R. Lopez-Huertas, G. Lopez-Campos, J. C. Aguilar, and P. Perez-Brena.2005. Oligonucleotide array for simultaneous detection of respiratory viruses using a reverse-line blot hybridization assay. J. Med. Virol.76:256-264.
    10.
    Conejero-Goldberg, C., E. Wang, C. Yi, T. E. Goldberg, L. Jones-Brando, F. M. Marincola, M. J. Webster, and E. F. Torrey.2005. Infectious pathogen detection arrays: viral detection in cell lines and postmortem brain tissue. BioTechniques39:741-751.
    11.
    Corless, C. E., M. Guiver, R. Borrow, V. Edwards-Jones, A. J. Fox, and E. B. Kaczmarski.2001. Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae in suspected cases of meningitis and septicemia using real-time PCR. J. Clin. Microbiol.39:1553-1558.
    12.
    Daum, L. T., M. W. Shaw, A. I. Klimov, L. C. Canas, E. A. Macias, D. Niemeyer, J. P. Chambers, R. Renthal, S. K. Shrestha, R. P. Acharya, S. P. Huzdar, N. Rimal, K. S. Myint, and P. Gould.2005. Influenza A (H3N2) outbreak, Nepal. Emerg. Infect. Dis.11:1186-1191.
    13.
    Davignon, L., E. A. Walter, K. M. Mueller, C. P. Barrozo, D. A. Stenger, and B. Lin.2005. Use of resequencing oligonucleotide microarrays for identification of Streptococcus pyogenes and associated antibiotic resistance determinants. J. Clin. Microbiol.43:5690-5695.
    14.
    Dunbar, S. A.2006. Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin. Chim. Acta363:71-82.
    15.
    Grondahl, B., W. Puppe, A. Hoppe, I. Kuhne, J. A. Weigl, and H. J. Schmitt.1999. Rapid identification of nine microorganisms causing acute respiratory tract infections by single-tube multiplex reverse transcription-PCR: feasibility study. J. Clin. Microbiol.37:1-7.
    16.
    Gruteke, P., A. S. Glas, M. Dierdorp, W. B. Vreede, J. W. Pilon, and S. M. Bruisten.2004. Practical implementation of a multiplex PCR for acute respiratory tract infections in children. J. Clin. Microbiol.42:5596-5603.
    17.
    Hardegger, D., D. Nadal, W. Bossart, M. Altwegg, and F. Dutly.2000. Rapid detection of Mycoplasma pneumoniae in clinical samples by real-time PCR. J. Microbiol. Methods41:45-51.
    18.
    Lin, B., K. M. Blaney, A. P. Malanoski, A. G. Ligler, J. M. Schnur, D. Metzgar, K. L. Russell, and D. A. Stenger.2006. Rapid testing for over 20 respiratory pathogens simultaneously in clinical samples using resequencing arrays. Naval Research Laboratory, Washington, DC.
    19.
    Lin, B., Z. Wang, G. J. Vora, J. A. Thornton, J. M. Schnur, D. C. Thach, K. M. Blaney, A. G. Ligler, A. P. Malanoski, J. Santiago, E. A. Walter, B. K. Agan, D. Metzgar, D. Seto, L. T. Daum, R. Kruzelock, R. K. Rowley, E. H. Hanson, C. Tibbetts, and D. A. Stenger.2006. Broad-spectrum respiratory tract pathogen identification using resequencing DNA microarrays. Genome Res.16:527-535.
    20.
    Madhi, S. A., and K. P. Klugman.2004. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat. Med.10:811-813.
    21.
    Malanoski, A. P., B. Lin, Z. Wang, J. M. Schnur, and D. A. Stenger.2006. Automated identification of multiple micro-organisms from resequencing DNA microarrays. Nucleic Acids Res.34:5300-5311.
    22.
    McDonough, E. A., C. P. Barrozo, K. L. Russell, and D. Metzgar.2005. A multiplex PCR for detection of Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila, and Bordetella pertussis in clinical specimens. Mol. Cell. Probes19:314-322.
    23.
    Miyashita, N., A. Saito, S. Kohno, K. Yamaguchi, A. Watanabe, H. Oda, Y. Kazuyama, and T. Matsushima.2004. Multiplex PCR for the simultaneous detection of Chlamydia pneumoniae, Mycoplasma pneumoniae and Legionella pneumophila in community-acquired pneumonia. Respir. Med.98:542-550.
    24.
    Molling, P., S. Jacobsson, A. Backman, and P. Olcen.2002. Direct and rapid identification and genogrouping of meningococci and porA amplification by LightCycler PCR. J. Clin. Microbiol.40:4531-4535.
    25.
    Osiowy, C.1998. Direct detection of respiratory syncytial virus, parainfluenza virus, and adenovirus in clinical respiratory specimens by a multiplex reverse transcription-PCR assay. J. Clin. Microbiol.36:3149-3154.
    26.
    Peltola, V. T., and J. A. McCullers.2004. Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr. Infect. Dis. J.23:S87-S97.
    27.
    Peltola, V. T., K. G. Murti, and J. A. McCullers.2005. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J. Infect. Dis.192:249-257.
    28.
    Puppe, W., J. A. Weigl, G. Aron, B. Grondahl, H. J. Schmitt, H. G. Niesters, and J. Groen.2004. Evaluation of a multiplex reverse transcriptase PCR ELISA for the detection of nine respiratory tract pathogens. J. Clin. Virol.30:165-174.
    29.
    Relman, D. A.1999. The search for unrecognized pathogens. Science284:1308-1310.
    30.
    Roth, S. B., J. Jalava, O. Ruuskanen, A. Ruohola, and S. Nikkari.2004. Use of an oligonucleotide array for laboratory diagnosis of bacteria responsible for acute upper respiratory infections. J. Clin. Microbiol.42:4268-4274.
    31.
    Saitoh-Inagawa, W., A. Oshima, K. Aoki, N. Itoh, K. Isobe, E. Uchio, S. Ohno, H. Nakajima, K. Hata, and H. Ishiko.1996. Rapid diagnosis of adenoviral conjunctivitis by PCR and restriction fragment length polymorphism analysis. J. Clin. Microbiol.34:2113-2116.
    32.
    Shuber, A. P., V. J. Grondin, and K. W. Klinger.1995. A simplified procedure for developing multiplex PCRs. Genome Res.5:488-493.
    33.
    Smith, D. J., A. S. Lapedes, J. C. de Jong, T. M. Bestebroer, G. F. Rimmelzwaan, A. D. Osterhaus, and R. A. Fouchier.2004. Mapping the antigenic and genetic evolution of influenza virus. Science305:371-376.
    34.
    Stone, B., J. Burrows, S. Schepetiuk, G. Higgins, A. Hampson, R. Shaw, and T. Kok.2004. Rapid detection and simultaneous subtype differentiation of influenza A viruses by real time PCR. J. Virol. Methods117:103-112.
    35.
    Vabret, A., F. Mouthon, T. Mourez, S. Gouarin, J. Petitjean, and F. Freymuth.2001. Direct diagnosis of human respiratory coronaviruses 229E and OC43 by the polymerase chain reaction. J. Virol. Methods97:59-66.
    36.
    Wang, D., L. Coscoy, M. Zylberberg, P. C. Avila, H. A. Boushey, D. Ganem, and J. L. DeRisi.2002. Microarray-based detection and genotyping of viral pathogens. Proc. Natl. Acad. Sci. USA99:15687-15692.
    37.
    Wang, D., A. Urisman, Y. T. Liu, M. Springer, T. G. Ksiazek, D. D. Erdman, E. R. Mardis, M. Hickenbotham, V. Magrini, J. Eldred, J. P. Latreille, R. K. Wilson, D. Ganem, and J. L. DeRisi.2003. Viral discovery and sequence recovery using DNA microarrays. PLoS Biol.1:E2.
    38.
    Wang, H. Y., R. L. Malek, A. E. Kwitek, A. S. Greene, T. V. Luu, B. Behbahani, B. Frank, J. Quackenbush, and N. H. Lee.2003. Assessing unmodified 70-mer oligonucleotide probe performance on glass-slide microarrays. Genome Biol.4:R5.
    39.
    Wang, Z., L. T. Daum, G. J. Vora, D. Metzgar, E. A. Walter, L. C. Canas, A. P. Malanoski, B. Lin, and D. A. Stenger.2006. Identifying influenza viruses with resequencing microarrays. Emerg. Infect. Dis.12:638-646.
    40.
    Whelen, A. C., and D. H. Persing.1996. The role of nucleic acid amplification and detection in the clinical microbiology laboratory. Annu. Rev. Microbiol.50:349-373.
    41.
    Wilson, K. H., W. J. Wilson, J. L. Radosevich, T. Z. DeSantis, V. S. Viswanathan, T. A. Kuczmarski, and G. L. Andersen.2002. High-density microarray of small-subunit ribosomal DNA probes. Appl. Environ. Microbiol.68:2535-2541.
    42.
    Wilson, W. J., C. L. Strout, T. Z. DeSantis, J. L. Stilwell, A. V. Carrano, and G. L. Andersen.2002. Sequence-specific identification of 18 pathogenic microorganisms using microarray technology. Mol. Cell. Probes16:119-127.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 45Number 2February 2007
    Pages: 443 - 452

    History

    Received: 8 September 2006
    Revision received: 27 October 2006
    Accepted: 15 November 2006
    Published online: 29 November 2006

    Permissions

    Request permissions for this article.

    Contributors

    Authors

    Baochuan Lin [email protected]
    Center for Bio/Molecular Science and Engineering, Code 6900, Naval Research Laboratory, Washington, DC 20375
    Kate M. Blaney
    NOVA Research Incorporated, Alexandria, Virginia 22308
    Anthony P. Malanoski
    Center for Bio/Molecular Science and Engineering, Code 6900, Naval Research Laboratory, Washington, DC 20375
    Adam G. Ligler
    NOVA Research Incorporated, Alexandria, Virginia 22308
    Joel M. Schnur
    Center for Bio/Molecular Science and Engineering, Code 6900, Naval Research Laboratory, Washington, DC 20375
    David Metzgar
    Department of Defense Center for Deployment Health Research, Naval Health Research Center, San Diego, California 92186
    Kevin L. Russell
    Department of Defense Center for Deployment Health Research, Naval Health Research Center, San Diego, California 92186
    David A. Stenger
    Center for Bio/Molecular Science and Engineering, Code 6900, Naval Research Laboratory, Washington, DC 20375

    Notes

    Supplemental material for this article may be found at http://jcm.asm.org/.

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Helicobacter pylori Infections in the Bronx, New York: Surveying Antibiotic Susceptibility and Strain Lineage by Whole-Genome Sequencing

    Helicobacter pylori Infections in the Bronx, New York: Surveying Antibiotic Susceptibility and Strain Lineage by Whole-Genome Sequencing

    ABSTRACT

    The emergence of drug resistance in Helicobacter pylori has resulted in a greater need for susceptibility-guided treatment. While the alleles associated with resistance to clarithromycin and levofloxacin have been defined, there are limited data regarding the molecular mechanisms underlying resistance to other antimicrobials. Using H. pylori isolates from 42 clinical specimens, we compared phenotypic and whole-genome sequencing (WGS)-based detection of resistance. Phenotypic resistance correlated with the presence of alleles of 23S rRNA (A2142G/A2143G) for clarithromycin (kappa coefficient, 0.84; 95% confidence interval [CI], 0.67 to 1.0) and gyrA (N87I/N87K/D91Y/D91N/D91G/D99N) for levofloxacin (kappa coefficient, 0.90; 95% CI, 0.77 to 1.0). Phenotypic resistance to amoxicillin in three isolates correlated with mutations in pbp1, pbp2, and/or pbp3 within coding regions near known amoxicillin binding motifs. All isolates were phenotypically susceptible to tetracycline, although four bore a mutation in 16S rRNA (A926G). For metronidazole, nonsense mutations and R16H substitutions in rdxA correlated with phenotypic resistance (kappa coefficient, 0.76; 95% CI, 0.56 to 0.96). Previously identified mutations in the rpoB rifampin resistance-determining region (RRDR) were not present, but 14 novel mutations outside the RRDR were found in rifampin-resistant isolates. WGS also allowed for strain lineage determination, which may be important for future studies in associating precise MICs with specific resistance alleles. In summary, WGS allows for broad analyses of H. pylori isolates, and our findings support the use of WGS for the detection of clarithromycin and levofloxacin resistance. Additional studies are warranted to better define mutations conferring resistance to amoxicillin, tetracycline, and rifampin, but combinatorial analyses for rdxA gene truncations and R16H mutations have utility for determining metronidazole resistance.

    REFERENCES

    1.
    McColl KE. 2010. Clinical practice. Helicobacter pylori infection. N Engl J Med 362:1597–1604.
    2.
    Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. 2001. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345:784–789.
    3.
    Chey WD, Leontiadis GI, Howden CW, Moss SF. 2017. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 112:212–239.
    4.
    Pan KF, Zhang L, Gerhard M, Ma JL, Liu WD, Ulm K, Wang JX, Zhang L, Zhang Y, Bajbouj M, Zhang LF, Li M, Vieth M, Liu RY, Quante M, Wang LH, Suchanek S, Zhou T, Guan WX, Schmid R, Classen M, You WC. 2016. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut 65:9–18.
    5.
    Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM, European Helicobacter and Microbiota Study Group and Consensus Panel. 2017. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut 66:6–30.
    6.
    López-Góngora S, Puig I, Calvet X, Villoria A, Baylina M, Muñoz N, Sanchez-Delgado J, Suarez D, García-Hernando V, Gisbert JP. 2015. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. J Antimicrob Chemother 70:2447–2455.
    7.
    Wenzhen Y, Yumin L, Quanlin G, Kehu Y, Lei J, Donghai W, Lijuan Y. 2010. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med 49:1103–1109.
    8.
    Lehours P, Siffre E, Megraud F. 2011. DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin. BMC Gastroenterol 11:112.
    9.
    Ducournau A, Benejat L, Sifre E, Bessede E, Lehours P, Megraud F. 2016. Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods. Clin Microbiol Infect 22:715–718.
    10.
    Miendje Deyi VY, Burette A, Bentatou Z, Maaroufi Y, Bontems P, Lepage P, Reynders M. 2011. Practical use of GenoType(R) HelicoDR, a molecular test for Helicobacter pylori detection and susceptibility testing. Diagn Microbiol Infect Dis 70:557–560.
    11.
    Cambau E, Allerheiligen V, Coulon C, Corbel C, Lascols C, Deforges L, Soussy CJ, Delchier JC, Megraud F. 2009. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol 47:3600–3607.
    12.
    Agudo S, Alarcon T, Urruzuno P, Martinez MJ, Lopez-Brea M. 2010. Detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies of pediatric patients by using a commercially available real-time polymerase chain reaction after NucliSens semiautomated DNA extraction. Diagn Microbiol Infect Dis 67:213–219.
    13.
    Chisholm SA, Owen RJ, Teare EL, Saverymuttu S. 2001. PCR-based diagnosis of Helicobacter pylori infection and real-time determination of clarithromycin resistance directly from human gastric biopsy samples. J Clin Microbiol 39:1217–1220.
    14.
    Chen D, Cunningham SA, Cole NC, Kohner PC, Mandrekar JN, Patel R. 2017. Phenotypic and molecular antimicrobial susceptibility of Helicobacter pylori. Antimicrob Agents Chemother 61:e02530-16.
    15.
    Sun L, Talarico S, Yao L, He L, Self S, You Y, Zhang H, Zhang Y, Guo Y, Liu G, Salama NR, Zhang J. 2018. Droplet digital PCR-based detection of clarithromycin resistance in Helicobacter pylori isolates reveals frequent heteroresistance. J Clin Microbiol 56:e00019-18.
    16.
    Lauener FN, Imkamp F, Lehours P, Buissonniere A, Benejat L, Zbinden R, Keller PM, Wagner K. 2019. Genetic determinants and prediction of antibiotic resistance phenotypes in Helicobacter pylori. J Clin Med 8:E53.
    17.
    Clinical and Laboratory Standards Institute. 2016. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria, 3rd ed. CLSI guideline M45. Clinical and Laboratory Standards Institute, Wayne, PA.
    18.
    Wingett SW, Andrews S. 2018. FastQ screen: a tool for multi-genome mapping and quality control. F1000Res 7:1338.
    19.
    Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477.
    20.
    Wattam AR, Davis JJ, Assaf R, Boisvert S, Brettin T, Bun C, Conrad N, Dietrich EM, Disz T, Gabbard JL, Gerdes S, Henry CS, Kenyon RW, Machi D, Mao C, Nordberg EK, Olsen GJ, Murphy-Olson DE, Olson R, Overbeek R, Parrello B, Pusch GD, Shukla M, Vonstein V, Warren A, Xia F, Yoo H, Stevens RL. 2017. Improvements to PATRIC, the all-bacterial Bioinformatics Database and Analysis Resource Center. Nucleic Acids Res 45:D535–D542.
    21.
    Brettin T, Davis JJ, Disz T, Edwards RA, Gerdes S, Olsen GJ, Olson R, Overbeek R, Parrello B, Pusch GD, Shukla M, Thomason JA, III, Stevens R, Vonstein V, Wattam AR, Xia F. 2015. RASTtk: a modular and extensible implementation of the RAST algorithm for building custom annotation pipelines and annotating batches of genomes. Sci Rep 5:8365.
    22.
    Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32:1792–1797.
    23.
    Gong Y, Yuan Y. 2018. Resistance mechanisms of Helicobacter pylori and its dual target precise therapy. Crit Rev Microbiol 44:371–392.
    24.
    Davis JJ, Gerdes S, Olsen GJ, Olson R, Pusch GD, Shukla M, Vonstein V, Wattam AR, Yoo H. 2016. PATtyFams: protein families for the microbial genomes in the PATRIC database. Front Microbiol 7:118.
    25.
    Cock PJ, Antao T, Chang JT, Chapman BA, Cox CJ, Dalke A, Friedberg I, Hamelryck T, Kauff F, Wilczynski B, de Hoon MJ. 2009. Biopython: freely available Python tools for computational molecular biology and bioinformatics. Bioinformatics 25:1422–1423.
    26.
    Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30:1312–1313.
    27.
    Stamatakis A, Hoover P, Rougemont J. 2008. A rapid bootstrap algorithm for the RAxML web servers. Syst Biol 57:758–771.
    28.
    Kumar N, Mariappan V, Baddam R, Lankapalli AK, Shaik S, Goh KL, Loke MF, Perkins T, Benghezal M, Hasnain SE, Vadivelu J, Marshall BJ, Ahmed N. 2015. Comparative genomic analysis of Helicobacter pylori from Malaysia identifies three distinct lineages suggestive of differential evolution. Nucleic Acids Res 43:324–335.
    29.
    Hays C, Burucoa C, Lehours P, Tran CT, Leleu A, Raymond J, Hays C, Burucoa C, Lehours P, Tran CT, Leleu A, Raymond J. 2018. Molecular characterization of Helicobacter pylori resistance to rifamycins. Helicobacter 23:e12451.
    30.
    Rimbara E, Noguchi N, Kawai T, Sasatsu M. 2008. Mutations in penicillin-binding proteins 1, 2 and 3 are responsible for amoxicillin resistance in Helicobacter pylori. J Antimicrob Chemother 61:995–998.
    31.
    Okamoto T, Yoshiyama H, Nakazawa T, Park ID, Chang MW, Yanai H, Okita K, Shirai M. 2002. A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J Antimicrob Chemother 50:849–856.
    32.
    Harris AG, Hazell SL, Netting AG. 2000. Use of digoxigenin-labelled ampicillin in the identification of penicillin-binding proteins in Helicobacter pylori. J Antimicrob Chemother 45:591–598.
    33.
    Bachir M, Allem R, Benejat L, Tifrit A, Medjekane M, Drici AE, Megraud F, Douidi KT. 2018. Molecular detection of mutations involved in Helicobacter pylori antibiotic resistance in Algeria. J Antimicrob Chemother 73:2034–2038.
    34.
    De Francesco V, Zullo A, Fiorini G, Saracino IM, Pavoni M, Vaira D. 2019. Role of MIC levels of resistance to clarithromycin and metronidazole in Helicobacter pylori eradication. J Antimicrob Chemother 74:772–774.
    35.
    Kim JM, Kim JS, Kim N, Kim YJ, Kim IY, Chee YJ, Lee CH, Jung HC. 2008. Gene mutations of 23S rRNA associated with clarithromycin resistance in Helicobacter pylori strains isolated from Korean patients. J Microbiol Biotechnol 18:1584–1589.
    36.
    Posteraro P, Branca G, Sanguinetti M, Ranno S, Cammarota G, Rahimi S, De Carlo M, Posteraro B, Fadda G. 2006. Rapid detection of clarithromycin resistance in Helicobacter pylori using a PCR-based denaturing HPLC assay. J Antimicrob Chemother 57:71–78.
    37.
    Tanih NF, Ndip LM, Ndip RN. 2011. Characterisation of the genes encoding resistance to metronidazole (rdxA and frxA) and clarithromycin (the 23S-rRNA genes) in South African isolates of Helicobacter pylori. Ann Trop Med Parasitol 105:251–259.
    38.
    Matteo MJ, Perez CV, Domingo MR, Olmos M, Sanchez C, Catalano M. 2006. DNA sequence analysis of rdxA and frxA from paired metronidazole-sensitive and -resistant Helicobacter pylori isolates obtained from patients with heteroresistance. Int J Antimicrob Agents 27:152–158.
    39.
    Rasheed F, Campbell BJ, Alfizah H, Varro A, Zahra R, Yamaoka Y, Pritchard DM. 2014. Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance. Helicobacter 19:387–399.
    40.
    Miftahussurur M, Shrestha PK, Subsomwong P, Sharma RP, Yamaoka Y. 2016. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. BMC Microbiol 16:256.
    41.
    Blumel B, Goelz H, Kist M, Glocker EO. 2018. Retrospective study on outcome of salvage Helicobacter pylori eradication therapies based on molecular genetic susceptibility testing. Helicobacter 23:e12494.
    42.
    World Health Organization. 2017. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Report WHO/EMP/IAU/2017.12. World Health Organization, Geneva, Switzerland.
    43.
    Chua EG, Debowski AW, Webberley KM, Peters F, Lamichhane B, Loke MF, Vadivelu J, Tay CY, Marshall BJ, Wise MJ. 2019. Analysis of core protein clusters identifies candidate variable sites conferring metronidazole resistance in Helicobacter pylori. Gastroenterol Rep (Oxf) 7:42–49.
    44.
    Gerrits MM, Godoy AP, Kuipers EJ, Ribeiro ML, Stoof J, Mendonca S, van Vliet AH, Pedrazzoli J, Jr, Kusters JG. 2006. Multiple mutations in or adjacent to the conserved penicillin-binding protein motifs of the penicillin-binding protein 1A confer amoxicillin resistance to Helicobacter pylori. Helicobacter 11:181–187.
    45.
    Park CG, Kim S, Lee EJ, Jeon HS, Han S. 2018. Clinical relevance of point mutations in the 23S rRNA gene in Helicobacter pylori eradication: a prospective, observational study. Medicine (Baltimore) 97:e11835.
    46.
    Hughes D, Andersson DI. 2017. Environmental and genetic modulation of the phenotypic expression of antibiotic resistance. FEMS Microbiol Rev 41:374–391.
    47.
    Toledo H, López-Solís R. 2010. Tetracycline resistance in Chilean clinical isolates of Helicobacter pylori. J Antimicrob Chemother 65:470–473.
    48.
    Tuan VP, Narith D, Tshibangu-Kabamba E, Dung HDQ, Viet PT, Sokomoth S, Binh TT, Sokhem S, Tri TD, Ngov S, Tung PH, Thuan NPM, Truc TC, Phuc BH, Matsumoto T, Fauzia KA, Akada J, Trang TTH, Yamaoka Y. 2019. A next-generation sequencing-based approach to identify genetic determinants of antibiotic resistance in Cambodian Helicobacter pylori clinical isolates. J Clin Med 8:E858.
    49.
    Nezami BG, Jani M, Alouani D, Rhoads DD, Sadri N, Nezami BG, Jani M, Alouani D, Rhoads DD, Sadri N. 2019. Helicobacter pylori mutations detected by next-generation sequencing in formalin-fixed paraffin embedded gastric biopsies are associated with treatment failure. J Clin Microbiol 57:e01834-18.
    50.
    Marques B, Donato MM, Cardoso O, Luxo C, Martinho A, Almeida N. 2019. Study of rdxA and frxA genes mutations in metronidazole-resistant and -susceptible Helicobacter pylori clinical isolates from the central region of Portugal. J Glob Antimicrob Resist 17:300–304.
    51.
    Secka O, Moodley Y, Antonio M, Berg DE, Tapgun M, Walton R, Worwui A, Thomas V, Corrah T, Thomas JE, Adegbola RA. 2014. Population genetic analyses of Helicobacter pylori isolates from Gambian adults and children. PLoS One 9:e109466.
    52.
    Thorell K, Yahara K, Berthenet E, Lawson DJ, Mikhail J, Kato I, Mendez A, Rizzato C, Bravo MM, Suzuki R, Yamaoka Y, Torres J, Sheppard SK, Falush D. 2017. Rapid evolution of distinct Helicobacter pylori subpopulations in the Americas. PLoS Genet 13:e1006546.
    53.
    Krebes J, Didelot X, Kennemann L, Suerbaum S. 2014. Bidirectional genomic exchange between Helicobacter pylori strains from a family in Coventry, United Kingdom. Int J Med Microbiol 304:1135–1146.
    54.
    Didelot X, Nell S, Yang I, Woltemate S, van der Merwe S, Suerbaum S. 2013. Genomic evolution and transmission of Helicobacter pylori in two South African families. Proc Natl Acad Sci U S A 110:13880–13885.
    55.
    Furuta Y, Konno M, Osaki T, Yonezawa H, Ishige T, Imai M, Shiwa Y, Shibata-Hatta M, Kanesaki Y, Yoshikawa H, Kamiya S, Kobayashi I. 2015. Microevolution of virulence-related genes in Helicobacter pylori familial infection. PLoS One 10:e0127197.
    56.
    Osaki T, Konno M, Yonezawa H, Hojo F, Zaman C, Takahashi M, Fujiwara S, Kamiya S. 2015. Analysis of intra-familial transmission of Helicobacter pylori in Japanese families. J Med Microbiol 64:67–73.
    57.
    Kurosawa M, Kikuchi S, Inaba Y, Ishibashi T, Kobayashi F. 2000. Helicobacter pylori infection among Japanese children. J Gastroenterol Hepatol 15:1382–1385.
    58.
    Kennemann L, Didelot X, Aebischer T, Kuhn S, Drescher B, Droege M, Reinhardt R, Correa P, Meyer TF, Josenhans C, Falush D, Suerbaum S. 2011. Helicobacter pylori genome evolution during human infection. Proc Natl Acad Sci U S A 108:5033–5038.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 58Number 324 February 2020
    eLocator: e01591-19
    Editor: Alexander Mellmann
    University Hospital Münster

    History

    Received: 23 September 2019
    23 October 2019
    Accepted: 27 November 2019
    Published online: 24 February 2020

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. antimicrobial susceptibility testing
    2. Helicobacter pylori
    3. whole-genome sequencing
    4. amoxicillin
    5. clarithromycin
    6. levofloxacin
    7. lineage
    8. metronidazole
    9. rifampin
    10. tetracyclines

    Contributors

    Authors

    Rajagopalan Saranathan
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA
    Michael H. Levi
    Department of Pathology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA
    Alice R. Wattam
    Biocomplexity Institute and Initiative, University of Virginia, Charlottesville, Virginia, USA
    Adel Malek
    Provincial Public Health Laboratory, Eastern Health Microbiology Services, St. John’s, New Foundland and Labrador, Canada
    Emmanuel Asare
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA
    Department of Pathology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA
    Daniel S. Behin
    Department of Medicine, Division of Gastroenterology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA
    Debra H. Pan
    Department of Pediatrics, Division of Gastroenterology and Nutrition, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA
    William R. Jacobs Jr.
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA
    Wendy A. Szymczak
    Department of Pathology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA

    Editor

    Alexander Mellmann
    Editor
    University Hospital Münster

    Notes

    Address correspondence to Wendy A. Szymczak, [email protected].
    William R. Jacobs, Jr., and Wendy A. Szymczak are co-last authors.

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Laboratory Analysis of an Outbreak of Candida auris in New York from 2016 to 2018: Impact and Lessons Learned

    ABSTRACT

    Candida auris is a multidrug-resistant yeast which has emerged in health care facilities worldwide; however, little is known about identification methods, patient colonization, environmental survival, spread, and drug resistance. Colonization on both biotic (patients) and abiotic (health care objects) surfaces, along with travel, appear to be the major factors for the spread of this pathogen across the globe. In this investigation, we present laboratory findings from an ongoing C. auris outbreak in New York (NY) from August 2016 through 2018. A total of 540 clinical isolates, 11,035 patient surveillance specimens, and 3,672 environmental surveillance samples were analyzed. Laboratory methods included matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) for yeast isolate identification, real-time PCR for rapid surveillance sample screening, culture on selective/nonselective media for recovery of C. auris and other yeasts from surveillance samples, antifungal susceptibility testing to determine the C. auris resistance profile, and Sanger sequencing of the internal transcribed spacer (ITS) and D1/D2 regions of the ribosomal gene for C. auris genotyping. Results included (a) identification and confirmation of C. auris in 413 clinical isolates and 931 patient surveillance isolates as well as identification of 277 clinical cases and 350 colonized cases from 151 health care facilities, including 59 hospitals, 92 nursing homes, 1 long-term acute care hospital (LTACH), and 2 hospices, (b) successful utilization of an in-house developed C. auris real-time PCR assay for the rapid screening of patient and environmental surveillance samples, (c) demonstration of relatively heavier colonization of C. auris in nares than in the axilla/groin, and (d) predominance of the South Asia clade I with intrinsic resistance to fluconazole and elevated MIC to voriconazole (81%), amphotericin B (61%), flucytosine (5FC) (3%), and echinocandins (1%). These findings reflect greater regional prevalence and incidence of C. auris and the deployment of better detection tools in an unprecedented outbreak.

    REFERENCES

    1.
    Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. 2009. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 53:41–44.
    2.
    Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, Jang HC. 2011. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol 49:3139–3142.
    3.
    Chowdhary A, Sharma C, Duggal S, Agarwal K, Prakash A, Singh PK, Jain S, Kathuria S, Randhawa HS, Hagen F, Meis JF. 2013. New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis 19:1670–1673.
    4.
    Wang X, Bing J, Zheng Q, Zhang F, Liu J, Yue H, Tao L, Du H, Wang Y, Wang H, Huang G. 2018. The first isolate of Candida auris in China: clinical and biological aspects. Emerg Microbes Infect 7:93.
    5.
    Magobo RE, Corcoran C, Seetharam S, Govender NP. 2014. Candida auris-associated candidemia, South Africa. Emerg Infect Dis 20:1250–1251.
    6.
    Emara M, Ahmad S, Khan Z, Joseph L, Al-Obaid I, Purohit P, Bafna R. 2015. Candida auris candidemia in Kuwait. Emerg Infect Dis 21:1091–1092.
    7.
    Calvo B, Melo AS, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F, Meis JF, Colombo AL. 2016. First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Infect 73:369–374.
    8.
    Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, Ryan L, Shackleton J, Trimlett R, Meis JF, Armstrong-James D, Fisher MC. 2016. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control 5:35.
    9.
    Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, Kemble SK, Pacilli M, Black SR, Landon E, Ridgway J, Palmore TN, Zelzany A, Adams EH, Quinn M, Chaturvedi S, Greenko J, Fernandez R, Southwick K, Furuya EY, Calfee DP, Hamula C, Patel G, Barrett P, MSD, Lafaro P, Berkow EL, Moulton-Meissner H, Noble-Wang J, Fagan RP, Jackson BR, Lockhart SR, Litvintseva AP, Chiller TM. 2016. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus - United States, May 2013-August 2016. MMWR Morb Mortal Wkly Rep 65:1234–1237.
    10.
    Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, Maor Y, Tarabia J, Schechner V, Adler A, Finn T. 2017. Multidrug-resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis 23:195–203.
    11.
    Morales-López SE, Parra-Giraldo CM, Ceballos-Garzón A, Martínez HP, Rodríguez GJ, Álvarez-Moreno CA, Rodríguez JY. 2017. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. Emerg Infect Dis 23:162–164.
    12.
    Ruiz Gaitán AC, Moret A, López Hontangas JL, Molina JM, Aleixandre López AI, Cabezas AH, Mollar Maseres J, Arcas RC, Gómez Ruiz MD, Chiveli MÁ, Cantón E, Pemán J. 2017. Nosocomial fungemia by Candida auris: first four reported cases in continental Europe. Rev Iberoam Micol 34:23–27.
    13.
    Saris K, Meis JF, Voss A. 2018. Candida auris. Curr Opin Infect Dis 31:334–340.
    14.
    Spivak ES, Hanson KE. 2018. Candida auris: an emerging fungal pathogen. J Clin Microbiol 56:e01588-17.
    15.
    Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R, Dinesh KR, Karim S, Singh SK, Hagen F, Meis JF. 2014. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis 33:919–926.
    16.
    Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, Colombo AL, Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo RE, Jabeen K, Asghar RJ, Meis JF, Jackson B, Chiller T, Litvintseva AP. 2017. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 64:134–140.
    17.
    Abastabar M, Haghani I, Ahangarkani F, Rezai MS, Taghizadeh Armaki M, Roodgari S, Kiakojuri K, Al-Hatmi AMS, Meis JF, Badali H. 2019. Candida auris otomycosis in Iran and review of recent literature. Mycoses 62:101–105.
    18.
    Chow NA, de Groot T, Badali H, Abastabar M, Chiller TM, Meis JF. 2019. Potential fifth clade of Candida auris, Iran, 2018. Emerg Infect Dis 25:1780–1781.
    19.
    Adams E, Candida auris Investigation Workgroup, Quinn M, Tsay S, Poirot E, Chaturvedi S, Southwick K, Greenko J, Fernandez R, Kallen A, Vallabhaneni S, Haley V, Hutton B, Blog D, Lutterloh E, Zucker H. 2018. Candida auris in healthcare facilities, New York, USA, 2013–2017. Emerg Infect Dis 24:1816–1824.
    20.
    Chowdhary A, Sharma C, Meis JF. 2017. Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog 13:e1006290.
    21.
    Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman A, Manuel R, Brown CS. 2018. Candida auris: a review of the literature. Clin Microbiol Rev 31:e00029-17.
    22.
    Mizusawa M, Miller H, Green R, Lee R, Durante M, Perkins R, Hewitt C, Simner PJ, Carroll KC, Hayden RT, Zhang SX. 2017. Can multidrug-resistant Candida auris be reliably identified in clinical microbiology laboratories? J Clin Microbiol 55:638–640.
    23.
    Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, Meis JF, Chowdhary A. 2015. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol 53:1823–1830.
    24.
    Leach L, Zhu Y, Chaturvedi S. 2017. Development and validation of a real-time PCR assay for rapid detection of Candida auris from surveillance samples. J Clin Microbiol 56:e01223-17.
    25.
    Clinical and Laboratory Standards Institute. 2017. Reference method for broth dilution antifungal susceptibility testing of yeasts—4th ed. CLSI document M27. Clinical and Laboratory Standards Institute, Wayne, PA.
    26.
    Zhang T, Chaturvedi V, Chaturvedi S. 2015. Novel Trichoderma polysporum strain for the biocontrol of Pseudogymnoascus destructans, the fungal etiologic agent of bat white nose syndrome. PLoS One 10:e0141316.
    27.
    Strollo S, Lionakis MS, Adjemian J, Steiner CA, Prevots DR. 2016. Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002–2012. Emerg Infect Dis 23:7–13.
    28.
    Magill SS, O'Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, Wilson LE, Kainer MA, Lynfield R, Greissman S, Ray SM, Beldavs Z, Gross C, Bamberg W, Sievers M, Concannon C, Buhr N, Warnke L, Maloney M, Ocampo V, Brooks J, Oyewumi T, Sharmin S, Richards K, Rainbow J, Samper M, Hancock EB, Leaptrot D, Scalise E, Badrun F, Phelps R, Edwards JR, Emerging Infections Program Hospital Prevalence Survey Team. 2018. Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med 379:1732–1744.
    29.
    Benedict K, Jackson BR, Chiller T, Beer KD. 2018. Estimation of direct healthcare costs of fungal diseases in the United States. Clin Infect Dis 68:1791–1797.
    30.
    Girard V, Mailler S, Chetry M, Vidal C, Durand G, van Belkum A, Colombo AL, Hagen F, Meis JF, Chowdhary A. 2016. Identification and typing of the emerging pathogen Candida auris by matrix-assisted laser desorption ionisation time of flight mass spectrometry. Mycoses 59:535–538.
    31.
    Lockhar SR. 2019. Candida auris and multidrug resistance: defining the new normal. Fungal Genet Biol 131:103243.
    32.
    Vincent BM, Lancaster AK, Scherz-Shouval R, Whitesell L, Lindquist S. 2013. Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol 11:e1001692.
    33.
    Berkow EL, Lockhart SR. 2018. Activity of novel antifungal compound APX001A against a large collection of Candida auris. J Antimicrob Chemother 73:3060–3062.
    34.
    O’Brien B, Chaturvedi S, Chaturvedi V. 13 January 2020. In vitro evaluation of antifungal drug combinations against multidrug-resistant Candida auris isolates from New York outbreak. Antimicrob Agents Chemother doi:
    35.
    Fakhim H, Chowdhary A, Prakash A, Vaezi A, Dannaoui E, Meis JF, Badali H. 2017. In vitro interactions of echinocandins with triazoles against multidrug-resistant Candida auris. Antimicrob Agents Chemother 61:e01056-17.
    36.
    Zhu Y, Barat SA, Borroto-Esoda K, Angulo D, Chaturvedi S, Chaturvedi V. 2019. In vitro efficacy of novel glucan synthase inhibitor, ibrexafungerp (SCY-078), against multidrug- and pan-resistant Candida auris isolates from the outbreak in New York. bioRxiv doi:
    37.
    Chow NA, US Candida auris Investigation Team, Gade L, Tsay SV, Forsberg K, Greenko JA, Southwick KL, Barrett PM, Kerins JL, Lockhart SR, Chiller TM, Litvintseva AP, US Candida auris Investigation Team. 2018. Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey. Lancet Infect Dis 18:1377–1384.
    38.
    Leach L, Russell A, Zhu Y, Chaturvedi S, Chaturvedi V. 2019. A rapid and automated sample-to-result Candida auris real-time PCR assay for high-throughput testing of surveillance samples with the BD Max open system. J Clin Microbiol 57:e00630-19.
    39.
    Mulberry G, Chaturvedi S, Chaturvedi V, Kim B. 2020. Toward point-of-care diagnostics of Candida auris. medRxiv doi:

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 58Number 425 March 2020
    eLocator: e01503-19
    Editor: Daniel J. Diekema
    University of Iowa College of Medicine

    History

    Received: 10 September 2019
    4 October 2019
    Accepted: 11 December 2019
    Published online: 18 December 2019

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. Candida auris
    2. mycology
    3. antifungals
    4. molecular biology
    5. phylogenetics

    Contributors

    Authors

    YanChun Zhu
    Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York, USA
    Brittany O’Brien
    Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York, USA
    Lynn Leach
    Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York, USA
    Alexandra Clarke
    Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York, USA
    Marian Bates
    Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York, USA
    Eleanor Adams
    Healthcare Epidemiology & Infection Control Program, New York State Department of Health, New Rochelle, New York, USA
    Belinda Ostrowsky
    Division of Healthcare Quality Promotion (DHQP), Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
    Monica Quinn
    Bureau of Healthcare Associated Infections, New York State Department of Health, Albany, New York, USA
    Elizabeth Dufort
    Division of Epidemiology, New York State Department of Health, Albany, New York, USA
    Karen Southwick
    Healthcare Epidemiology & Infection Control Program, New York State Department of Health, New Rochelle, New York, USA
    Richard Erazo
    Healthcare Epidemiology & Infection Control Program, New York State Department of Health, New Rochelle, New York, USA
    Valerie B. Haley
    Bureau of Healthcare Associated Infections, New York State Department of Health, Albany, New York, USA
    Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, Albany, New York, USA
    Coralie Bucher
    Bureau of Healthcare Associated Infections, New York State Department of Health, Albany, New York, USA
    Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York, USA
    Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, New York, USA
    Ronald J. Limberger
    Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York, USA
    Debra Blog
    Division of Epidemiology, New York State Department of Health, Albany, New York, USA
    Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, Albany, New York, USA
    Emily Lutterloh
    Bureau of Healthcare Associated Infections, New York State Department of Health, Albany, New York, USA
    Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, Albany, New York, USA
    Sudha Chaturvedi
    Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York, USA
    Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, New York, USA

    Editor

    Daniel J. Diekema
    Editor
    University of Iowa College of Medicine

    Notes

    Address correspondence to Sudha Chaturvedi, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Laboratory Diagnosis of COVID-19: Current Issues and Challenges

    ABSTRACT

    The COVID-19 outbreak has had a major impact on clinical microbiology laboratories in the past several months. This commentary covers current issues and challenges for the laboratory diagnosis of infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In the preanalytical stage, collecting the proper respiratory tract specimen at the right time from the right anatomic site is essential for a prompt and accurate molecular diagnosis of COVID-19. Appropriate measures are required to keep laboratory staff safe while producing reliable test results. In the analytic stage, real-time reverse transcription-PCR (RT-PCR) assays remain the molecular test of choice for the etiologic diagnosis of SARS-CoV-2 infection while antibody-based techniques are being introduced as supplemental tools. In the postanalytical stage, testing results should be carefully interpreted using both molecular and serological findings. Finally, random-access, integrated devices available at the point of care with scalable capacities will facilitate the rapid and accurate diagnosis and monitoring of SARS-CoV-2 infections and greatly assist in the control of this outbreak.

    REFERENCES

    1.
    Del Rio C, Malani PN. 28 February 2020. COVID-19—new insights on a rapidly changing epidemic. JAMA doi:
    2.
    Fauci AS, Lane HC, Redfield RR. 2020. Covid-19—navigating the uncharted. N Engl J Med 382:1268–1269.
    3.
    Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS. 28 February 2020. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med doi:
    4.
    Paules CI, Marston HD, Fauci AS. 2020. Coronavirus infections-more than just the common cold. JAMA 323:707.
    5.
    Lu H, Stratton CW, Tang YW. 2020. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol 92:401–402.
    6.
    Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, Ng DYM, Wan CKC, Yang P, Wang Q, Peiris M, Poon L. 2020. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem 66:549–555.
    7.
    Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, Bleicker T, Brunink S, Schneider J, Schmidt ML, Mulders D, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MPG, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 25:2000045.
    8.
    Loeffelholz MJ, Tang YW. 2020. Laboratory diagnosis of emerging human coronavirus infections — the state of the art. Emerg Microbes Infect 9:747–756.
    9.
    Chan PK, To WK, Ng KC, Lam RK, Ng TK, Chan RC, Wu A, Yu WC, Lee N, Hui DS, Lai ST, Hon EK, Li CK, Sung JJ, Tam JS. 2004. Laboratory diagnosis of SARS. Emerg Infect Dis 10:825–831.
    10.
    Emery SL, Erdman DD, Bowen MD, Newton BR, Winchell JM, Meyer RF, Tong S, Cook BT, Holloway BP, McCaustland KA, Rota PA, Bankamp B, Lowe LE, Ksiazek TG, Bellini WJ, Anderson LJ. 2004. Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerg Infect Dis 10:311–316.
    11.
    Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. 2020. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis 24:30113–30114.
    12.
    Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J. 2020. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 382:1177–1179.
    13.
    To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW, Luo CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY. 2020. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 23:30196–30191.
    14.
    Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brunink S, Schneider J, Ehmann R, Zwirglmaier K, Drosten C, Wendtner C. 1 April 2020. Virological assessment of hospitalized patients with COVID-2019. Nature doi:
    15.
    Kim C, Ahmed JA, Eidex RB, Nyoka R, Waiboci LW, Erdman D, Tepo A, Mahamud AS, Kabura W, Nguhi M, Muthoka P, Burton W, Breiman RF, Njenga MK, Katz MA. 2011. Comparison of nasopharyngeal and oropharyngeal swabs for the diagnosis of eight respiratory viruses by real-time reverse transcription-PCR assays. PLoS One 6:e21610.
    16.
    Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. 11 March 2020. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA doi:
    17.
    Druce J, Garcia K, Tran T, Papadakis G, Birch C. 2012. Evaluation of swabs, transport media, and specimen transport conditions for optimal detection of viruses by PCR. J Clin Microbiol 50:1064–1065.
    18.
    Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Li M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JTK, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. 2020. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 382:1199–1207.
    19.
    Goff J, Rowe A, Brownstein JS, Chunara R. 2015. Surveillance of acute respiratory infections using community-submitted symptoms and specimens for molecular diagnostic testing. PLoS Curr 7:ecurrents.outbreaks.0371243baa7f3810ba1279e30b96d3b6.
    20.
    To KK, Lu L, Yip CC, Poon RW, Fung AM, Cheng A, Lui DH, Ho DT, Hung IF, Chan KH, Yuen KY. 2017. Additional molecular testing of saliva specimens improves the detection of respiratory viruses. Emerg Microbes Infect 6:e49.
    21.
    To KK, Tsang OT, Chik-Yan Yip C, Chan KH, Wu TC, Chan JMC, Leung WS, Chik TS, Choi CY, Kandamby DH, Lung DC, Tam AR, Poon RW, Fung AY, Hung IF, Cheng VC, Chan JF, Yuen KY. 12 February 2020. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis doi:
    22.
    Wang WK, Chen SY, Liu IJ, Chen YC, Chen HL, Yang CF, Chen PJ, Yeh SH, Kao CL, Huang LM, Hsueh PR, Wang JT, Sheng WH, Fang CT, Hung CC, Hsieh SM, Su CP, Chiang WC, Yang JY, Lin JH, Hsieh SC, Hu HP, Chiang YP, Wang JT, Yang PC, Chang SC, SARS Research Group of the National Taiwan University/National Taiwan University Hospital. 2004. Detection of SARS-associated coronavirus in throat wash and saliva in early diagnosis. Emerg Infect Dis 10:1213–1219.
    23.
    Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, Gao G, Wang S, Ma C, Xie R, Wang F, Tan C, Zhu L, Guo Y, Zhang F. 28 March 2020. Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients. Clin Infect Dis doi:
    24.
    Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, Ng OT, Marimuthu K, Ang LW, Mak TM, Lau SK, Anderson DE, Chan KS, Tan TY, Ng TY, Cui L, Said Z, Kurupatham L, Chen MI, Chan M, Vasoo S, Wang LF, Tan BH, Lin RTP, Lee VJM, Leo YS, Lye DC, Singapore 2019 Novel Coronavirus Outbreak Research Team. 3 March 2020. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA doi:
    25.
    Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, Wang YY, Xiao GF, Yan B, Shi ZL, Zhou P. 2020. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 9:386–389.
    26.
    Cheng PK, Wong DA, Tong LK, Ip SM, Lo AC, Lau CS, Yeung EY, Lim WW. 2004. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet 363:1699–1700.
    27.
    Isakbaeva ET, Khetsuriani N, Beard RS, Peck A, Erdman D, Monroe SS, Tong S, Ksiazek TG, Lowther S, Pandya-Smith I, Anderson LJ, Lingappa J, Widdowson MA, SARS Investigation Group. 2004. SARS-associated coronavirus transmission, United States. Emerg Infect Dis 10:225–231.
    28.
    Leung WK, To KF, Chan PK, Chan HL, Wu AK, Lee N, Yuen KY, Sung JJ. 2003. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 125:1011–1017.
    29.
    Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. 2020. A novel coronavirus emerging in China—key questions for impact assessment. N Engl J Med 382:692–694.
    30.
    Shi X, Gong E, Gao D, Zhang B, Zheng J, Gao Z, Zhong Y, Zou W, Wu B, Fang W, Liao S, Wang S, Xie Z, Lu M, Hou L, Zhong H, Shao H, Li N, Liu C, Pei F, Yang J, Wang Y, Han Z, Shi X, Zhang Q, You J, Zhu X, Gu J. 2005. Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases. Am J Gastroenterol 100:169–176.
    31.
    Xu D, Zhang Z, Jin L, Chu F, Mao Y, Wang H, Liu M, Wang M, Zhang L, Gao GF, Wang FS. 2005. Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. Eur J Clin Microbiol Infect Dis 24:165–171.
    32.
    Yeo C, Kaushal S, Yeo D. 2020. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol 5:335–337.
    33.
    Blow JA, Dohm DJ, Negley DL, Mores CN. 2004. Virus inactivation by nucleic acid extraction reagents. J Virol Methods 119:195–198.
    34.
    Burton JE, Easterbrook L, Pitman J, Anderson D, Roddy S, Bailey D, Vipond R, Bruce CB, Roberts AD. 2017. The effect of a non-denaturing detergent and a guanidinium-based inactivation agent on the viability of Ebola virus in mock clinical serum samples. J Virol Methods 250:34–40.
    35.
    Kumar M, Mazur S, Ork BL, Postnikova E, Hensley LE, Jahrling PB, Johnson R, Holbrook MR. 2015. Inactivation and safety testing of Middle East respiratory syndrome coronavirus. J Virol Methods 223:13–18.
    36.
    Duan X, Wang X, Yu P, Liu W, Li X, Zhang L, Zhang G, Tang H, Chen Q, Wu X, Tao Z. 2020. Effect of virus inactivation on weak positive results of nucleic acid test for 2019 novel coronavirus. Chin J Lab Med http://rs.yiigle.com/yufabiao/1184369.htm. (In Chinese.)
    37.
    Nie S, Roth RB, Stiles J, Mikhlina A, Lu X, Tang YW, Babady NE. 2014. Evaluation of Alere i Influenza A&B for rapid detection of influenza viruses A and B. J Clin Microbiol 52:3339–3344.
    38.
    Wang H, Deng J, Tang YW. 2018. Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test. Expert Rev Mol Diagn 18:403–409.
    39.
    Ling L, Kaplan SE, Lopez JC, Stiles J, Lu X, Tang YW. 2017. Parallel validation of three molecular devices for simultaneous detection and identification of influenza A and B and respiratory syncytial viruses. J Clin Microbiol 56:e01691-17.
    40.
    Chen Y, Chan KH, Hong C, Kang Y, Ge S, Chen H, Wong EY, Joseph S, Patteril NG, Wernery U, Xia N, Lau SK, Woo PC. 2016. A highly specific rapid antigen detection assay for on-site diagnosis of MERS. J Infect 73:82–84.
    41.
    Lau SK, Woo PC, Wong BH, Tsoi HW, Woo GK, Poon RW, Chan KH, Wei WI, Peiris JS, Yuen KY. 2004. Detection of severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in SARS patients by enzyme-linked immunosorbent assay. J Clin Microbiol 42:2884–2889.
    42.
    Sastre P, Dijkman R, Camunas A, Ruiz T, Jebbink MF, van der Hoek L, Vela C, Rueda P. 2011. Differentiation between human coronaviruses NL63 and 229E using a novel double-antibody sandwich enzyme-linked immunosorbent assay based on specific monoclonal antibodies. Clin Vaccine Immunol 18:113–118.
    43.
    Liu IJ, Chen PJ, Yeh SH, Chiang YP, Huang LM, Chang MF, Chen SY, Yang PC, Chang SC, Wang WK, SARS Research Group of the National Taiwan University College of Medicine-National Taiwan University Hospital. 2005. Immunofluorescence assay for detection of the nucleocapsid antigen of the severe acute respiratory syndrome (SARS)-associated coronavirus in cells derived from throat wash samples of patients with SARS. J Clin Microbiol 43:2444–2448.
    44.
    Sizun J, Arbour N, Talbot PJ. 1998. Comparison of immunofluorescence with monoclonal antibodies and RT-PCR for the detection of human coronaviruses 229E and OC43 in cell culture. J Virol Methods 72:145–152.
    45.
    Diao B, Wen K, Chen J, Liu Y, Yuan Z, Han C, Chen J, Pan Y, Chen L, Dan Y, Wang J, Chen Y, Deng G, Zhou H, Wu Y. 13 March 2020. Diagnosis of acute respiratory syndrome coronavirus 2 infection by detection of nucleocapsid protein. medRxiv https://www.medrxiv.org/content/10.1101/2020.03.07.20032524v1.
    46.
    Chen X, Zhou B, Li M, Liang X, Wang H, Yang G, Wang H, Le X. 2004. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J Infect Dis 189:1158–1163.
    47.
    Chan CM, Tse H, Wong SS, Woo PC, Lau SK, Chen L, Zheng BJ, Huang JD, Yuen KY. 2009. Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus. J Clin Virol 45:54–60.
    48.
    Briese T, Mishra N, Jain K, Zalmout IS, Jabado OJ, Karesh WB, Daszak P, Mohammed OB, Alagaili AN, Lipkin WI. 2014. Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia. mBio 5:e01146-14.
    49.
    Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, Sun Z, Liu F, Wu K, Zhong B, Mei Y, Zhang W, Chen Y, Li Y, Shi M, Lan K, Liu Y. 2020. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microbes Infect 9:313–319.
    50.
    Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, Jiang YZ, Xiong Y, Li YJ, Li XW, Li H, Fan GH, Gu XY, Xiao Y, Gao H, Xu JY, Yang F, Wang XM, Wu C, Chen L, Liu YW, Liu B, Yang J, Wang XR, Dong J, Li L, Huang CL, Zhao JP, Hu Y, Cheng ZS, Liu LL, Qian ZH, Qin C, Jin Q, Cao B, Wang JW. 2020. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J 11:1.
    51.
    Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. 2020. A new coronavirus associated with human respiratory disease in China. Nature 579:265–269.
    52.
    Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273.
    53.
    Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK, Washington State 2019-nCoV Case Investigation Team. 2020. First case of 2019 novel coronavirus in the United States. N Engl J Med 382:929–936.
    54.
    Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W, Seilmaier M, Drosten C, Vollmar P, Zwirglmaier K, Zange S, Wolfel R, Hoelscher M. 2020. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 382:970–971.
    55.
    Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395:514–523.
    56.
    Ai JW, Zhang Y, Zhang HC, Xu T, Zhang WH. 2020. Era of molecular diagnosis for pathogen identification of unexplained pneumonia, lessons to be learned. Emerg Microbes Infect 9:597–600.
    57.
    Cui J, Li F, Shi ZL. 2019. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17:181–192.
    58.
    Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395:565–574.
    59.
    Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH, Fung AY, Ng AC, Zou Z, Tsoi HW, Choi GK, Tam AR, Cheng VC, Chan KH, Tsang OT, Yuen KY. 4 March 2020. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens. J Clin Microbiol doi:
    60.
    China National Health Commission. 2020. New coronavirus pneumonia prevention and control protocol, 7th ed. National Commission of the People’s Republic of China. (In Chinese.) http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf.
    61.
    Kam KQ, Yung CF, Cui L, Lin Tzer Pin R, Mak TM, Maiwald M, Li J, Chong CY, Nadua K, Tan NWH, Thoon KC. 28 February 2020. A well infant with coronavirus disease 2019 (COVID-19) with high viral load. Clin Infect Dis doi:
    62.
    Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, Peiris M, Poon LLM, Zhang W. 19 March 2020. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis doi:
    63.
    Cheng VCC, Wong SC, Chen JHK, Yip CCY, Chuang VWM, Tsang OTY, Sridhar S, Chan JFW, Ho PL, Yuen KY. 3 March 2020. Escalating infection control response to the rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong. Infect Control Hosp Epidemiol doi:
    64.
    Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, Xu H. 27 February 2020. Positive RT-PCR test results in patients recovered from COVID-19. JAMA doi:
    65.
    Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, Zhu J, Zhang Q, Wu J, Liu L. 2020. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol 26:25726.
    66.
    Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. 2020. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science 367:1444–1448.
    67.
    Chan-Yeung M, Xu RH. 2003. SARS: epidemiology. Respirology 8:S9–S14.
    68.
    Liu Y, Eggo RM, Kucharski AJ. 2020. Secondary attack rate and superspreading events for SARS-CoV-2. Lancet 395:e47.
    69.
    Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J. 21 March 2020. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis doi:
    70.
    Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, Sun R, Wang Y, Hu B, Chen W, Zhang Y, Wang J, Huang B, Lin Y, Yang J, Cai W, Wang X, Cheng J, Chen Z, Sun K, Pan W, Zhan Z, Chen L, Ye F. 2020. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 27:25727.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 58Number 626 May 2020
    eLocator: e00512-20
    Editor: Alexander J. McAdam
    Boston Children's Hospital

    History

    Published online: 3 April 2020

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. COVID-19
    2. SARS-CoV-2
    3. specimen type
    4. molecular testing
    5. serology
    6. result interpretation

    Contributors

    Authors

    Cepheid, Danaher Diagnostic Platform, Shanghai, China
    Jonathan E. Schmitz
    Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    David H. Persing
    Cepheid, Sunnyvale, California, USA
    Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

    Editor

    Alexander J. McAdam
    Editor
    Boston Children's Hospital

    Notes

    Address correspondence to Yi-Wei Tang, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Infectious Middle East Respiratory Syndrome Coronavirus Excretion and Serotype Variability Based on Live Virus Isolates from Patients in Saudi Arabia

    Infectious Middle East Respiratory Syndrome Coronavirus Excretion and Serotype Variability Based on Live Virus Isolates from Patients in Saudi Arabia

    ABSTRACT

    The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) has infected at least 1,082 people, including 439 fatalities. So far, no empirical virus isolation study has been done to elucidate infectious virus secretion or serotype variability. Here, we used 51 respiratory samples from 32 patients with confirmed MERS-CoV infection for virus isolation in Vero B4 and Caco-2 cells. We found Caco-2 cells to significantly enhance isolation success over routinely used Vero cells. Isolation success correlated with viral RNA concentration and time after diagnosis as well as with the amount of IgA antibodies secreted in respiratory samples used for isolation. Results from plaque reduction neutralization assays using a representative range of serum samples and virus isolates suggested that all circulating human MERS-CoV strains represent one single serotype. The choice of prototype strain is not likely to influence the success of candidate MERS-CoV vaccines. However, vaccine formulations should be evaluated for their potential to induce IgA.

    REFERENCES

    1.
    Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814–1820.
    2.
    European Centre for Disease Prevention and Control. 2015. Severe respiratory diseases associated with Middle East respiratory syndrome coronavirus (MERS-CoV), 15th update. European Centre for Disease Prevention and Control, Stockholm, Sweden.
    3.
    Mackay IM, Arden KE. 2015. Middle East respiratory syndrome: an emerging coronavirus infection tracked by the crowd. Virus Res 202:60–88.
    4.
    Drosten C, Muth D, Corman V, Hussain R, Al Masri M, HajOmar W, Landt O, Assiri A, Eckerle I, Al Shangiti A, Al-Tawfiq JA, Albarrak A, Zumla A, Rambaut A, Memish Z. 2015. An observational, laboratory-based study of outbreaks of Middle East respiratory syndrome coronavirus in Jeddah and Riyadh, Kingdom of Saudi Arabia, 2014. Clin Infect Dis 60:369–377.
    5.
    Memish ZA, Al-Tawfiq JA, Makhdoom HQ, Assiri A, Alhakeem RF, Albarrak A, Alsubaie S, Al-Rabeeah AA, Hajomar WH, Hussain R, Kheyami AM, Almutairi A, Azhar EI, Drosten C, Watson SJ, Kellam P, Cotten M, Zumla A. 2014. Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome. J Infect Dis 210:1590–1594.
    6.
    Poissy J, Goffard A, Parmentier-Decrucq E, Favory R, Kauv M, Kipnis E, Mathieu D, Guery B. 2014. Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases. J Clin Virol 61:275–278.
    7.
    Meyer B, Drosten C, Muller MA. 2014. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res 194:175–183.
    8.
    Raj VS, Farag EA, Reusken CB, Lamers MM, Pas SD, Voermans J, Smits SL, Osterhaus AD, Al-Mawlawi N, Al-Romaihi HE, AlHajri MM, El-Sayed AM, Mohran KA, Ghobashy H, Alhajri F, Al-Thani M, Al-Marri SA, El-Maghraby MM, Koopmans MP, Haagmans BL. 2014. Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014. Emerg Infect Dis 20:1339–1342.
    9.
    Muller MA, Meyer B, Corman VM, Al-Masri M, Turkestani A, Ritz D, Sieberg A, Aldabbagh S, Bosch BJ, Lattwein E, Alhakeem RF, Assiri AM, Albarrak AM, Al-Shangiti AM, Al-Tawfiq JA, Wikramaratna P, Alrabeeah AA, Drosten C, Memish ZA. 2015. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis 15:559–564.
    10.
    Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, van Boheemen S, Gopal R, Ballhause M, Bestebroer TM, Muth D, Muller MA, Drexler JF, Zambon M, Osterhaus AD, Fouchier RM, Drosten C. 2012. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 17(39):pii=20285. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20285.
    11.
    Buchholz U, Muller MA, Nitsche A, Sanewski A, Wevering N, Bauer-Balci T, Bonin F, Drosten C, Schweiger B, Wolff T, Muth D, Meyer B, Buda S, Krause G, Schaade L, Haas W. 2013. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro Surveill 18(8):pii=20406. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20406.
    12.
    Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ, Haagmans BL. 2013. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495:251–254.
    13.
    Cotten M, Watson SJ, Zumla AI, Makhdoom HQ, Palser AL, Ong SH, Al Rabeeah AA, Alhakeem RF, Assiri A, Al-Tawfiq JA, Albarrak A, Barry M, Shibl A, Alrabiah FA, Hajjar S, Balkhy HH, Flemban H, Rambaut A, Kellam P, Memish ZA. 2014. Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. mBio 5(1):e01062-13.
    14.
    de Wit E, Rasmussen AL, Falzarano D, Bushmaker T, Feldmann F, Brining DL, Fischer ER, Martellaro C, Okumura A, Chang J, Scott D, Benecke AG, Katze MG, Feldmann H, Munster VJ. 2013. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A 110:16598–16603.
    15.
    Chan KH, Yan MK, To KK, Lau SK, Woo PC, Cheng VC, Li WS, Chan JF, Tse H, Yuen KY. 2013. Use of the human colorectal adenocarcinoma (Caco-2) cell line for isolating respiratory viruses from nasopharyngeal aspirates. J Med Virol 85:874–879.
    16.
    Couch RB, Atmar RL, Franco LM, Quarles JM, Wells J, Arden N, Nino D, Belmont JW. 2013. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 207:974–981.

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 53Number 9September 2015
    Pages: 2951 - 2955
    Editor: A. M. Caliendo

    History

    Received: 21 May 2015
    12 June 2015
    Accepted: 18 June 2015
    Published online: 8 July 2015

    Permissions

    Request permissions for this article.

    Contributors

    Authors

    Doreen Muth
    Institute of Virology, University of Bonn Medical Centre, Bonn, Germany
    German Centre for Infection Research (DZIF), Bonn-Cologne, Germany
    Institute of Virology, University of Bonn Medical Centre, Bonn, Germany
    German Centre for Infection Research (DZIF), Bonn-Cologne, Germany
    Benjamin Meyer
    Institute of Virology, University of Bonn Medical Centre, Bonn, Germany
    Abdullah Assiri
    Ministry of Health, Riyadh, Kingdom of Saudi Arabia
    Malak Al-Masri
    Ministry of Health, Riyadh, Kingdom of Saudi Arabia
    Mohamed Farah
    Central Military Laboratory and Blood Bank, Microbiology Division, Prince Sultan Military City, Riyadh, Kingdom of Saudi Arabia
    Katja Steinhagen
    EUROIMMUN AG, Lübeck, Germany
    Erik Lattwein
    EUROIMMUN AG, Lübeck, Germany
    Jaffar A. Al-Tawfiq
    Johns Hopkins Aramco Healthcare, Dahran, Kingdom of Saudi Arabia
    Indiana University School of Medicine, Indianapolis, Indiana, USA
    Ali Albarrak
    Saudi Center for Disease Control, Ministry of Health, Riyadh, Kingdom of Saudi Arabia
    Marcel A. Müller
    Institute of Virology, University of Bonn Medical Centre, Bonn, Germany
    Christian Drosten
    Institute of Virology, University of Bonn Medical Centre, Bonn, Germany
    German Centre for Infection Research (DZIF), Bonn-Cologne, Germany
    Ziad A. Memish
    Ministry of Health, Riyadh, Kingdom of Saudi Arabia
    College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia

    Editor

    A. M. Caliendo
    Editor

    Notes

    Address correspondence to Christian Drosten, [email protected], or Ziad A. Memish, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

  • Journal of Clinical MicrobiologyArticle
    Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2

    REFERENCES

    1.
    To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW, Luo CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY. 2020. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis doi:
    2.
    Kim YG, Yun SG, Kim MY, Park K, Cho CH, Yoon SY, Nam MH, Lee CK, Cho YJ, Lim CS. 2017. Comparison between saliva and nasopharyngeal swab specimens for detection of respiratory viruses by multiplex reverse transcription-PCR. J Clin Microbiol 55:226–233.
    3.
    Caly L, Druce J, Roberts J, Bond K, Tran T, Kostecki R, Yoga Y, Naughton W, Taiaroa G, Seemann T, Schultz MB, Howden BP, Korman TM, Lewin SR, Williamson DA, Catton MG. 2020. Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med J Aust doi:
    4.
    To KK, Tsang OT, Chik-Yan Yip C, Chan KH, Wu TC, Chan JMC, Leung WS, Chik TS, Choi CY, Kandamby DH, Lung DC, Tam AR, Poon RW, Fung AY, Hung IF, Cheng VC, Chan JF, Yuen KY. 2020. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis doi:
    5.
    Ranney ML, Griffeth V, Jha AK. 2020. Critical supply shortages—the need for ventilators and personal protective equipment during the Covid-19 pandemic. N Engl J Med doi:

    Information & Contributors

    Information

    Published In

    Journal of Clinical Microbiology
    Volume 58Number 823 July 2020
    eLocator: e00776-20
    Editor: Alexander J. McAdam
    Boston Children’s Hospital

    History

    Published online: 21 April 2020

    Permissions

    Request permissions for this article.

    KEYWORDS

    1. COVID-19
    2. clinical microbiology
    3. RT-PCR
    4. SARS-CoV-2

    Contributors

    Authors

    Department of Microbiology, Royal Melbourne Hospital, Melbourne, Australia
    Katherine Bond
    Department of Microbiology, Royal Melbourne Hospital, Melbourne, Australia
    Bowen Zhang
    Department of Microbiology, Royal Melbourne Hospital, Melbourne, Australia
    Mark Putland
    Department of Emergency Medicine, Royal Melbourne Hospital, Melbourne, Australia
    Department of Microbiology, Royal Melbourne Hospital, Melbourne, Australia
    Microbiological Diagnostic Unit, Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

    Editor

    Alexander J. McAdam
    Editor
    Boston Children’s Hospital

    Notes

    Address correspondence to Deborah A. Williamson, [email protected].

    Metrics & Citations

    Metrics

    Citations

    View Options

    Media

    Figures

    Other

    Tables

    Share

There are no results at this time

American Society for Microbiology ("ASM") is committed to maintaining your confidence and trust with respect to the information we collect from you on websites owned and operated by ASM ("ASM Web Sites") and other sources. This Privacy Policy sets forth the information we collect about you, how we use this information and the choices you have about how we use such information.
FIND OUT MORE about the privacy policy